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The presence of protein inclusions called Lewy bodies (LBs) that are mainly composed of 
misfolded and accumulated α-synuclein (αSyn) represents a hallmark of Parkinson´s disease 
(PD). Oligomeric αSyn species are thought to play a central role in the neurodegeneration of 
PD. Elevated levels of oxidative or nitrative stresses have been implicated in αSyn-related 
toxicity. Phosphorylation of αSyn on serine 129 (S129) is prominently found in Lewy bodies 
and modulates autophagic aggregates clearance. The neighboring tyrosine residues Y125, 
Y133 and Y136 are phosphorylation and nitration sites. Overexpression of αSyn in the 
unicellular eukaryotic model Saccharomyces cerevisiae results in growth impairment and 
cytoplasmic protein inclusions resembling the aggregates observed within LBs. In this study, 
yeast was used as reference cell to study the contribution of tyrosine modifications on αSyn-
related toxicity. Y133 is required for protective S129 phosphorylation and for S129-
independent proteasome clearance. αSyn can be nitrated and forms stable dimers 
originating from covalent crosslinking of two tyrosine residues. LC-MS analysis of tyrosine 
residues involved in nitration and crosslinking revealed that the C-terminus, rather than the 
N-terminus of αSyn, is modified by nitration and di-tyrosine formation. The nitration level of 
wild-type αSyn was higher than the A30P mutant that is non-toxic in yeast. A30P formed 
more dimers than wild-type αSyn supporting dimer formation as a cellular detoxification 
pathway in yeast. In contrast to A30P, expression of αSyn significantly increased the 
accumulation of reactive oxygen species, which was independent from tyrosine 
modifications. Deletion of the yeast flavohemoglobin gene YHB1 resulted in an increase of 
cellular nitrative stress and enhanced aggregation and cytotoxicity of A30P. Yhb1 protected 
yeast from A30P-induced mitochondrial fragmentation. Deletion of YHB1 elevated the level 
of reactive nitrogen species in A30P expressing cells, which can be diminished by mutating 
the nitration sites. Protein analysis showed that Yhb1 affects nitration but not dimerization 
levels of A30P indicating that nitrated tyrosine residues, but not di-tyrosine crosslinked 
dimers, contribute to αSyn cytotoxicity and aggregation. Under nitrative stress, deletion of 
YHB1 severely inhibited yeast growth in cells expressing wild-type and A30P αSyn. A30P 
was as toxic as wild-type αSyn indicating that increase in nitrative stress converts A30P to a 
toxic protein. Overexpression of neuroglobin, the human homolog of YHB1, protected against 
αSyn inclusion formation in mammalian cells. This study suggests that C-terminal Y133 plays 
a major role in αSyn aggregate clearance by supporting the protective S129 phosphorylation 
for autophagy and by promoting proteasome clearance. C-terminal tyrosine nitration 
increases pathogenicity and can be partially detoxified by αSyn di-tyrosine dimers. This novel 
complex interplay between S129 phosphorylation and C-terminal tyrosine modifications of 





Morbus Parkinson ist durch Lewy Bodies als Protein-Einschlusskörper gekennzeichnet, die 
hauptsächlich aus dem Protein α-Synuclein (αSyn) bestehen. Dieses Protein hat 
zytotoxische Intermediate und erhöhter oxidativer sowie nitrosativer Stress sind an der 
Toxizität von αSyn beteiligt. Phosphorylierung von αSyn an Serin 129 (S129) wurde in Lewy 
Bodies gefunden und reguliert den Autophagie-abhängigen Aggregat-Abbau. Die 
benachbarten Tyrosin-Reste Y125, Y133 und Y136 sind Phosphorylierungs- und 
Nitrierungsstellen. Überexpression von αSyn in Saccharomyces cerevisiae als unizelluläres 
eukaryotisches Zell-Modell löst Wachstumsstörungen sowie die Fehlfaltung des Proteins mit 
darauffolgenden zytoplasmatischen Aggregationen aus, die an die in den Lewy Bodies 
beobachteten Aggregate erinnern. Mithilfe dieses Hefemodells für Morbus Parkinson wurde 
die Wirkung von Tyrosin-Modifikationen auf die von αSyn hervorgerufene Toxizität 
untersucht. Es konnte gezeigt werden, dass Y133 für die protektive Phosphorylierung von 
S129 und für den S129-abhängigen Proteasom-Abbau benötigt wird. αSyn kann nitriert 
werden und formt daraufhin stabile Dimere, die durch kovalente Verbindung von zwei 
Tyrosinen entstehen. LC-MS Analysen von Tyrosin-Resten, die bei der Nitrierung und 
Dimerisierung involviert sind, haben gezeigt, dass der C-Terminus von αSyn mehr als der N-
Terminus durch Nitrierung und Di-Tyrosin-Bildung modifiziert wird. Der Grad an Nitrierung 
des normalen αSyn war höher als bei der A30P-Variante, die in Hefe nicht toxisch ist. Die 
A30P-Mutante bildete mehr Dimere im Vergleich zum αSyn Wildtyp, was darauf hindeutet, 
dass die Dimerizierung ein zellulärer Detoxifikationsmechanismus in Hefe sein könnte. Im 
Gegensatz zu der A30P-Mutante, erhöhte die Expression von αSyn unabhängig von der 
Tyrosin-Modifikation die Akkumulation von reaktiven Sauerstoffspezies. Die Deletion des 
Yeast Flavohemoglobin Gens, YHB1, führte zu einer Erhöhung von Nitrierungsstress sowie 
zum Anstieg von Aggregation und Zytotoxizität der A30P-Mutante. Yhb1 wirkte protektiv 
gegen A30P-induzierte Mitochondrien-Fragmentierung. Die Deletion von YHB1 führte zum 
Anstieg von reaktiven Stickstoffspezies in Zellen, die A30P exprimieren, was durch den 
Austausch der Tyrosin-Reste verringert werden kann. Yhb1 beeinflusst den Nitrierungs-, 
aber nicht den Dimerisierungslevel von A30P. Es sind daher eher nitrierte Tyrosin-Reste als 
Di-Tyrosin-Verbindungen an der Zytotoxizität und Aggregation von αSyn beteiligt. Unter 
nitrativen Stress-Bedingungen, bei dem Peroxynitrit als Stickstoffmonoxid-Donor eingesetzt 
wurde, führte die Deletion von YHB1 zur Wachstumshemmung von Wildtyp αSyn- und A30P-
exprimierenden Zellen. Dabei war die A30P-Mutante gleichermaßen toxisch wie das normale 
αSyn. Der Anstieg von Nitrierungsstress verwandelt daher A30P vermutlich in ein toxisches 
Protein. Die Überexpression vom NGB, dem humanen Homolog von YHB1, wirkte protektiv 




wesentliche Rolle im αSyn-Aggregate-Abbau. Dieser Rest fördert die protektive S129-
Phosphorylierung und damit den Autophagie-Abbau und stimuliert den Proteasom-Abbau. C-
terminale Tyrosin-Nitrierung erhöht die Pathogenität und kann durch Di-Tyrosin-Dimere 
teilweise detoxifiziert werden. Diese neue komplexe Wechselwirkung zwischen der S129 
Phosphorylierung und den C-terminalen Tyrosin-Modifikationen von αSyn ist wahrscheinlich 




1.1 Parkinson´s disease 
1.1.1 Epidemiology 
Parkinson´s disease (PD) is the second most frequent neurodegenerative disorder after 
Alzheimer´s disease. It causes a wide range of physical and mental impairments. Six million 
people are affected worldwide by PD with the prevalence of approximately 0.3 % of the 
population in industrialized countries (Dexter and Jenner, 2013). The cause of PD remains 
unknown although several risk factors such as environmental factors, aging and genetic 
susceptibility were identified to contribute to the onset of the pathogenic process. No curative 
therapies exist that slow the degenerative progression. PD therapies are usually restricted to 
systematic treatments. The average age of diagnoses is around 60 years. The prevalence 
increases to 1 % in the population older than 60 years and to 4 % older than 80. Hence, PD 
is considered as an age-related disease (de Lau and Breteler, 2006; de Rijk et al., 2000; 
Dexter and Jenner, 2013). Whereas in 95 % of PD patients an idiopathic background is 
diagnosed, approx. 5 % of patients are affected by inherited forms of PD. The familial cases 
of PD result in early-onset of disease and are caused by point missense mutations and 
multiplications of certain genes, e.g. SNCA, Parkin, PINK1, LRRK2, DJ-1 and ATP13A2 
(Bonifati et al., 2003; Di Fonzo et al., 2007; Kitada et al., 1998; Polymeropoulos et al., 1997; 
Valente et al., 2001; Zimprich et al., 2004). In 1817, the British physician James Parkinson 
firstly described the core clinical features of the disorder in his historic publication “An Essay 
on the Shaking Palsy”, which are today classified as common symptoms of PD (Parkinson, 
2002). Characteristic clinical symptoms comprise akinesia (muscle rigidity), bradykinesia 
(slowness of movement), resting tremor and loss of postural reflexes. Furthermore, PD can 
also cause dysarthria, hypomimia, dysphagia, anosmia, insomnia and urinary incontinence 
(Galvin et al., 2001; Jankovic, 2008).  
 
1.1.2 Pathophysiology and Etiology 
Although many parts of the brain are affected by PD, its best known pathological hallmark is 
the selective loss of dopamine-producing neurons in the substantia nigra (SN), a core 
complex of melanin- and iron-containing neurons in the ventral midbrain involved in motor 
control (German et al., 1989; German et al., 1992). SN is a part of basal ganglia which 
regulates the dopamine maintenance of the striatum, the largest component of basal ganglia 
controlling complex regulatory circuits of voluntary movements. Although degeneration also 
occurs in other neuron types (Pillon et al., 1989), the mid-section of the substantia nigra, 
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zona compacta, is mostly affected by neurodegeneration. Loss of dopaminergic neurons is 
accompanied by the loss of neuromelanin neurons leading to depigmentation (Fearnley and 
Lees, 1991; Fedorow et al., 2005; Gibb and Lees, 1991). Degeneration of nigral 
dopaminergic neurons consequently results in dopamine depletion in the striatum leading to 
observed motoric and non-motoric dysfunctions of PD (Hornykiewicz, 2001; Obeso et al., 
2002). The persistent reduction of dopamine misbalances other neurotransmitters including 
acetylcholine, glutamate or γ-aminobutyric acid (GABA), which can result in mental disorders 
such as emotional instability and depression (Giupponi et al., 2008). PD is also described to 
be associated with non-motoric and non-dopaminergic symptoms that extend beyond the 
nigrostiatal dopamine pathway and often occur years or even decades prior to the clinical 
diagnosis (Chaudhuri et al., 2006; Sung and Nicholas, 2013). At the time of symptom onset, 
approx. 50 % of dopamine-producing neurons are already degenerated (Fearnley and Lees, 
1991). Degeneration of neurons coincides with the formation of intraneuronal proteinaceous 
inclusion bodies that can be observed in post mortem brain histology. Firstly, these inclusion 
bodies were described in 1912 by Friedrich Lewy and were later referred to as Lewy bodies 
(LBs). Together with the loss of dopaminergic neurons in the midbrain, LBs are defined as 
characteristic pathological hallmarks of PD (Gibb and Lees, 1988). LBs consist of various 
molecules including α-synuclein (αSyn), neurofilaments and ubiquitin (Baba et al., 1998; 
Spillantini et al., 1998; Spillantini et al., 1997). Similar pathologies are observed in other 
neurodegenerative diseases such as dementia with LBs, multiple lateral sclerosis and 
Alzheimer´s disease, which are summarized as synucleinopathies (Hashimoto and Masliah, 
1999; Spillantini et al., 1998; Spillantini and Goedert, 2000). 
 
1.2 α-synuclein in Parkinson´s disease 
In 1997, Spillantini and colleagues discovered the small neuronal protein αSyn as the major 
constituent of LBs (Spillantini et al., 1997). In the same year, a missense mutation in the 
αSyn encoding gene was identified that causes autosomal dominant inherited form of PD 
resulting in earlier disease-onset than sporadic PD (Polymeropoulos et al., 1997). Since 
these findings, αSyn has been implicated as a key pathogenic factor in sporadic and familial 
form of PD. αSyn is a highly soluble protein of 140 amino acids, which is enriched in high 
concentration at presynaptic terminals (Maroteaux et al., 1988; Totterdell and Meredith, 
2005). It is presumably involved in the regulation of SNARE-complex assembly of 
presynaptic vesicles and vesicle release of neurotransmitters (Abeliovich et al., 2000; Burre 
et al., 2010; Chandra et al., 2004; Lundblad et al., 2012). Moreover, several lines of evidence 
suggest a role in regulation of cell differentiation and phospholipid metabolism (Golovko et 
al., 2009; Oliveira et al., 2015). However, the physiological function of αSyn is still not 
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completely defined. The nuclear localization of αSyn is a matter of intense debate. Numerous 
studies have shown that αSyn is localized in the nucleus (Huang et al., 2011; Yu et al., 
2007). It may impair histone acetylation and thereby promote neurotoxicity (Goers et al., 
2003; Kontopoulos et al., 2006).  
αSyn is composed of three distinct regions (Figure 1). The N-terminus comprises of six 11-
amino acid repeats with a highly conserved hexamer motif (KTKEGV), which likely favours 
binding to phospholipid membranes (Jensen et al., 1998; Karube et al., 2008; Vamvaca et 
al., 2009). Interaction of αSyn to phospholipids promotes an unfolded-to-folded transition of 
the protein resulting in the formation of two long α-helices interacting with the lipid micelles of 
the membrane (Chandra et al., 2003; Davidson et al., 1998; Sharon et al., 2001). The 
hydrophobic middle part of αSyn is defined as non-amyloid-β component (NAC) and 
promotes formation of amyloid-like fibrils known as β-sheets (Giasson et al., 2001; Waxman 
et al., 2009). The acidic C-terminus, which is highly negatively charged, facilitates protein 
solubility and exhibits chaperone-like activity (Ahn et al., 2006; Souza et al., 2000b). αSyn 
can be targeted to nuclear compartments, which can be induced by oxidative stress (Specht 
et al., 2005; Xu et al., 2006). 
 
Figure 1. Schematic overview of human αSyn with the three distinct domains. 
The six imperfect KTKEGV repeats are shown in dark blue. The N-terminus is indicated in 
blue, the non-amyloid-β component (NAC domain) in yellow and the acidic C-terminus in red. 
The N-terminus exhibits a binding affinity to phospholipids. The strong hydrophobic NAC 
domain promotes aggregate formation and the acidic C-terminus promotes solubility of αSyn. 
Grey arrows indicate the seven disease-associated mutation sites A18T, A29S, A30P, E46K, 
H50Q, G51D and A53T (for details and references, see Recchia et al., 2004; Sekiyama et 
al., 2014). 
 
αSyn is encoded by the SNCA gene in the PARK1 gene locus (Campion et al., 1995; Chen 
et al., 1995) and belongs to a protein family of soluble proteins including β-synuclein and γ-
synuclein (Clayton and George, 1998; Jakes et al., 1994; Maroteaux and Scheller, 1991). 
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Seven independent point mutations in the SNCA gene locus as well as duplications or 
triplications of the wild-type αSyn locus have been described in familial inherited forms of PD 
(Figure 1; Appel-Cresswell et al., 2013; Athanassiadou et al., 1999; Kruger et al., 1998; 
Lesage et al., 2013; Polymeropoulos et al., 1997; Singleton et al., 2003; Zarranz et al., 
2004). This makes αSyn a hallmark protein in the pathogenesis of PD and other 
synucleinopathies, which sparked an intense research to uncover the correlation between 
structural features of αSyn and its toxicity (Karpinar et al., 2009). All known missense 
mutations are confined to the N-terminal repeat region of αSyn. Numerous reports have 
shown that the mutated αSyn variants exhibit aberrant molecular properties and physical 
features (Sahay et al., 2015). They affect oligomerization, aggregation, formation of fibrillar 
structures and subcellular distribution of the αSyn protein through the cell (Conway et al., 
1998; Conway et al., 2000; Goncalves and Outeiro, 2013; Greenbaum et al., 2005; Lazaro et 
al., 2014; Li et al., 2001). For instance, the substitution of an alanine to proline at position 30 
of A30P mutant disrupts the α-helix and thereby reduces the affinity for binding phosholipid 
vesicles and shows increased propensities to aggregate (Jensen et al., 1998; Jo et al., 2002; 
Kruger et al., 1998; Li et al., 2001; Sahay et al., 2015).  
 
1.3 α-synuclein aggregation and propagation  
Parkinson´s disease is characterized among others by pathological accumulation of 
misfolded αSyn proteins. These αSyn species are suggested to disrupt molecular 
mechanisms of specific cellular processes resulting in mitochondrial dysfunction, inhibition of 
protein degradation, ER-Golgi trafficking defects, disruption of vesicle-membrane fusion and 
impairment of histone acetylation (Chinta et al., 2010; Cooper et al., 2006; Devi et al., 2008; 
Emmanouilidou et al., 2010; Hsu et al., 2000; Kontopoulos et al., 2006; Martinez-Vicente et 
al., 2008; Snyder et al., 2003; Thayanidhi et al., 2010). αSyn aggregation was implicated in 
disruption of membranes, cytoskeleton changes and induction of oxidative stress (Chen et 
al., 2007; Junn and Mouradian, 2002; van Rooijen et al., 2009). αSyn was defined for a long 
time as a natively unfolded monomeric protein (Weinreb et al., 1996). This view was recently 
questioned by Bartels and colleagues showing αSyn as a helically folded tetramer that is 
resistant to amyloid-like aggregation (Bartels et al., 2011). Aggregation of αSyn is assumed 
to constitute the central pathological process in synucleinopathies. However, it is still not 
clear, which αSyn forms are the pathological species, how the aggregation pathway is 
initiated and whether LBs represent toxic or protective features. Accumulating evidence 
suggests oligomeric or protofibrillar forms of αSyn, rather than mature aggregates and fibrils, 
to be responsible for neurotoxicity (Choi et al., 2013; Conway et al., 2000; Karpinar et al., 
2009; Winner et al., 2011). A wide range of factors can trigger αSyn misfolding and 
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accumulation, e.g. mitochondrial dysfunction, abnormal proteasome function, oxidative 
stress, metals and neurotoxins such as 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
(Hashimoto et al., 1999; Kowall et al., 2000; Lee et al., 2002; Uversky et al., 2001; Vila et al., 
2000; Yamin et al., 2003a). The initiation of the αSyn aggregation pathway either starts in the 
cytoplasm or in association with the plasma membrane. In the cytoplasm, unfolded αSyn 
monomers interact to generate unstable dimers, which are further converted to oligomers, 
protofibrillar oligomers and mature amyloid fibrils. Further accumulation of amyloid fibrils 
results in deposits within LBs (Auluck et al., 2010). Up to a third of the cellular αSyn 
population in the cell is bound to synaptic membranes (Visanji et al., 2011). The N-terminal 
region of αSyn possesses a high binding affinity to phospholipids. The N-terminus binds to 
the membrane and triggers together with the central domain an unfolded-to-folded transition 
of αSyn resulting in the formation of two amphipathic α-helices that interact with the lipid 
micelles (Chandra et al., 2003; Lorenzen et al., 2014). At high concentrations, this 
conformational change subsequently leads to the formation of membrane-bound-β-sheet-rich 
structures that self-assemble to oligomers and fibrils (Zhu et al., 2003). αSyn does not 
accomplish its regular biological role in this composition but gains cytotoxic ability.  
Recently, a novel concept of progressive interneuronal spreading of Lewy pathology 
emerged that might contribute to the development and progression of PD and other 
synucleinopathies (Braak et al., 2003). Braak and colleagues suggest a prion-like 
propagation of pathological αSyn forms by transmission from one neuron to another. Several 
lines of evidence support this idea showing that propagation of pathological αSyn between 
cells leads to subsequent initiation of “LB-like aggregates” in the acceptor cells as well as 
progressive neurodegeneration (Desplats et al., 2009; Luk et al., 2012a; Luk et al., 2012b; 
Masuda-Suzukake et al., 2013; Recasens et al., 2014; Sacino et al., 2014).  
 
1.4 Posttranslational modifications of α-synuclein 
Posttranslational modifications (PTMs) represent consistent markers of αSyn pathology 
within LBs (Anderson et al., 2006; Duda et al., 2000; Fujiwara et al., 2002; Giasson et al., 
2000; Hasegawa et al., 2002; Paleologou et al., 2010). The precise contribution of different 
PTMs to the disease is still controversial. Several studies illustrated that PTMs influence the 
αSyn aggregation process and contribute to cellular neurotoxicity (Chen and Feany, 2005; 
Hodara et al., 2004; Norris et al., 2003; Oueslati et al., 2010). Major PTMs of αSyn include 
phosphorylation, ubiquitination, sumoylation, nitration, glycosylation or acetylation at multiple 
amino acid residues (Figure 2; Bartels et al., 2014; Dorval and Fraser, 2006; Duda et al., 
2000; Fujiwara et al., 2002; Giasson et al., 2000; Guerrero et al., 2013; Hasegawa et al., 





Figure 2. Posttranslational modifications of αSyn in Lewy bodies.  
The locations of amino acid residues of the main disease-associated PTMs of αSyn 
(phosphorylation, nitration, ubiquitination, sumoylation and acetylation) identified in LBs are 
shown (for details and references, see Schmid et al., 2013). 
 
PTMs such as phosphorylation, ubiquitination or sumoylation are primarily involved in 
modulating αSyn degradation by various proteolytic pathways. These PTMs are suggested to 
act as molecular switches that determine the preference of αSyn for a certain proteolytic 
process indicating their important role in balancing the protein level of αSyn. Since 
discovering posttranslationally modified αSyn in human cerebrospinal fluid and blood plasma 
(Borghi et al., 2000; El-Agnaf et al., 2003; Foulds et al., 2011), PTMs are considered as 
potential targets for biomarkers.  
 
1.4.1 Phosphorylation of α-synuclein 
The predominant αSyn modification in LBs is phosphorylation at the residue serine 129 
(S129). Approximately 90 % of αSyn found in LBs is phosphorylated at this residue, whereas 
only 4 % of the soluble monomeric αSyn is accordingly modified at physiological conditions 
(Anderson et al., 2006; Fujiwara et al., 2002). The molecular function of phosphorylation at 
S129 and its relevance in pathogenicity is still under debate (Tenreiro et al., 2014a). It was 
shown to play a role in regulation of αSyn localization, aggregation and toxicity. Studies in 
several mammalian models of PD have demonstrated a protective role of S129 
phosphorylation on neuronal dysfunction (Gorbatyuk et al., 2008; Kuwahara et al., 2012). In 
contrast, neurotoxicity tests in rats revealed no protective effect of S129 phosphorylation on 
αSyn toxicity (McFarland et al., 2009). In a Drosophila model of PD, a pathogenic role of 
αSyn S129 phosphorylation was observed (Chen and Feany, 2005). There, increase in the 
phosphorylation status of αSyn correlates with enhanced neurotoxicity. A number of 
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heterologous studies in yeast support a suppressive effect of S129 phosphorylation on αSyn 
aggregation, vesicle trafficking and cytotoxicity (Sancenon et al., 2012; Zabrocki et al., 2008). 
This modification modulates clearance of αSyn inclusions in yeast cells (Tenreiro et al., 
2014b). Phosphorylation at S129 suppressed the defects induced by impaired sumoylation 
such as increased number of cells with inclusions and reduced yeast growth 
(Shahpasandzadeh et al., 2014).  
In human cells, several kinase families participate in S129 phosphorylation of αSyn, including 
Polo-like kinases (PLKs), G protein-coupled receptor kinases (GRKs), casein kinases (CKs) 
1 and 2 and the leucine-rich repeat kinase 2 (LRRK2) (Oueslati et al., 2013; Pronin et al., 
2000; Qing et al., 2009; Waxman and Giasson, 2008). GRK5-dependent phosphorylation of 
αSyn plays an important role in the pathogenesis of PD (Arawaka et al., 2006). The yeast 
Cdc5, ortholog of human PLK2, phosphorylates αSyn at the conserved S129 residue and 
rescues αSyn toxicity upon overexpression of the kinase (Gitler et al., 2009; Wang et al., 
2012). Similar protective effects were provided by the yeast kinase Yck3, corresponding to 
human CK-1 (Zabrocki et al., 2008). Co-expression of PLK2 or GRK5 with αSyn in yeast 
significantly increased αSyn S129 phosphorylation (Shahpasandzadeh et al., 2014). 
Thereby, αSyn-induced cytotoxicity, which resulted from impairment of sumoylation, could be 
rescued by GRK5-mediated S129 phosphorylation. Recent studies in yeast revealed that 
expression of phosphorylation deficient variants, S129A or S129G, promotes αSyn-induced 
toxicity and inclusion formation (Tenreiro et al., 2014b). These findings support a protective 
function of S129 phosphorylation in yeast. 
 
1.4.2 Nitration of α-synuclein 
Nitrated αSyn represents another classical posttranslational modification found in LBs (Duda 
et al., 2000; Giasson et al., 2000). Nitration is a chemical process which incorporates a nitro 
group (NO2-) into proteins, lipids or nucleic acids via a radical-based mechanism. Tyrosine 
residues are the preferred nitration sites of proteins. Nitration changes the tyrosine residue 
into a negatively charged hydrophilic 3-nitrotyrosine (Figure 3). This modification modulates 
key properties of the amino acid including phenol group pKa redox potential, hydrophobicity 
and volume, which leads to profound structural and functional changes (Radi, 2012). 
Tyrosine nitration is a marker for nitrative stress, which is mediated by reactive nitrogen 
species (RNS) such as peroxynitrite anion (ONOO-, PON) or nitrogen dioxide (•NO2) formed 
as secondary products of the small gaseous molecule nitric oxide (•NO) metabolism 
(Ischiropoulos, 1998; Radi, 2004; Schildknecht et al., 2013). •NO is enzymatically generated 




Figure 3. Tyrosine nitration and di-tyrosine formation. 
(A) The free radicals nitric oxide (•NO) and superoxide (•O2-) react to generate peroxynitrite 
(ONOO-). Under physiological pH conditions, 20–30 % of peroxynitrite is protonated to 
peroxynitrous acid (ONOOH). This strong oxidant is chemically unstable and dissociates 
readily into the highly reactive nitrogen dioxide (•NO2) and hydroxyl radicals (•OH). •NO2 
radicals represent the actual nitrating species, which can react with tyrosine residues to 
generate tyrosyl radicals. In the presence of high concentrations of carbon 
dioxide/bicarbonate (CO2) in the cell, ONOO- can also interact with CO2, which either results 
in the production of NO2- and CO2 (two thirds of product) or •NO2 and CO3• - (one third of 
product). These radicals can interact with tyrosine residues to produce tyrosyl radicals. 
Further reaction with •NO2 results in the formation of 3-nitrotyrosine. (B) •NO2, CO3• - and •OH 
radicals react in radical-based mechanism with tyrosine residues and an unstable tyrosyl 
radical is formed. This tyrosyl radical either reacts with a •NO2 radical to form 3-nitrotyrosine 
or alternatively reacts with another tyrosyl residues, which results in the formation of a 
covalent 3,3´di-tyrosine bond (modified from Schildknecht et al., 2013). 
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Nitric oxide can serve as an endogenous signalling molecule involved in the regulation of 
physiological processes, e.g. cardiovascular, immune and nervous system (Martinez-Ruiz 
and Lamas, 2009; Moncada, 1999; Schildknecht and Ullrich, 2009). NO-mediated signalling 
processes are summarized as “redox regulation” (Frein et al., 2005; Schildknecht and Ullrich, 
2009).  
αSyn possesses four tyrosine residues at position 39, 125, 133 and 136 that were identified 
as nitration sites (Sevcsik et al., 2011). In vitro studies demonstrated that all four tyrosine 
residues are also phosphorylation targets (Ahn et al., 2002; Ellis et al., 2001; Mahul-Mellier et 
al., 2014; Nakamura et al., 2001; Negro et al., 2002; Takahashi et al., 2002). In vivo, only 
Y39 and Y125 were identified as phosphorylation sites (Kiely et al., 2013; Mahul-Mellier et 
al., 2014). Y39 is located within the N-terminal KTKEGV repeat region and the other three 
tyrosine residues are located at the C-terminal end of αSyn in close neighbourhood to the 
protective S129 phosphorylation site. Exposure of αSyn to nitrative agents results in the 
formation of αSyn oligomers and higher molecular weight αSyn species that are resistant to 
strong denaturing conditions. This suggests that αSyn proteins are covalently crosslinked 
(Paxinou et al., 2001; Souza et al., 2000a; Takahashi et al., 2002; Uversky et al., 2005; 
Yamin et al., 2003b). This oligomerization can be abolished in vitro when αSyn lacks the four 
tyrosine residues at positions 39, 125, 133 and 136 (Norris et al., 2003).  
Nitrating agents such as PON can nitrate tyrosine residues of αSyn to generate 3-
nitrotyrosine (3-NT). Alternatively, highly stable 3,3’-di-tyrosine oligomers can be formed 
including dimers, trimers and higher oligomeric species (Hodara et al., 2004; Pfeiffer et al., 
2000; Souza et al., 2000a). The majority of studies were performed in vitro after exposure of 
αSyn to nitrating agents leading to non-specific nitration at all tyrosine residues. It is still 
unclear, whether the nitration-modified αSyn intermediates are toxic and what are the 
functional consequences of these modifications. Even the precise positions or preferred 
combinations of the tyrosines involved in di-tyrosine formation in vivo are unknown yet.  
 
1.5 Detoxification of nitric oxide by hemoglobins  
Nitric oxide is a free radical which acts under normal conditions as signalling molecule in a 
diverse set of physiological processes (Martinez-Ruiz and Lamas, 2009; Schildknecht and 
Ullrich, 2009). High concentrations of nitric oxide harm the cell due to increased oxidative 
and nitrative stresses. Eukaryotes evolved many strategies for combating the damaging 
effects of nitric oxide. The use of detoxification enzymes is one valuable strategy to prevent 
the attack by nitric oxide. The flavohemoglobins are prominent among the detoxification 
enzymes. The heme of the hemoglobin domain binds •NO and catalyses the conversion of 
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•NO to the more stable nitrous oxide (N2O) via a NO dioxygenase reaction to detoxify the 
nitric oxide radical. In yeast, the gene YHB1 (yeast flavohemoglobin) is involved in oxidative 
and nitrative stress responses (Cassanova et al., 2005). This gene encodes a nitric oxide 
oxidoreductase, which protects against nitration of cellular targets and against cell growth 
inhibition under aerobic and anaerobic conditions (Liu et al., 2000). Expression of YHB1 is 
increased under aerobic conditions (Crawford et al., 1995; Zhao et al., 1996).  
A BLAST search for human homologues of yeast YHB1 revealed 49 % sequence similarity of 
the globin domain of Yhb1 to the human neuroglobin. Both Yhb1 and neuroglobin contain a 
globin domain and are members of the globin gene family. Neuroglobins are oxygen-binding 
proteins that are highly conserved among other vertebrates and are expressed in the central 
and peripheral nervous system. They provide protection against hypoxic induced cell injury in 
the brain, which is associated with ROS and RNS accumulation (Greenberg et al., 2008).  
 
1.6 Degradation pathways of α-synuclein 
One hypothesis of αSyn-induced toxicity includes gain of toxic function due to increased 
expression levels which is caused by the multiplication of the SNCA gene leading to 
enhanced amounts of misfolded or aggregated αSyn (Outeiro and Lindquist, 2003; Petroi et 
al., 2012; Singleton et al., 2003). This is further confirmed by findings which demonstrate that 
inhibition of degradation pathways resulting in inefficient protein clearance is sufficient to 
trigger neurotoxicity (Vilchez et al., 2014). The understanding of αSyn turnover machinery is 
an essential aspect to uncover the pathological mechanism of PD.  
In eukaryotic cells, degradation of non-functional or potentially toxic proteins is primarily 
carried out by two pathways, the ubiquitin-proteasome or the autophagy-lysosome/vacuole 
system (Goldberg, 2003; Klionsky and Emr, 2000). Both pathways were suggested to 
contribute to αSyn degradation (Webb et al., 2003). The ubiquitin-proteasome pathway 
mostly degrades short-lived, soluble proteins (Goldberg, 2003). Numerous studies 
demonstrated that the 26S proteasome is important for αSyn degradation (Bennett et al., 
1999; McLean et al., 2001; Tofaris et al., 2001). It is considered as the main degradation 
pathway for αSyn under normal conditions (Ebrahimi-Fakhari et al., 2011). The involvement 
of the 26S proteasome in αSyn toxicity is conserved in yeast (Chen et al., 2005; Outeiro and 
Lindquist, 2003; Sharma et al., 2006). 
The ubiquitin-proteasome pathway shows only a minor contribution in yeast compared to the 
autophagy-vacuole system for degradation of αSyn aggregates (Petroi et al., 2012). 
Generally, the autophagy-lysosome/vacuole system is suggested to degrade longer-lived 
macromolecules such as large oligomeric and aggregated species (Klionsky and Emr, 2000; 
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Lee et al., 2004). It takes care of misfolded proteins under pathological conditions when the 
ubiquitin-proteasome system is impaired as during αSyn-induced toxicity (Ebrahimi-Fakhari 
et al., 2011; Lee et al., 2004). Numerous studies demonstrated a contribution of the 
autophagy-lysosome/vacuole system to αSyn degradation. The autophagy-stimulating drug 
rapamycin promotes αSyn clearance (Webb et al., 2003) and causes reduction of αSyn 
aggregates (Zabrocki et al., 2005).  
PTMs serve as molecular switches that determine the preference of αSyn degradation for a 
certain proteolytic pathway. It was shown that de-ubiquitinated αSyn is preferentially 
degraded by autophagy system, whereas mono-ubiquitinated αSyn favours the proteasome 
(Rott et al., 2011). S129-phorphorylated αSyn is targeted to the 26S proteasome in an 
ubiquitin-independent manner (Machiya et al., 2010). In yeast, increased phosphorylation of 
αSyn mediated by PLK2 leads to aggregate clearance by the autophagy-vacuole system and 
suppressed cytotoxicity (Oueslati et al., 2013). Further studies in yeast revealed that 
sumoylation preferentially directs αSyn aggregates towards autophagy (Shahpasandzadeh et 
al., 2014). Impaired αSyn sumoylation results in growth inhibition and increased aggregate 
formation. Phosphorylation at S129 suppresses this defect by shifting the fate of αSyn to 
increased ubiquitination and proteasome degradation (Shahpasandzadeh et al., 2014).  
 
1.7 Saccharomyces cerevisiae as model for Parkinson´s disease  
The budding yeast Saccharomyces cerevisiae is a simple eukaryotic model system which is 
used to uncover the correlation between structural features of αSyn and its toxicity. Although 
a homologue of the SNCA gene is not present in the yeast genome (Lavedan, 1998), it 
provides a unique tool to study the molecular basis of PD in vivo (Franssens et al., 2010). 
Protein quality control systems are highly conserved between yeast and humans manifesting 
yeast as valuable model system for studying protein misfolding and cellular pathways 
associated with neurodegenerative diseases (Botstein et al., 1997; Tenreiro et al., 2013). 
Due to its high susceptibility to genetic manipulations, the short generation time of ~90 
minutes and a wide range of genetic tools available, yeast is ideally convenient to study the 
function of genes implicated in human disease (Mager and Winderickx, 2005).  
The yeast genome is well characterized. It consists of 16 chromosomes and contains 6217 
genes (Goffeau et al., 1996). 44 % of the yeast genes reveal significant sequence similarities 
to human genes (Hughes, 2002). Yeast and humans share significant cellular pathways that 
regulate key aspects of eukaryotic cell biology, including cell cycle, vesicular transport and 
programmed cell death (Bonifacino and Glick, 2004; Botstein et al., 1997; Brodsky and 
Skach, 2011; Hartwell, 2002; Munoz et al., 2012).  
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Heterologous expression of different forms of human αSyn in yeast cells recapitulates central 
features of PD, including dose-dependent toxicity and aggregation (Outeiro and Lindquist, 
2003; Petroi et al., 2012). In yeast, aggregation of αSyn causes vesicle traffic defects, 
proteasome dysfunction and damage to cellular membranes (Cooper et al., 2006; Gitler et 
al., 2008; Outeiro and Lindquist, 2003; Soper et al., 2008). Aggregation of αSyn induces 
mitochondrial dysfunction and the formation of reactive oxygen and nitrogen species in yeast 
cells (Flower et al., 2005; Hsu et al., 2000; Junn and Mouradian, 2002; Outeiro and Lindquist, 
2003; Parihar et al., 2008; Parihar et al., 2009; Su et al., 2010; Witt and Flower, 2006), which 
is similar to mammalian cells.  
To probe the toxicity of αSyn in yeast, transgenic yeast cells were engineered carrying 
human αSyn (Outeiro and Lindquist, 2003; Petroi et al., 2012). Thereby, αSyn was C-
terminally fused to GFP via KLID linker. The fusion construct is integrated into the genome or 
is externally present on a plasmid under the control of galactose-inducible promoter (GAL1-
promoter). The benefit of the GAL1-promoter is that it can be switched on and off by 
supplementing galactose into the medium as an inducer of expression. This allows 
investigating the situation in the presence or absence of the gene of interest.  
When expressing a single copy of the gene in yeast, αSyn associates with plasma 
membrane in a highly selective manner and has no obvious effect on yeast viability 
(Figure 4). Expression of two GAL1-driven copies causes formation of cytoplasmic inclusions 
and expression of three copies results in yeast growth impairment and strong increase in 
aggregate formation. Thus, αSyn toxicity increases in a copy number-dependent manner, 
similar to a familial form of PD linked with allele multiplication of the wild-type SNCA locus 
driven by its own human promoter (Chartier-Harlin et al., 2004; Hardy et al., 2006; Singleton 
et al., 2003). Three GAL1-driven copies of wild-type αSyn and two copies of A53T were 
determined as thresholds for cytotoxicity and aggregation in yeast (Petroi et al., 2012). 
Similar to wild-type and A53T αSyn, expression of E46K mutant results in significant growth 




Figure 4. Localization of αSyn in yeast and its impact on growth. 
(A) GFP-fused human αSyn (SNCA) is expressed from the galactose-inducible yeast GAL1-
promoter (PGAL1). GFP was C-terminally fused to αSyn via KLID linker. (B) Fluorescence 
microscopy of time-dependent aggregate formation of αSyn, expressed from a high-copy 
plasmid (2µ). After one hour (h) induction of αSyn expression, the protein is localized at the 
plasma membrane. Two hours of αSyn expression results in nucleation of αSyn at the 
plasma membrane and formation of small membrane-localised aggregates. After six hours of 
αSyn expression, large cytoplasmic aggregates are formed. Scale bar = 1 µm. (C) Growth 
behaviour of yeast cells expressing increasing copy numbers of GAL1-driven wild-type αSyn 
fused to GFP (WT-GFP) and two different familial mutants of αSyn. Growth analysis 
indicates decreased growth with increasing copy number of wild-type and A53T αSyn but not 
A30P; oe, overexpression (Popova et al., 2015).  
 
An unusual feature of the yeast system, which is different from PD and other models, is that 
the A30P variant only forms inclusions when highly expressed and fails to display a growth 
inhibition in yeast, because aggregation of A30P is only transient (Dixon et al., 2005; Petroi 
et al., 2012). Expression of A30P αSyn has different toxicity properties in yeast compared to 
human cells. Whereas wild-type and A53T αSyn are delivered to the plasma membrane, 
A30P is located in the cytoplasm. Three integrated copies of A30P αSyn do not impair yeast 
growth. Only overexpression from a high-copy number plasmid results in formation of 
fluorescent foci, similar to the foci obtained by the other variants. However, the impact of 
A30P overexpression on yeast growth is not considerable in comparison with wild-type and 
A53T variants (Petroi et al., 2012). 
Introduction 
17 
1.8 Aims of the study 
A pathological hallmark of PD is the accumulation of posttranslationally modified αSyn 
aggregates in susceptible neurons in the form of LBs. PTMs of αSyn are important triggers 
for aggregation and cytotoxicity properties. Nitrative stress leading to αSyn nitration is 
implicated in the pathogenesis of the disease. Four tyrosine residues of αSyn were identified 
as nitration sites. αSyn nitration results in the formation of 3-NT or alternatively in the 
formation of covalently crosslinked di-tyrosine dimers. It is still not resolved whether the 
nitration-modified αSyn intermediates are toxic or what is the functional consequence of 
these modifications. The precise positions or preferred combinations of the tyrosines 
involved in di-tyrosine formation in vivo are also still elusive. Moreover, the interplay between 
nitration and other PTMs such as phosphorylation at the protective S129 residue was never 
sufficiently addressed.  
In this study, the budding yeast was used as reference cell to study the impact of nitration on 
αSyn aggregation and αSyn-mediated toxicity. The toxic wild-type αSyn and the A30P 
mutant that is not toxic in yeast were compared. In the first part of the thesis, nitration, 
phosphorylation and dimerization sites were determined in vivo using LC-MS. In vitro nitrated 
αSyn after PON-exposure was used to examine the effect of nitration on αSyn dimer and 
oligomer formation. αSyn tyrosine mutants inhibited in modification were explored by growth 
and aggregation tests to address the question, whether nitration is involved in αSyn 
aggregation and toxicity. A yeast strain was used that lacks YHB1, a gene involved in 
nitrative stress response, to investigate αSyn-induced cytotoxicity under increased 
intracellular nitrative stress. Tyrosine and S129 mutants impaired in modifications were 
analyzed by growth, aggregation and immunoblot analysis using a phospho-S129 antibody in 
order to elucidate, whether there is an interplay between nitration and phosphorylation at 
S129. In the last part of the thesis, it was examined how tyrosine modifications affect 
autophagy or proteasome-mediated clearance of αSyn aggregates.  
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2 Materials and Methods 
2.1 Materials 
2.1.1 Companies of chemicals, molecular biological substances and equipment 
Chemicals for the preparation of buffers, solutions and media were obtained from the 
companies Carl Roth GmbH & CO. KG (Karlsruhe, Germany), Invitrogen (Carlsbad, USA), 
Roche (Basel, Switzerland), Sigma-Aldrich (St. Louis, USA), AppliChem GmbH 
(Darmstadt, Germany), Becton Dickinson (Franklin Lakes, USA) and Merck KGaA 
(Darmstadt, Germany). Agarose was used from Biozyme Scientific GmbH (Hessisch 
Oldendorf, Germany). Bradford solution “Roti®-Quant” for the determination of protein 
concentration was used from Carl Roth GmbH & CO. KG (Karlsruhe, Germany). 
Restriction enzymes and polymerases were purchased from Thermo Fisher Scientific 
(Waltham, USA). For RNA degradation, RNase A from Roche (Basel, Switzerland) was 
used. Proteases, trypsin and Asp-N, were purchased from Serva Electrophoresis GmbH 
(Heidelberg, Germany) and Sigma-Aldrich (St. Louis, USA). Primary antibodies were 
purchased from Abcam (Cambridge, UK), JaICA (Shizuoka, Japan), Upstate 
Biotechnology Inc (Lake Placid, USA), Wako Pure Chemical Industries Ltd (Osaka, 
Japan), Santa Cruz Biotechnology Inc (Dallas, USA), AnaSpec Inc (Fremont, USA) and 
Thermo Fisher Scientific (Waltham, USA). Secondary antibodies were purchased from 
Invitrogen (Carlsbad, USA) and Jackson ImmunoResearch Laboratories (West Grove, 
USA). Synthetic oligonucleotides were purchased from Sigma-Aldrich (St. Louis, USA). For 
cloning, the GeneArt® Seamless Cloning and Assembly Enzyme Mix from Invitrogen 
(Carlsbad, USA) was used. Substitution of amino acids was performed with the QuikChange 
II Site-Directed Mutagenesis Kit from Agilent Technologies (Santa Clara, USA). As DNA-
size and protein-weight standards the DNA-marker “GeneRuler 1kb DNA ladder” and the 
protein-marker “PageRuler Prestained Protein Ladder” were used from Thermo Fisher 
Scientific (Waltham, USA). Saccharomyces cerevisiae wild-type and deletion strains were 
purchased from EUROSCARF (Frankfurt, Germany). Mammalian expression vector 
pcDNA3.1 was obtained from Invitrogen (Carlsbad, USA).  
Solutions were filtered to sterility using Filtropur S 0.2 and S 0.45 filters from Sarstedt AG & 
Co (Nümbrecht, Germany). For plasmid DNA purification from Escherichia coli and DNA 
extraction from agarose gels the kits “QIAGEN Plasmid Mini Prep Kit” and “QIAquick Gel 
Extraction Kit” from QIAGEN (Hilden, Germany) were used. DNA concentrations were 
measured using the “NanoDrop ND-1000 photospectrometer” from Peqlab Biotechnologie 
GmbH (Erlangen, Germany). PCR reactions were performed using the “MWG Biotech Inc 
Primus 96 Thermal Cycler” from MWG-Biotech (Ebersberg, Germany). Gel electrophoresis 
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was done in the “Mini-Sub Cell GT” chamber using the “Powerpac 300” power supply from 
Bio-Rad Laboratories (Hercules, USA). SDS-PAGE and protein immunoblotting were 
performed using the “Mini-PROTEAN® 3 Cell”, “Mini Trans-Blot® Electrophoretic Cell” and 
the “Powerpac 300” power supply from Bio-Rad Laboratories (Hercules, USA). For protein 
transfer, the nitrocellulose membrane “AmershamTM ProtranTM 0.45 µm NC” from GE 
Healthcare (Little Chalfont, UK) and the “AmershamTM Hybond-PTM 0.45 µm PVDF” from GE 
Healthcare (Little Chalfont, UK) were used. Chemiluminescence was detected using the 
“AmershamTM HyperfilmTM ECL” from GE Healthcare (Little Chalfont, UK). Exposing 
HyperfilmsTM for immunoblot techniques occurred with the “Optimax X-ray Film Processor” 
from PROTEC GmbH & Co. KG (Oberstenfeld, Germany). Optical density was measured by 
T80 UV/VIS spectrometer from PG Instruments Ltd (Lutterworth, UK) or alternatively by the 
microplate reader “Infinite® M200” from Tecan Group (Männedorf, Switzerland). 
Centrifugations were performed with the centrifuge “Biofuge pico” from the company 
Heraeus (Hanau, Germany), “Centrifuge 5804R” from Eppendorf AG (Hamburg, Germany), 
“Centrifuge 4K15” from Sigma Laborzentrifugen GmbH (Osterode am Harz, Germany) or 
“Sorvall RC-3B Plus Refrigerated Centrifuge” from Thermo Fisher Scientific (Waltham, 
USA). Incubation of agar plates at 37 °C was performed in the incubator “BD 53/E2” from 
BINDER GmbH (Tuttlingen, Germany) and incubation at 30 °C was performed in the 
incubator “BE 400” from Memmert GmbH + Co. KG (Schwabach, Germany). Other 
instrumentation, manufacturers or certain variations are named in the further work. 
 
2.1.2 Strains, plasmids and oligonucleotides 
The Saccharomyces cerevisiae strains, plasmids and oligonucleotides used in this study are 
listed in Table 1 to 3. Escherichia coli strain DH5α [Δ80dlacZ ΔM15, recA1, endA1, gyrA96, 
thi-1, hsdR17 (rK-, mK+), supE44, relA1, deoR, Δ(lacZYA-argF) U169] was used for general 
cloning procedures and purification of plasmid DNA (Meselson and Yuan, 1968; Woodcock 
et al., 1989). Human αSyn cDNA sequence and the corresponding A30P sequence were 
expressed from yeast high expression vector pME2795 (2µ) under the GAL1-promoter and 
CYC1 terminator as described previously (Petroi et al., 2012). YHB1 sequence was amplified 
on genomic DNA from Saccharomyces cerevisiae and cloned into pME2788 low expression 
vector (CEN/ARS) or pME2792 high expression vector (2µ) proceeded by GAL1-promoter 
and CYC1 terminator (Mumberg et al., 1994). NGB was amplified on cDNA sequence and 
cloned into pME2788 low expression vector (CEN/ARS). Additionally, NGB was cloned into 
the mammalian high expression vector pcDNA3.1 (Invitrogen), which is proceeded by CMV 
promoter. The 4(Y/F) αSyn mutant constructs were generated by site-directed mutagenesis 
using QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies). Plasmids 
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pME3763, pME3764, pME4095 and pME4101 were used as templates to substitute 
successively the four tyrosines (Y39, Y125, Y133, and Y136) by phenylalanine. Plasmids 
pME3763, pME3764 and pME4095 were used as templates to substitute serine 129 to 
alanine. For growth and microscopy studies, αSyn variants were used that are C-terminally 
tagged with GFP via the KLID linker (Petroi et al., 2012). For Ni2+-NTA affinity 
chromatography, αSyn and A30P were C-terminally fused to His6-tag using pME3760 and 
pME3761 as templates. All constructs were verified by DNA sequencing. As negative control, 
the empty vector pME2788, pME2792 and pME2795, or the GFP expressing vector 
pME3759 was used. 
 
Table 1. Yeast strains 
Strain Genotype Source 
BY4741 MATa; his3Δ 1; leu2Δ0; met15Δ0; ura3Δ0 EUROSCARF 
∆yhb1 
Y05887 (EUROSCARF): BY4741; MATa; his3D1; leu2D0; 




Table 2. Plasmids 
Plasmid Description Source 
pME2788 
pRS413-GAL1-promoter, CYC1-terminator, HIS3, CEN/ARS, 
pUC origin, AmpR 
(Mumberg et al., 
1994) 
pME2792 
pRS426-GAL1-promoter, CYC1-terminator, HIS3, 2µm, pUC 
origin, AmpR 
(Mumberg et al., 
1994) 
pME2795 
pRS426-GAL1-promoter, CYC1-terminator, URA3, 2µm, pUC 
origin, AmpR 
(Mumberg et al., 
1994) 
pME3759 pME2795 with GAL1::GFP (Petroi et al., 2012) 
pME3760 pME2795 with GAL1::SNCAWT (Petroi et al., 2012) 
pME3761 pME2795 with GAL1::SNCAA30P (Petroi et al., 2012) 
pME3763 pME2795 with GAL1::SNCAWT::GFP (Petroi et al., 2012) 
pME3764 pME2795 with GAL1::SNCAA30P::GFP (Petroi et al., 2012) 
pME4088 pME2795 with GAL1::SNCAWTY125F::GFP (Lazaro et al., 2014) 
pME4095 pME2795 with GAL1::SNCAWT::6 x HIS 
(Shahpasandzadeh 
et al., 2014) 
pME4101 pME2795 with GAL1::SNCAA30P::6 x HIS This study 
pME4104 pME2788 with GAL1::NGB This study 
pME4351 pME2788 with GAL1::YHB1 This study 
pME4352 pME2795 with GAL1::SNCAWTY39/125/133/136F::GFP This study 
pME4353 pME2795 with GAL1::SNCAWTY39/125/133/136F::6 x HIS This study 
pME4354 pME2795 with GAL1::SNCAA30PY39/125/133/136F::6 x HIS This study 
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Plasmid Description Source 
pME4355 pME2795 with GAL1::SNCAA30PY39/125/133/136F::GFP This study 
pME4356 pcDNA3.1 Invitrogen 
pME4357 pcDNA3.1. with CMV::NGB::mCherry This study 
pME4451 pME2795 with GAL1::SNCAWTY39F::GFP This study 
pME4452 pME2795 with GAL1::SNCAWTY39F::6 x HIS This study 
pME4453 pME2795 with GAL1::SNCAWTY125F::6 x HIS This study 
pME4454 pME2795 with GAL1::SNCAWTY125/133/136F::GFP This study 
pME4455 pME2795 with GAL1::SNCAWTY125/133/136F::6 x HIS This study 
pME4456 pME2795 with GAL1::SNCAWTS129A::GFP This study 
pME4457 pME2795 with GAL1::SNCAWTS129A::6 x HIS This study 
pME4460 pME2795 with GAL1::SNCAWT Y133F::6 x HIS This study 
pME4461 pME2795 with GAL1:: SNCAWT Y133F ::GFP This study 
pME4462 pME2795 with GAL1::SNCAWT Y136F::6 x HIS This study 
pME4463 pME2795 with GAL1:: SNCAWT Y136F ::GFP This study 
pME4466 pME2795 with GAL1:: SNCAA30P S129A ::GFP This study 
pME4467 pME2795 with GAL1:: SNCAA30P Y133F ::GFP This study 
pME4470 pME2795 with GAL1::SNCAWT::mCherry  This study 
pME4471 cDNA_NGB (neuroglobin) This study 
pME4472 pME2792 with GAL1::YHB1 This study 
 
 
Table 3. Oligonucleotides 
Name Size Sequence (5’- 3’) Use 
NTTP79 21-mer GCT GCA TAA CCA CTT TAA CTA GAL1 forward primer used for sequencing 
BP20 
 
18-mer GTT AGA GCG GAT GTG GGG CYC1 reverse primer used for sequencing 
BP40 27-mer 
AAG GAT CCA TGC TAG CCG 
AAA AAA CCC  
YHB1 forward primer used for YHB1 
amplification with BamHI restriction site  
BP41 28-mer 
GAC TCG AGC TAA ACT TGC 
ACG GTT GAC A 
YHB1 reverse primer used for YHB1 
amplification with XhoI restriction site  
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Name Size Sequence (5’- 3’) Use 
BP42 33-mer 
TTA CTA GTA TGG ATG TAT TCA 
TGA AAG GAC TTT 
SNCA forward primer used for C-terminal 
6 x HIS tag with SpeI restriction  
BP43 45-mer 
TTC TCG AGT TAG TGG TGG 
TGG TGG TGG TGG GCT TCA 
GGT TCG TAG  
SNCA reverse primer used for C-terminal 
6 x HIS tag with XhoI restriction site  
BP46 37-mer 
CAA AAG AGG GTG TTC TCG 
CAG TAG GCT CCA AAA CCA A 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 39 to 
alanine in SNCA 
BP47 37-mer 
TTG GTT TTG GAG CCT ACT 
GCG AGA ACA CCC TCT TTT G 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 39 to 
alanine in SNCA 
BP59 34-mer 
GCT TAT GAA ATG CCT GCC 
GAG GAA GGG TAT CAA G 
Quick change mutagenesis forward primer 
used for substitution of serine129 to 
alanine in SNCA 
BP60 34-mer 
CTT GAT ACC CTT CCT CGG 
CAG GCA TTT CAT AAG C 
Quick change mutagenesis reverse primer 
used for substitution of serine129 to 
alanine in SNCA 
BP61 29-mer 
AAA CTA GTA TGG AGC GCC 
CGG AGC CCG AG 
NGB forward primer used for NGB 
amplification with SpeI restriction site  
BP62 26-mer 
AAC TCG AGT TAC TCG CCA 
TCC CAG CC 
NGB reverse primer used for NGB 
amplification with XhoI restriction site  
BP69 28-mer 
GAC AAT GAG GCT TTT GAA 
ATG CCT TCT G 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 125 to 
phenylalanine in SNCA 
BP70 28-mer 
CAG AAG GCA TTT CAA AAG 
CCT CAT TGT C 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 125 to 
phenylalanine in SNCA 
BP71 29-mer 
GAG GGT GTT CTC TTT GTA 
GGC TCC AAA AC 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 39 to 
phenylalanine in SNCA 
BP72 29-mer 
GTT TTG GAG CCT ACA AAG 
AGA ACA CCC TC 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 39 to 
phenylalanine in SNCA 
BP73 38-mer 
CTT CTG AGG AAG GGT TTC 
AAG ACT TCG AAC CTG AAG CC 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 133 and 
136 to phenylalanine in SNCA 
BP74 38-mer 
GGC TTC AGG TTC GAA GTC 
TTG AAA CCC TTC CTC AGA AG 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 133 and 
136 to phenylalanine in SNCA 
BP147 34-mer 
TGG AAT TCT GCA GAT ATG 
GAG CGC CCG GAG CCC G 
NGB forward primer used for NGB 
amplification with subsequent seamless 
cloning with EcoRV restriction  
BP148 30-mer 
CTT GCT CAC ATC GAT CTC 
GCC ATC CCA GCC 
NGB reverse primer used for NGB 
amplification with subsequent seamless 
cloning with EcoRV restriction 
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Name Size Sequence (5’- 3’) Use 
BP149 33-mer 
ATC GAT GTG AGC AAG GGC 
GAG GAG GAT AAC ATG 
mCherry forward primer used for mCherry 
amplification with subsequent seamless 
cloning with EcoRV restriction 
BP150 33-mer 
GCC ACT GTG CTG GAT CTA 
CTT GTA CAG CTC GTC 
mCherry reverse primer used for mCherry 
amplification with subsequent seamless 
cloning with EcoRV restriction 
BP151 19-mer TAA TAC GAC TCA CTA TAG G T7 forward primer used for sequencing 
BP240 31-mer 
CTT CTG AGG AAG GGT TTC 
AAG ACT ACG AAC C 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 133 to 
phenylalanine in SNCA 
BP241 31-mer 
GGT TCG TAG TCT TGA AAC 
CCT TCC TCA GAA G 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 133 to 




GAA GGG TAT CAA GAC TTC 
GAA CCT GAA GCC TAA 
Quick change mutagenesis forward primer 
used for substitution of tyrosine 136 to 
phenylalanine in SNCA 
BP248 33-mer 
TTA GGC TTC AGG TTC GAA 
GTC TTG ATA CCC TTC 
Quick change mutagenesis reverse primer 
used for substitution of tyrosine 136 to 
phenylalanine in SNCA 
 
2.1.3 Enzymes  
Table 4. Enzymes 








Restriction enzymes     
BamHI                                    
(10x buffer BamHI) 
10 U/µL             
4000 U 
37 °C G´G A T C C 
Thermo Fisher 
Scientific  
EcoRV                                     
(10x buffer R (red)) 
10 U/µL           
2000 U 
37 °C GAT´ATC 
Thermo Fisher 
Scientific 
XhoI                                           
(10x buffer R (red)) 
10 U/µL        
2000 U 
37 °C C´T C G A G 
Thermo Fisher 
Scientific 
SpeI                                         
(10x Tango buffer) 
10 U/µL            
400 U 
37 °C A´C T A G T 
Thermo Fisher 
Scientific 
DpnI                                        
(10x Tango buffer) 
10 U/µL              
500 U 









72 °C  
Thermo Fisher 
Scientific 
T4 DNA ligase                  
(10x T4 DNA ligase 
buffer) 
1 U/µL               
500 U 
16 °C / 22 °C  
Thermo Fisher 
Scientific 
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(5x HF buffer) 
2 U/µL               
500 U 
72 °C  
Thermo Fisher 
Scientific 
PfuTurbo Cx hotstart 
DNA polymerase 
(10x PfuTurbo Cx 
reaction buffer) 
2.5 U/µL            
100 U 
68 °C  
Agilent 
Technologies 
RNase A 50 U/mg 25 °C   Roche 
Trypsin                          
(Trypsin resuspension 
buffer) 





(100 mM NH4HCO3 
[pH 8.5]) 
1:100 37 °C  Sigma-Aldrich 
 
2.1.4 Media  
If not indicated otherwise, buffers and media were dissolved in H2O and autoclaved for 
20 minutes at 121 °C and 2 bar. Thermally unstable substances were dissolved and filtered 
to sterility using Filtropur S 0.2 filters (Sarstedt AG & Co). For cultivation of bacterial and 
yeast strains the following media were used. 
 
Table 5. Media 
Ingredients Agar-plates Liquid medium 
   
LB medium (Escherichia coli)   
Bacto-Tryptone 10 g 10 g 
Yeast extract 5 g 5 g 
NaCl 10 g 10 g 
Agar 20 g  
H2O ad 1000 mL ad 1000 mL 
   
SC medium (Saccharomyces cerevisiae)   
YNB-aa-as (yeast nitrogen base w/o AA and AS) 0.9 g 1.5 g 
Ammonium sulfate 3.0 g 5.0 g 
200 mM Inositol 0.6 mL 1.0 mL 
Amino acid powder mix 1.2 g 2.0 g 
Glucose/Galactose 12 g  
Raffinose/Galactose  20 g 
Agar 9 g  
H2O ad 600 mL ad 1000 mL 
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Ingredients Agar-plates Liquid medium 
   
YEPD medium (Saccharomyces cerevisiae)   
Bacto-Peptone 6 g 6 g 
Yeast extract 3 g 3 g 
Glucose/Galactose 6 g 6 g 
Agar 6 g  
H2O ad 300 mL ad 300 mL 
   
MV medium (Saccharomyces cerevisiae) [pH 7.2]   
YNB-aa-as (yeast nitrogen base w/o AA and AS) 1.45 g  
Ammonium sulfate  5.52 g  
Succinic acid  10 g  
Potassium hydroxide  10 g  
Glucose/Galactose  20 g  
Agar  20 g  
H2O ad 1000 mL  
adjust pH with 10 mM KOH   
   
Amino acid mix (-His, -Leu, -Trp, -Ura)   
Adenine (Ade), L-Alanine (Ala),                                    2 g (each)  
L-Argenine (Arg), L-Asparagine (Asn),                            
L-Aspartic acid (Asp), L-Cysteine (Cys),                         
L-Glutamine (Gln), L-Glutamic acid (Glu),                
Glycine (Gly), L-Isoleucine (Ile),                                       
L-Lysine (Lys), L-Methionine (Met),                                
L-Phenylalanine (Phe), L-Proline (Pro),                              
L-Serine (Ser), L-Threonine (Thr),                                   
L-Tyrosine (Tyr), L-Valine (Val),    
para-Aminobenzoic acid (Paba) 0.2 g  
 
2.1.5 Antibiotics 
For antibiotic selection, stock solutions of all antibiotics used in this study were prepared. 
Autoclaved media had to cool down to approx. 50 °C before the antibiotic stock solutions 
were added. The final concentrations for all antibiotics are listed below. 
 
Table 6. Antibiotics 
Antibiotic stock solution storage temperature final concentration 
Ampicillin 100 mg/mL -20 °C 100 µg/mL 
G418 100 mg/mL -20 °C 200 µg/mL 
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2.1.6 Antibodies 
Table 7. Primary antibodies 
Antibody Animal Type Dilution Source 
anti-3-nitrotyrosine mouse monoclonal 1:1400 Abcam 
anti-di-tyrosine mouse monoclonal 1:1000 JaICA 
anti-nitroY39 αSyn mouse monoclonal 1:1000 Upstate Biotechnology Inc 
anti-phosphoY133 αSyn rabbit polyclonal 1:1000 Abcam 
anti-phosphoY125 αSyn rabbit polyclonal 1:1000 Abcam 
anti- phosphoS129 αSyn mouse monoclonal 1:2500 Wako Pure Chemical Industries Ltd 
anti-αSyn rabbit polyclonal 1:2500 Santa Cruz Biotechnology Inc 
anti-αSyn mouse monoclonal  1:2000 AnaSpec Inc 
anti-GAPDH mouse monoclonal 1:5000 Thermo Fisher Scientific 
 
 
Table 8. Secondary antibodies 
Antibody Type Dilution Source 
HRP-conjugated      
















2.2.1 Cultivation of cells 
2.2.1.1 Cultivation of Escherichia coli 
Escherichia coli strains were grown in 5 mL Lysogeny Broth (LB) medium (1 % (w/v) bacto-
tryptone, 0.5 % (w/v) yeast extract, 1 % (w/v) NaCl, for solid medium: 2 % (w/v) agar) on a 
rotation shaker (Infors AG) at 37 °C overnight (Bertani, 1951). In this study, the Escherichia 
coli strain DH5α was used for general cloning procedures and purification of plasmid DNA. 
To select the colonies harboring the plasmid of interest, 100 µg/mL of ampicillin (Carl Roth 
GmbH & CO. KG) was added to LB medium. Solid LB media contained 2 % agar (Carl Roth 
GmbH & CO. KG). 
 
2.2.1.2 Cultivation of Saccharomyces cerevisiae 
Saccharomyces cerevisiae strains were cultivated in 10 mL YEPD medium (2 % (w/v) bacto-
peptone, 1 % (w/v) yeast extract, 2 % (w/v) glucose, for solid medium: 2 % (w/v) agar) at 
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30 °C on a rotation shaker (Fröbel Labortechnik GmbH) overnight. On solid YEPD medium 
Saccharomyces cerevisiae strains were cultivated at 30 °C for two to three days. In this 
study, strains BY4741 (EUROSCARF) and ∆yhb1 (5887-EUROSCARF) were used. For 
cultivation of the ∆yhb1 strain, 200 µg/mL G418 (Geneticin® Selective Antibiotic, Thermo 
Fisher Scientific) was added to YEPD medium. After transformation, plasmid carrying strains 
were selected in Synthetic Complete (SC) medium (0,15 % (w/v) YNB-aa-as (yeast nitrogen 
base w/o AA and AS), 0.5 % (w/v) ammonium sulfate, 0.2 mM inositol, 0.2 % (w/v) amino 
acid powder mix, for liquid medium: 2 % (w/v) raffinose, for solid medium: 2 % (w/v) glucose, 
1.5 % (w/v) agar) supplemented with appropriate amino acids (Guthrie and Fink, 1991). 
Transformants harboring αSyn constructs were selected in SC medium lacking uracil (SC-
Ura). For growth of cells co-expressing αSyn with YHB1 or NGB, SC medium lacking uracil 
and histidine (SC-Ura-His) was used. As carbon source SC medium contained either 2 % 
raffinose / 2 % glucose for growth without αSyn induction or 2 % galactose to induce the 
GAL1-promoter of αSyn. Expression of αSyn was induced for five hours by shifting overnight 
cultures from 2 % raffinose- to 2 % galactose-containing medium at an OD600 of 0.1. Cell 
growth was controlled by measuring the optical density at 600 nm using the T80 UV/VIS 
spectrometer (PG Instruments Ltd).  
 
2.2.1.3 Cell storage 
For long-term storage Escherichia coli and Saccharomyces cerevisiae strains were stored 
at -80 °C in 1.8 mL CryoPure Tubes (Sarstedt AG & Co). To prevent freezing damage, 
Escherichia coli cells were mixed with 50 % (v/v) glycerol (Carl Roth GmbH & CO. KG). For 
storage of Saccharomyces cerevisiae, cells were mixed with 15 % (v/v) glycerol. 
 
2.2.2 Nucleic acid methods 
2.2.2.1 Purification of DNA 
Linear DNA fragments were purified using the QIAquick Gel Extraction Kit (QIAGEN) 
according to the manufacturer’s instructions. QIAquick Kits contain a silica membrane 
assembly which binds DNA in high-salt buffer and allows elution of the DNA with water. The 
purification procedure removes primers, nucleotides, enzymes, mineral oil, salts, agarose, 
ethidium bromide, and other impurities from DNA samples. To elute DNA from the columns, 
30 µL dH2O was used. The concentration of purified DNA was determined by a NanoDrop 
ND-1000 spectrophotometer (Peqlab Biotechnologie GmbH). Purified DNA was stored at      
-20 °C or used for further procedures. 
 
Materials and Methods 
28 
2.2.2.2 Isolation of plasmid DNA from Escherichia coli 
Escherichia coli colonies containing a plasmid harboring the gene of interest were grown in 
5 mL LB medium supplemented with 100 µg/mL of ampicillin at 37 °C overnight. Cells were 
collected by centrifugation at 13 000 rpm for one minute in a benchtop centrifuge (Biofuge 
pico, Heraeus) and plasmid DNA was isolated using the QIAprep Spin Miniprep Kit 
(QIAGEN) according to the manufacturer’s advice. For elution of DNA from the columns, 
30 µL dH2O was used. After purification, DNA concentration was determined by a NanoDrop 
ND-1000 spectrophotometer (Peqlab Biotechnologie GmbH). Purified plasmid DNA was 
stored at -20 °C or used for further procedures. 
 
2.2.2.3 Isolation of genomic DNA from Saccharomyces cerevisiae 
Isolation of yeast genomic DNA was performed according to standard procedures (Hoffman 
and Winston, 1987). Saccharomyces cerevisiae cells were grown in 10 mL YEPD medium at 
30 °C overnight. After harvesting the cells by centrifugation at 3000 rpm for three minutes, 
the cell suspension was washed in 1 mL TE buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA 
[pH 8.0]). Afterwards, 200 µL breaking buffer (2 % (v/v) triton X-100, 1 % (w/v) SDS, 100 mM 
NaCl, 10 mM Tris-HCl [pH8.0], 1 mM EDTA [pH8.0]) together with 200 µL of 
phenol:chloroform:isoamyl-alcohol (25:24:1) and 0.25-0.5 mm glass beads were added to the 
cell precipitates. Cells were broken by mechanical agitation at 4 °C for 10 minutes using a 
vortex mixer (Vortex-Genie 2, Scientific Industries Inc) and centrifuged at 13 000 rpm at 4 °C 
for five minutes. For DNA precipitation, the supernatant was collected and mixed with 1 mL 
cold ethanol (96 %). After short centrifugation, the precipitates were incubated with 400 µL 
TE buffer and 3 μL RNase (10 mg/mL, Roche) to a final concentration of 75 µg/mL at 37 °C 
for 50 minutes. Thereafter, 1 mL cold ethanol (96 % (v/v)) was added and the samples were 
centrifuged at 13 000 rpm for five minutes. After discarding the supernatant, the DNA 
precipitate was additionally centrifuged at 13 000 rpm for 30 seconds and dried at room 
temperature. Finally, genomic DNA was dissolved in 50 µL TE buffer and verified by agarose 
gel electrophoresis. 
 
2.2.2.4 DNA agarose gel electrophoresis 
Analytical and preparative separation of DNA fragments was performed using DNA agarose 
gel electrophoresis (Lee et al., 2012). During this procedure, lower molecular weight nucleic 
acids migrate faster through the gel than larger fragments. Thereby, DNA size can be 
estimated. For DNA agarose gel electrophoresis, 1 % agarose gel (1 % (w/v) agarose, 
0.001 mg/mL ethidium bromide) was prepared in TAE buffer (40 mM Tris base, 20 mM acetic 
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acid, 1 mM EDTA). For subsequent visualization of DNA, the gel was supplemented with 
ethidium bromide to a final concentration of 0.001 mg/mL. The samples were mixed with 
6x DNA loading dye (10 % (v/v) ficoll typ 400, 0.25 % (w/v) bromphenol blue, 0.25 % (w/v) 
xylene cyanol ff, 200 mM EDTA [pH 8.0]) and separated until the bromophenol blue band 
reached the last third of the gel. As size standard, the GeneRuler 1kb DNA ladder (250 to 
10 000 bp, Thermo Fisher Scientific) was loaded onto the gel. The separation was performed 
in a Mini-Sub Cell GT chamber (Bio-Rad Laboratories) using Bio-Rad Powerpac 300 power 
supply (Bio-Rad Laboratories) in an electric field at 90 V in TAE buffer. Afterwards, UV light 
with 254 nm was applied to detect the DNA and a photograph was taken using a gel 
documentation imager (Gel iX20 Imager Windows Version, Intas Science Imaging 
Instruments GmbH). 
 
2.2.2.5 DNA isolation from agarose gels 
For purification of DNA fragments from a DNA mixture, the fragments were separated 
according to their length by agarose gel electrophoresis. Then, the desired fragment was 
excised from the gel and purified using the QIAquick Gel extraction Kit (QIAGEN). This 
purification method depends on the ability of DNA to bind to silica membranes. After elution 
of DNA fragments in 30 µL dH2O from the column, the fragments were stored at -20 °C or 
used for further procedures. 
 
2.2.2.6 Polymerase chain reaction (PCR) 
PCR is a technique to amplify specific DNA in vitro, which allows the amplification of DNA 
fragments with partly known sequences (Saiki et al., 1988). The polymerase chain reaction is 
based on two specific oligonucleotides which anneal to the 5’ ends of DNA fragment of 
interest. Next, the DNA polymerase binds to the oligonucleotides and synthesizes the 
complementary strand. The oligonucleotides used for PCR reactions were purchased from 
Sigma-Aldrich (St. Louis, USA) and are listed in Table 3. For cloning reactions the high 
fidelity DNA polymerase Phusion High-Fidelity DNA Polymerase (Thermo Fisher Scientific) 
was required which exhibits a 3’ → 5’ exonuclease activity. Due to its proof reading function, 
an accurate oligonucleotide extension reaction with very low error rate can be obtained. 
Temperature of annealing depends on the melting temperature of used oligonucleotides. 
Usually, the annealing temperature is 5 °C below the melting temperature. Chromosomal 
DNA or plasmid DNA was used as template DNA. The polymerase chain reaction was 
performed in a Thermo cycler (MWG Biotech Inc Primus 96 Thermal Cycler, MWG-Biotech). 
An example for a Phusion reaction mix and PCR program is listed in Table 9 and 10. 
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Table 9. Reaction mix for Phusion DNA polymerase 
Component 50 µL Reaction Final concentration 
5x HF buffer 10 μL 1 x 
dNTP mix 1 μL 200 µM each 
Primer 1 1 μL 0.2 µM 
Primer 2 1 μL 0.2 µM 
Template DNA x µL 300-500 ng 
DMSO 1.5 µL 3 % 
Phusion DNA polymerase 0.5 μL 0.02 U/µL 
 
Table 10. PCR program for Phusion DNA polymerase 
Cycle step Temperature Time Cycles 
Denaturation 98 °C 3 min 1 
Denaturation 98 °C 30 sec 30 
Annealing  Tm-5 °C 30 sec 30 
Elongation 72 °C 15-30 sec/kb 30 
Final extension 72 °C 10 min 1 
Pause 4 °C ∞ 1 
 
If the amplified DNA fragments were required for analytical PCR reaction, the thermostable 
Taq polymerase (Thermo Fisher Scientific) was applied. This DNA polymerase lacks a proof 
reading function leading to higher error prone oligonucleotides extension. For analytical PCR 
reaction, the transformants were used as DNA template. Thereby, clones can be tested for 
the correct integration of DNA fragments into a vector. The colonies to be analyzed were 
picked from a plate and resuspended in 25 μL PCR reaction mix. Positive colonies were 
isolated using the QIAprep Spin Miniprep Kit (QIAGEN) and used for subsequent 
investigation in yeast. An example for a Taq reaction mix and PCR program is listed in Table 
11 and 12. 
 
Table 11. Reaction mix for Taq DNA polymerase 
Component 25 µL Reaction Final concentration 
10x Taq DNA polymerase buffer 2.5 μL 1 x 
dNTP mix 1 μL 200 µM each 
Primer 1 1 µL 0.4 µM 
Primer 2 1 μL 0.4 µM 
Taq DNA polymerase 1 μL 0.04 U/µL 
Mg2SO4 3 µL 3 mM 
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Table 12. PCR program for Taq DNA polymerase 
Cycle step Temperature Time Cycles 
Denaturation 95 °C 3 min 1 
Denaturation 95 °C 30 sec 30 
Annealing Tm-5 °C 30 sec 30 
Elongation 72 °C 1 min/kb 30 
Final extension 72 °C 10 min 1 
Pause 4 °C ∞ 1 
 
2.2.2.7 Digestion of DNA 
Restriction enzymes purchased from Thermo Fisher Scientific were used to digest DNA 
molecules according to the manufacturer’s instructions. Restriction enzymes cut DNA 
fragments at specific recognition sequences. PCR amplified DNA fragments and plasmid 
DNA were digested with the appropriate restriction enzymes. Usually, 10 U enzyme was 
used per 3-6 µg DNA. Final volume of 30 µL reaction mixture was incubated in 
corresponding reaction buffer at 37 °C for two to four hours. Afterwards, digested DNA 
fragments were purified from the digestion mixture using the QIAquick Gel extraction Kit 
(QIAGEN). 
 
2.2.2.8 Ligation of DNA 
T4 DNA ligase (Thermo Fisher Scientific) was used for ligation of linearized vector and the 
respective insert. In presence of ATP, it catalysis the formation of phosphodiester bond 
between 3’-OH and a 5’-PO4 ends of nucleic acids. For ligation, 100 or 300 ng of the 
prepared vector DNA and a threefold number of insert DNA was used. Ligation was carried 
out in T4 ligase buffer (Thermo Fisher Scientific) using 2 µL T4 DNA ligase (2 U) in a final 
volume of 20 μL at 16 °C overnight. Subsequently, 1 µL of ligation mix was used for 
transformation into Escherichia coli DH5α strains and incubated on selective LB plates 
containing 100 µg/mL ampicillin at 37 °C overnight. Alternatively to T4 DNA ligation, the 
GeneArt® Seamless Cloning and Assembly Enzyme Mix (Invitrogen) was used to assemble 
DNA fragments. For assembly reaction, 100 ng linearized vector DNA was mixed with 200 ng 
insert DNA and 4 µL of 5x reaction buffer. After adjusting the total volume of 20 µL with 
dH2O, 1 µL of 10x enzyme mix was added to the reaction mixture and incubated at room 
temperature for 30 minutes. Finally, 8 µL of ligation mix was transformed into Escherichia coli 
DH5α strains and incubated on selective LB plates containing 100 µg/mL ampicillin at 37 °C 
overnight. In order to verify successful integration of the insert into the vector, plasmid DNA 
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was isolated using the QIAprep Spin Miniprep Kit (QIAGEN) and sequenced as described in 
section 2.2.2.10.  
 
2.2.2.9 Quick change site-directed mutagenesis 
The quick change site-directed mutagenesis system was used to modify amino acids in 
proteins. This method is based on PCR amplification allowing introduction of multiple 
mutations, deletions and insertions into genes in vitro (Wang and Malcolm, 1999). Thereby, 
one pair of complementary oligonucleotide primer containing the mutation of interest 
introduces the mutation during a PCR amplification process. The mutagenic oligonucleotide 
primers used in this method were designed individually according to the desired mutation. 
Both 5´-phosphorylated mutagenic primers should be 25 to 45 bases in length with melting 
temperature above or equal to 78 °C. The desired mutagenic section should be located at 
the middle of the primer and flaked on both sides by stretches of 10 to 20 bases 
complementary to the template DNA. Importantly, the amplification of target DNA was carried 
out using the thermostable high fidelity PfuTurbo Cx hotstart DNA polymerase (Agilent 
Technologies), which replicates target DNA without displacing the mutagenic primers. For 
this study, plasmid DNA containing the gene of interest was used as template DNA. An 
example for a quick change site-directed mutagenesis reaction mix and PCR program is 
listed in Table 13 and 14.  
 
Table 13. Reaction mix for PfuTurbo Cx hotstart DNA polymerase 
Component 50 µL Reaction Final concentration 
10x PfuTurbo Cx reaction buffer 5 μL 1 x 
methylated plasmid DNA x µL 300-500 ng 
mutagenic primer 1 1 μL 0.2 µM 
mutagenic primer 2 1 μL 0.2 µM 
dNTP mix 1 μL 200 µM each 
DMSO 1.5 µL 3 % 
PfuTurbo Cx hotstart DNA polymerase 1 µL 0.05 U/μL 
 
 
Table 14. PCR program for PfuTurbo Cx hotstart DNA polymerase 
Cycle step Temperature Time Cycles 
Denaturation 95 °C 5 min 1 
Denaturation 95 °C 30 sec 20 
Annealing  60 °C       1 min 20 
Elongation 68 °C 60 sec/kb 20 
Final extension 68 °C 10 min 1 
Pause 4 °C ∞ 1 
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Afterwards, the PCR product was purified by the QIAquick Gel extraction Kit (QIAGEN). In 
order to remove parental DNA template and to select for mutation-containing synthesized 
DNA, 2 μL of DpnI endonuclease (20 U) and 2 µL Tango buffer (Thermo Fisher Scientific) 
was directly added to 16 µL mutagenesis reaction and incubated at 37 °C for two hours. This 
restriction enzyme specifically digests methylated DNA. DNA isolated from Escherichia coli 
strains is commonly methylated, therefore, the synthesized DNA is susceptible to DpnI 
digestion. As control for effective elimination of parental DNA template reaction, one reaction 
mix was simultaneously incubated lacking DpnI restriction enzyme. Subsequently, 15 µL of 
digested reaction mix was transformed into Escherichia coli DH5α strains and incubated on 
selective LB plates containing 100 µg/mL ampicillin at 37 °C overnight. In order to verify 
mutated genes, plasmid DNA was isolated using the QIAprep Spin Miniprep Kit (QIAGEN) 
and sequenced as described in section 2.2.2.10.  
 
2.2.2.10  Sequencing of DNA 
All DNA constructs used for this work were verified by the Göttingen Genomics Laboratory 
(G2L, Göttingen, Germany) or the Seqlab-Microsynth GmbH (Göttingen, Germany) using the 
Sanger Cycle Sequencing method (Sanger et al., 1992). For each G2L sequencing reaction 
300 ng plasmid DNA purified by the QIAprep Spin Miniprep Kit (QIAGEN) was mixed with 
1 μL of respective sequencing primer (5 pmol) and adjusted to a final volume of 5 µL. 
Annealing temperature was chosen between 53 °C and 60 °C according to the length and 
nucleotide composition of sequencing primer. For each DNA sample sequenced by the 
Seqlab test laboratory 1200 ng plasmid DNA in a volume of 12 µL was mixed with 3 µL of 
respective sequencing primer (30 pmol). The received sequences were analyzed using the 
Chromas 2.3.0.0 software (Technelysium Pty Ltd) and the multiple sequence align tool 
MultAlin (Corpet, 1988). Yeast chromosomal sequences were obtained from the SGD 
(Saccharomyces genome database) website (www.yeastgenome.org) (Cherry et al., 2012). 
 
2.2.3 Transfer of DNA 
2.2.3.1 Transformation of plasmid DNA into Escherichia coli 
Plasmid DNA was transformed into Escherichia coli performing the heat shock method 
(Inoue et al., 1990). For transformation, 100 µL competent DH5α Escherichia coli cells were 
thawed for 20 minutes on ice and mixed with 0.5 µg of the desired plasmid DNA or 10 µL of 
ligation reaction. To allow annealing of plasmid DNA to the cell envelope of Escherichia coli 
cells, the mixture was incubated for 10 minutes on ice. Afterwards, the cells were heated at 
42 °C for 90 seconds and stored on ice for five minutes. Thereby, the cells take up the 
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plasmid DNA. After transformation, cells were supplemented with 1 mL LB medium and 
recovered at 37 °C for 45 minutes. Finally, 100 µL cell suspension was transferred to LB 
plates containing the respective antibiotics to select for transformants containing the desired 
plasmid DNA. For sufficient transformation yield, remaining cell suspension was centrifuged 
at 13 000 rpm in a benchtop centrifuge (Biofuge pico, Heraeus) for one minute and the 
supernatant was decanted. The precipitate was resuspended in 100 µL LB medium and 
platted on another LB plate. After incubation overnight at 37 °C, the colonies were analyzed 
by PCR and sequencing as described in section 2.2.2.6 and 2.2.2.10.  
 
2.2.3.2 Transformation of plasmid DNA into Saccharomyces cerevisiae 
Transformation of plasmid DNA into Saccharomyces cerevisiae cells was performed by the 
LiAc/SS Carrier DNA/PEG method (Ito et al., 1983). In this technique, alkali cations treated 
yeast cells take up plasmid DNA after heat pulse in the presence of polyethylene glycol. For 
transformation, 800 µL of an overnight culture grown in 10 mL YEPD medium at 30 °C was 
used to inoculate 10 mL YEPD medium and incubated at 30 °C on a rotation shaker (Fröbel 
Labortechnik GmbH) for five hours. Afterwards, the total cell culture was harvested by 
centrifugation at 3000 rpm for three minutes using the centrifuge 5804R (Eppendorf AG). The 
cell precipitate was repeatedly washed with 10 mL, 5 mL and 2 mL of LiOAc/TE buffer 
(100 mM LiOAc, 1 mM Tris-HCL [pH 8.0], 0.1 mM EDTA [pH 8.0]) and dissolved in 400 µL 
LiOAc/TE buffer. From now on, the yeast cells are competent for transformation. 50 µL of cell 
suspension was mixed with 5 µL SS carrier DNA (single stranded salmon sperm DNA), 
800 µL of 50 % polyethylene glycol 4000 (PEG 4000, Carl Roth GmbH & CO. KG) dissolved 
in LiOAc/TE buffer and 2.5 µL plasmid DNA. After incubation of the transformation mixture at 
30 °C for 30 minutes, cells were exposed to heat shock at 42 °C for 25 minutes. After 
centrifugation at 13 000 rpm for one minute, the cell precipitate was resuspended in 1 mL 
YEPD medium and incubated at 30 °C for one hour. Subsequently, cells were collected by 
centrifugation at 13 000 for one minute, the supernatant was discarded and the remaining 
cell suspension was transferred on solid SC medium which lacks the appropriate amino acid 
to select for colonies carrying the plasmid with corresponding auxotrophic marker. After two 
to three days cultivation at 30 °C, colonies were restreaked on new solid SC medium to 
select for colonies carrying the desired plasmid. 
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2.2.4 Protein methods 
2.2.4.1 Production of crude extracts of yeast cells 
The strains to be analyzed were grown in 10 mL SC medium containing the respective amino 
acids and 2 % raffinose at 30 °C overnight. For induction of the GAL1-promoter, the 
overnight culture was centrifuged at 3000 rpm for three minutes and the cell precipitate was 
used to inoculate 10 mL SC medium containing 2 % galactose. The cultures were rotative 
grown at 30 °C for five hours. Afterwards, the samples were stored for 10 minutes on ice and 
centrifuged at 3000 rpm for one minute at 4 °C. The cell precipitate was then washed with 
1 mL TE buffer (10 mM Tris-HCl [pH 8.0], 1 mM EDTA [pH 8.0]) and dissolved in 200 µL 
buffer R (50 mM Tris-HCl [pH 7.5], 1 mM EDTA [pH 8.0], 50 mM DTT, 6 µL/mL protease 
inhibitor (1 Cocktail Tablet in 1 mL dH2O), 100 µL/mL phosphatase inhibitor (1 Cocktail 
Tablet in 1 mL dH2O), 1 mM NaF, 8 mM β-glycerol phosphate, 0.5 mM Na3VO4). Additionally, 
the same amount of 0.25-0.5 mm glass beads was added to the mixture. In order to break 
the cells, the samples were vigorously shaken at 4 °C using a vortex mixer (Vortex-Genie 2, 
Scientific Industries Inc) for 10 minutes. Subsequently, the suspension was centrifuged at 
13 000 rpm for one minute at 4 °C and the crude cell extract was obtained by collecting the 
supernatant. After determination of the protein concentration by the Bradford assay 
(Bradford, 1976), the protein samples were resuspended in 6x sample buffer (250 mM Tris-
HCl [pH 6.8], 15 % (v/v) β-mercaptoethanol, 7 % (w/v) SDS, 30 % (v/v) glycerol, 0.3 % (w/v) 
bromophenol blue) and boiled at 95 °C for 10 minutes. In order to analyze the isolated 
protein extracts, the samples were loaded onto a SDS polyacrylamide gel and separated by 
electrophoresis as described in section 2.2.4.5. 
 
2.2.4.2 Determination of protein concentration 
The protein content of a sample was determined by the Bradford protein concentration assay 
which is based on the proportional binding of Coomassie dye to proteins (Bradford, 1976). 
Thereby, the protein concentration is quantified by comparison to that of a series of known 
protein standards. In this study, BSA (Albumin Fraktion V, AppliChem GmbH) was used as 
protein reference. In order to exhibit a linear calibration line, 2 µL, 5 µL, 10 µL, 15 µL, 20 µL 
and 40 µL of 1 mg/mL BSA solutions were added to 990 µL of 1:5 diluted Bradford reagent 
(Roti®-Quant, Carl Roth GmbH & CO. KG) and incubated for five minutes at room 
temperature. Subsequently, extinction was measured at 595 nm using a light absorption 
photometer (T80 UV/VIS spectrometer, PG Instruments Ltd). The same procedure was 
performed with 10 µL of the protein sample of interest in 990 µL of 1:5 diluted Bradford 
reagent. On the basis of the linear calibration line, the protein concentration was calculated. 
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Alternatively, protein concentration was determined using a microplate reader (Infinite® 
M200, Tecan Group). Here, 200 µL of 1:5 diluted Bradford reagent was mixed with 5 µL of 
1:10 or 1:100 diluted protein sample and measured at 595 nm after five minutes incubation. 
For standard curve, 0 µL, 1 µL, 2 µL, 5 µL, 10 µL and 20 µL of 1 mg/mL BSA solution was 
used with 200 µL of 1:5 diluted Bradford reagent. All samples were prepared in triplicates. 
 
2.2.4.3 Ni2+-NTA affinity chromatography  
Purification of HIS6-tagged recombinant proteins expressed in Saccharomyces cerevisiae 
was performed using the Ni2+-NTA affinity chromatography (Porath et al., 1975). This 
technique is based on the high binding affinity of nickel ions to histidine residues. Thereby, 
immobilized nickel ions of nickel-nitrilotriacetic acid beads (Ni2+-NTA) located on a highly 
crosslinked agarose matrix bind to HIS-tagged proteins and retain them until elution by 
competition with imidazole. At first, a HIS6-tag was fused to the C-terminus of the protein of 
interest and cloned into the desired plasmid. After verification of effective cloning, the 
constructs were transformed into yeast strains of interest and selected on selective 
SC medium. Cells cultured overnight in 200 mL selective SC liquid medium supplemented 
with 2 % glucose were collected by centrifugation at 4000 rpm for 20 minutes using the 
centrifuge 5804R (Eppendorf AG) and washed with 5 mL dH2O. The total cell precipitate was 
used to inoculate 1.5 L YEPD medium containing 2 % galactose. After 12 hours induction of 
αSyn expression at 30 °C, cells were harvested by centrifugation at 4000 rpm for 20 minutes 
at 4 °C in the Sorvall RC-3B Plus Refrigerated Centrifuge (Thermo Fisher Scientific) and 
lysed by 25 mL 1.85 M NaOH containing 7.5 % ß-mercaptoethanol on ice for 10 minutes. To 
precipitate the protein crude extract, 25 mL 50 % trichloroacetic acid (TCA, Carl Roth GmbH 
& CO. KG) were added to the cell lysate and incubated on ice for 30 minutes. After 
centrifugation at 4000 rpm for 15 minutes at 4 °C, the precipitate was washed with 25 mL of 
100 % acetone and resuspended in 25 mL buffer A (6 M guanidine HCl, 100 mM sodium 
phosphate buffer [pH 8.0], 10 mM Tris-HCl [pH 8.0]). Then, the mixture was rotated at 25 °C 
for at least one hour and again centrifuged as described above. The collected supernatant 
was calibrated by 1 M Tris [pH 8.5] to pH 7.0 and supplemented with imidazole (AppliChem 
GmbH) to reach the total concentration of 20 mM. For column preparation, 1 mL of Ni2+-NTA 
agarose (Qiagen) was added into a Poly-Prep® Chromatography Column (Bio-Rad 
Laboratories). After equilibration with 5 mL of buffer A containing 20 mM imidazole, the 
protein crude extracts were applied to the columns. Afterwards, the columns were washed 
with 10 mL buffer A containing 20 mM imidazole and equilibrated with 5 mL buffer B (8 M 
urea, 100 mM sodium phosphate buffer [pH 6.3], 10 mM Tris-HCl [pH 6.3]). Elution of the 
HIS6-tagged protein was carried out using four times 1 mL of 200 mM imidazole resolved in 
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buffer B. Thereby, imidazole rings bind to the nickel ions and disrupt the binding of histidine 
residues. The protein content of the elution fractions was determined by Bradford protein 
concentration assay. Afterwards, the protein samples were resuspended in 6x sample buffer 
and boiled for 10 minutes at 95 °C. The protein samples were stored at -80 °C or subjected 
to immunoblot analysis (2.2.4.6). To reuse the columns, they were first washed with 20 mL 
dH2O followed by 10 mL 0.2 M NaOH and another washing step with 20 mL dH2O. After 
equilibration of the columns by 5 mL buffer A, they were stored in ethanol (20 % (v/v)). 
 
2.2.4.4 Trichloroacetic acid protein precipitation 
2,2,2-trichloroacetic acid (TCA) is widely used for precipitating soluble proteins from an 
aqueous solution. TCA triggers protein precipitation by inducing hydrophobic aggregation 
(Sivaraman et al., 1997). For TCA protein precipitation, 100 % TCA solution (500 g TCA in 
350 mL dH2O) was added to the protein sample with a ratio of 1:4 and incubated at 4 °C for 
10 minutes. After centrifugation at 13 000 rpm for five minutes at 4 °C, the supernatant was 
discarded and the protein precipitate was washed with cold acetone. Next, the protein 
precipitate was centrifuged at 13 000 rpm for five minutes at 4 °C and the washing step was 
repeated. The precipitate was dried at 95 °C for five minutes and dissolved in 2x sample 
buffer. After heating the protein precipitates at 95 °C for 10 minutes, the samples were stored 
at -80 °C or used for further procedures. 
 
2.2.4.5 Discontinuous SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE is an electrophoretic technique which is used to separate proteins by their 
molecular mass (Laemmli, 1970). The charge of proteins as well as the three dimensional 
fold is superimposed by the addition of SDS which denatures the proteins and mediates a 
strong negative charge. Due to this effect, the proteins are separated by mass and not by 
charge. The vertical SDS gel used for protein separation is composed of a stacking and a 
separation gel. The stacking gel contains 5 % polyacrylamide and allows fast migration of the 
proteins until the separation gel containing 12 % polyacrylamide is reached. This 
concentration is suitable for separation of proteins of medium size. First, the separation gel 
(2.5 mL 1.5 M Tris-HCl / 0.4 % (w/v) SDS [pH 8.8], 3.5 mL dH2O, 4 mL acrylamide solution 
[30 % acrylamide, 0.8 % bisacrylamide], 30 µL APS [10 % (w/v)], 15 µL TEMED) was poured 
and covered with isopropanol. After the separation gel was completely polymerized, the 
isopropanol was removed and the stacking gel (1.5 mL 500 mM Tris-HCl / 0.4 % (w/v) SDS 
[pH 6.8], 3.9 mL dH2O, 0.6 mL acrylamide solution [30 % acrylamide, 0.8 % bisacrylamide], 
40 µL APS [10 % (w/v)], 20 µL TEMED) was poured on top of the separation gel. According 
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to the volume of the samples, 1 mm or 1.5 mm 10-well comb was inserted into the stacking 
gel. Before the protein samples were loaded onto the gel, they were mixed with 6x sample 
buffer and denatured at 95 °C for 10 minutes. Electrophoresis was performed in running 
buffer (25 mM Tris base, 250 mM glycine, 0.1 % (w/v) SDS) using the Mini-PROTEAN® 
3 Cell and the Bio-Rad Powerpac 300 power supply (Bio-Rad Laboratories) at 100 V until the 
samples reached the separation gel. Thereafter, the electric current was raised to 200 V and 
electrophoresis was performed until the blue band of the 6x sample buffer ran out of the gel. 
PageRuler Prestained Protein Ladder (10 to 180 kDa, Thermo Fisher Scientific) was used as 
size standard to monitor separation of the proteins. 
 
2.2.4.6 Protein immunoblotting  
The protein immunoblotting technique is used to identify individual proteins in a protein 
mixture by specific recognition of antigens by antibodies on a carrier membrane. The 
proteins were first separated by discontinuous SDS-polyacrylamide gel electrophoresis and 
afterwards transferred electrophoretically on a nitrocellulose membrane (AmershamTM 
ProtranTM 0.45 µm NC, GE Healthcare) or polyvinylidenflouride (PVDF) membrane 
(AmershamTM Hybond-PTM 0.45 µm PVDF, GE Healthcare), respectively (Towbin et al., 
1979). The transfer was performed in transfer buffer (25 mM Tris base, 192 mM glycine, 
0.02 % (w/v) SDS) with 20 % methanol using a Mini Trans-Blot® Electrophoretic Cell (Bio-
Rad Laboratories). Due to the prior treatment with SDS, the proteins have a strong negative 
charge. By applying an electric current of 100 V to the blotting device for 1.5 hours, the 
proteins migrate towards the anode, which allows the transfer to the membrane. A schematic 
assembly of an immunoblot transfer stack is shown in Figure 5. 
 
 
Figure 5. Schematic assembly of an immunoblot device.  
For immunoblotting using tank transfer system, the polyacrylamide gel and the nitrocellulose 
membrane are placed between two layers of gel-blotting papers (Schleicher and Schuell 
BioScience GmbH) that have to be soaked in transfer buffer before the stack is assembled. 
The electric current moves from the cathode to the anode. In this way, proteins are 
transferred from the polyacrylamide gel to the membrane. 
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As soon as the proteins were transferred to the membrane, they could be visualized with 
specific antibodies. In order to achieve this, membrane was shaken after blotting in TBST 
buffer (10 mM Tris-HCl [pH 8.0], 150 mM NaCl, 0.05 % (v/v) tween-20) containing 5 % milk 
powder for at least one hour. Thereby, the free binding sites of the membrane are blocked to 
avoid binding of the antibody directly to the membrane. Next, a primary antibody, diluted in 
TBST buffer with 5 % milk powder, was incubated with the membrane overnight. Primary and 
secondary antibodies that were used in this study are listed in Table 7 and 8. Subsequently, 
the membrane was washed with TBST buffer three times for 20 minutes. The second 
antibody, which specifically binds to the first antibody and is conjugated to horseradish 
peroxidase, was diluted 1:2000 or 1:5000 in TBST buffer with 5 % (w/v) milk powder and 
incubated with the membrane for one hour. After removing the unbound antibody by washing 
the membrane as described before, the proteins were detected using the Enhanced 
Chemiluminescence (ECL) technology. For that an ECL solution was prepared by mixing 
ECL solution 1 (1 mL 1 M Tris [pH 8.5], 9 mL dH2O, 45 µL paracoumaric acid [400 mM in 
DMSO], 100 µL luminol [250 mM in DMSO]) with ECL solution 2 (1 mL 1 M Tris [pH 8.5], 
9 mL dH2O, 6.2 µL H2O2). The ECL solution was immediately casted onto the membrane and 
incubated for two minutes. Hereby, the enzymatic reaction of the horseradish peroxidase 
was started. This enzyme catalyzes the transfer of electrons from H2O2 to the luminol 
substrate which is thereby converted to a light releasing substance. The membrane was then 
covered in foil and exposed in the dark to AmershamTM HyperfilmTM- ECL (GE Healthcare) in 
time periods of several seconds and minutes leading to chemiluminescence signals 
visualized on the film. For the hybridization of the anti-nitrotyrosine antibody, the proteins 
were transferred to a PVDF membrane. Before electrophoretic blotting, the PVDF membrane 
had to be activated by methanol for 15 seconds. The following procedure was performed as 
described above. Detected bands were quantified using the Java-based image processing 
software ImageJ (Wayne Rasband, National Institutes of Health). To remove the antibodies, 
the membrane was incubated in 10 mL stripping solution (50 mM Tris-HCl [pH 7.0], 2 % (w/v) 
SDS, 50 mM DTT) at 60 °C for 30 minutes. Afterwards, the membrane was washed in TBST 
buffer for five minutes and the free binding sites of the membrane were blocked by 
incubating the membrane in TBST buffer containing 5 % (w/v) milk powder for at least one 
hour.    
 
2.2.4.7 Staining of proteins with Coomassie brilliant blue R-250 
Coomassie brilliant blue R-250 (Serva Electrophoresis GmbH) was used to stain unspecific 
protein bands on SDS gel (Fairbanks et al., 1971) based on its capability to attach to basic 
side chains of amino acids. Detection limit of Coomassie dye amounts of 100 ng per protein 
Materials and Methods 
40 
band. Therefore, proteins separated on SDS gel were fixated for two hours in the fixation 
solution (40 % (v/v) ethanol, 10 % (v/v) acetic acid) and washed in H2O for one minute. The 
gel was then incubated overnight with Coomassie stain solution (50 % (v/v) methanol, 10 % 
(v/v) acetic acid, 0.2 % (w/v) Coomassie brilliant blue R-250) and again rinsed in water. To 
remove background, the gel was incubated in Coomassie destain solution (50 % (v/v) 
methanol, 10 % (v/v) acetic acid) for at least 30 minutes and washed three times in water for 
one minute. 
 
2.2.4.8 Silver staining 
A more sensitive technique to visualize protein bands on an SDS gel is the silver staining 
(Blum et al., 1987). In this method, silver ions bind to glutamic acid-, aspartic acid-, and 
cysteine residues of the proteins which are then reduced to elementary silver by 
formaldehyde resulting in a dark staining of the protein bands. Detection limit of silver stain is 
at 1-10 ng per band. The proteins separated on SDS gel were first incubated in fixing 
solution (40 % (v/v) ethanol, 10 % (v/v) acetic acid) for at least two hours or overnight and 
then washed three times for 20 minutes in 30 % ethanol. After incubation in 0.02 % sodium 
thiosulfate for one minute the gel was rinsed three times for 20 seconds with H2O and 
incubated in 0.2 % silver-nitrate solution for 20 minutes. The gel was again washed two times 
with H2O for 20 seconds and the developing solution (3 % (w/v) sodium carbonate, 0.05 % 
(v/v) formaldehyde [37 % (v/v)], 0.0004 % (w/v) sodium thiosulfate) was applied on the gel. 
As soon as the protein bands are visible (~ five minutes), the gel was washed twice with H2O 
for one minutes and the reaction was stopped by incubating the gel in 0.5 % glycine for 
five minutes. Finally, the gel was washed in H2O for 30 minutes. All procedure steps were 
performed under shaking.  
 
2.2.4.9 In vitro protein nitration with peroxynitrite 
In vitro nitration of proteins was carried of using the highly reactive nitrating agent 
peroxynitrite (PON, Cayman Chemical). Because of its oxidizing ability, the peroxynitrite 
anion can participate directly in electron oxidation reactions with biomolecules (Lymar and 
Hurst, 1998). In proteins, tyrosine residues can be nitrated by PON that may alter protein 
function. For nitration, 20 µL of purified protein was filled into a 50 µL reaction tube. 1 µL of 
PON was placed into the lid of the reaction tube. Because the reactivity of PON is highly pH-
dependent, 1 µL of 0.3 M HCl was additionally placed into the lid. To induce the reaction, the 
tube was immediately vortexed for approx. 10 seconds. Subsequently, the nitrated protein 
was subjected to immunoblot analysis.  
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2.2.5 Liquid chromatography-mass spectrometry  
2.2.5.1 In-gel protein digestion with trypsin  
Digesting and recovering proteins from stained protein bands excised from polyacrylamide 
gel were performed using trypsin restriction (Shevchenko et al., 1996). This protein hydrolase 
cleaves the peptide chain at specific sites. Its property is used to identify proteins by 
analyzing the resultant peptides using Liquid chromatography-mass spectrometry (LC-MS). 
In order to prepare proteins of interest for LC-MS, they were separated by 12 % SDS-PAGE 
and stained with Coomassie dye as described in section 2.2.4.5 and 2.2.4.7. To improve the 
recovery rate of the samples and to prevent contamination with silicon, detergents and 
plastic softening agents, low-bind cups (Protein Lobind Tubes, Eppendorf AG) and vinyl 
gloves were used in all procedure steps. Excised polyacrylamide gel slices of Coomassie 
stained proteins were digested with the proteases according to the protocol of Shevchenko 
and supplier’s instructions. After excising the target bands from the polyacrylamide gel, 50 µL 
acetonitrile were added to the gel fractions and incubated for 10 minutes at room 
temperature. Next, the supernatant was removed and the polyacrylamide gel slices were 
dried using a vacuum concentrator (Savant SPD111V SpeedVac concentrator, Thermo 
Fisher Scientific) at 50 °C for 10 minutes. Then, the samples were incubated with 150 µL 
100 mM ammonium bicarbonate containing 10 mM DTT at 56 °C for one hour. After spinning 
down the condense water by centrifugation at 13 000 rpm for one minute and decanting the 
supernatant, the polyacrylamide gel fractions were incubated with 150 µL 100 mM 
ammonium bicarbonate containing 55 mM iodoacetamide at room temperature in the dark for 
45 minutes. The supernatant was again removed and the samples were incubated with 
150 µL 100 mM ammonium bicarbonate for 10 minutes. Afterwards, the ammonium 
bicarbonate was changed against 150 µL acetonitrile and the samples were shaken for 
10 minutes. The supernatant was again extracted and the samples were covered with 150 µL 
ammonium bicarbonate for 10 minutes. After additional incubation of the gel fractions with 
acetonitrile as described above, the samples were subjected to a drying step in the vacuum 
concentrator at 50 °C for 10 minutes. After that, the polyacrylamide gel slices were covered 
by approx. 50 µL trypsin digestion buffer (Serva Trypsin (Serva Electrophoresis GmbH) in 
25 mM ammonium bicarbonate (1:2.5)) and digested on ice for 45 minutes. Subsequently, 
the trypsin containing solution was discarded, the samples were covered by approx. 50 µL of 
25 mM ammonium bicarbonate [pH 8.0] and incubated at 37 °C overnight. After 
centrifugation at 13 000 rpm for one minute, the supernatant was collected and the gel slices 
were incubated in 50 µL 20 mM ammonium bicarbonate for 10 minutes. After centrifugation 
as described before, the supernatant was again gathered and the gel slices were incubated 
for 20 minutes in 50 µL 50 % acetonitrile containing 5 % formic acid. The samples were 
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centrifuged at 13 000 rpm for one minute and the supernatant was again collected. 
Acetonitrile/formic acid extraction was repeated twice. Finally, the united supernatant was 
humidified using the vacuum concentrator at 50 °C and stored at room temperature. 
 
2.2.5.2 In-solution protein digestion with Asp-N 
Trypsin digested αSyn peptides were additionally digested by Asp-N to obtain appropriate 
peptides for LC-MS. For double digestion, αSyn peptides were digested by trypsin as 
described in section 2.2.5.1. Afterwards, humidified peptides were dissolved in 30 µL 
100 mM ammonium bicarbonate [pH 8.0] and incubated with Asp-N (1:100, Sigma-Aldrich) at 
37 °C overnight. Finally, the peptides were humidified using the vacuum concentrator at 
50 °C and stored at room temperature. 
 
2.2.5.3 C18 StageTip purification 
Before performing analysis by LC-MS, the peptide mixture was purified by the C18 StageTip 
purification method using self-made C18 stop-and-go-extraction tips (C18 StageTips) 
(Rappsilber et al., 2007). During this procedure, peptides are enriched and purified from 
urea, salts and other contaminants through binding to reversed-phase material (C18) and 
eluted in organic solution. StageTips were prepared by placing a small portion of C18 
material in a pipette tip. For equilibration, 100 µL methanol containing 0.1 % (v/v) formic acid 
was added into the StageTips and centrifuged at 13 000 rpm for two minutes. After 
discarding the flow through, 100 µL of 70 % (v/v) acetonitrile containing 0.1 % (v/v) formic 
acid was added and centrifuged at 13 000 rpm for two minutes. After the flow through was 
discarded, the 100 µL dH2O containing 0.1 % (v/v) formic acid was added and centrifuged at 
13 000 rpm for two minutes. The flow through was discarded and the StageTip equilibration 
was completed by repeating the last step. Humidified peptides were resolved in 20 µL of 2 % 
(v/v) acetonitrile containing 0.1 % (v/v) formic acid and incubated in an ultrasonic bath 
(Bandelin Sonorex™ Digital 10 P ultrasonic bath, Bandelin electronic GmbH & Co. KG) at 
35 °C at maximum power for three minutes. The peptide mixtures were loaded onto the 
StageTips, centrifuged at 1000 rpm for five seconds and incubated for five minutes at room 
temperature. Afterwards, the peptide samples were centrifuged at 4000 rpm for five minutes 
and the flow through was reloaded onto the StageTips and centrifuged at 4000 rpm for 
five minutes. Next, the flow through was discarded and the columns were washed twice with 
100 µL dH2O containing 0.1 % (v/v) formic acid by centrifugation at 10 000 rpm for 
two minutes. After the StageTips were transferred into a low-bind cup, 60 µL acetonitrile 
containing 0.1 % (v/v) formic acid was added and incubated for five minutes at room 
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temperature. Finally, the StageTips were centrifuged for five minutes at 4000 rpm and the 
peptides were humidified using the vacuum concentrator at 50 °C. In order to prepare the 
resultant protein fragments for mass spectrometry, peptides were resolved in 20 µL of 
2 % (v/v) acetonitrile containing 0.1 % (v/v) formic acid and incubated in an ultrasonic bath at 
35 °C at maximum power for three minutes. Mass spectrometry was performed by Dr. Oliver 
Valerius (Department of Molecular Microbiology and Genetics, Georg-August-Universität 
Göttingen) using Orbitrap Velos Pro (Thermo Fisher Scientific). 
 
2.2.5.4 Mass spectrometry analysis of α-synuclein 
The single digestions as well as the double digested tryptic/AspN peptides were analyzed by 
LC-MS. Peptides of 1-5 μL sample solution were trapped and washed with 0.07 % (v/v) 
trifluoroacetic acid containing 2.6 % (v/v) acetonitrile on an Acclaim® PepMap 100 column 
(100 μm x 2 cm, C18, 3 μm, 100 Å, P/N164535, Thermo Fisher Scientific) at a flow rate of 
25 μL/min for five minutes. Analytical peptide separation by reverse phase chromatography 
was performed on an Acclaim® PepMap RSLC column (75 μm x 25 cm, C18, 3 μm, 100 Å, 
P/N164534, Thermo Fisher Scientific) running a 40 minutes gradient from 100 % solvent A 
(0.1 % (v/v) formic acid) to 65 % solvent B (80 % (v/v) acetonitrile, 0.1 % (v/v) formic acid) 
and further to 95 % solvent B within one minute at flow rates of 300 nL/min (Fisher 
Chemicals). Chromatographically eluting peptides were on-line ionized by nano-electrospray 
(nESI) using the Nanospray Flex Ion Source (Thermo Fisher Scientific) at 2.4 kV and 
continuously transferred into the mass spectrometer. Full scans within m/z of 300-1850 were 
recorded with the Orbitrap-FT analyzer at a resolution of 30 000 with parallel data-dependent 
top 10 MS2-fragmentation in the LTQ Velos Pro linear ion trap. LC-MS method programming 
and data acquisition was performed with the software Xcalibur 2.2 (Thermo Fisher Scientific). 
MS/MS2 data processing for protein analysis and PTM identification was done with the 
Proteome Discoverer 1.4 (PD, Thermo Fisher Scientific) software using the SequestHT 
search engine (Thermo Fisher Scientific) and Saccharomyces cerevisiae protein database 
extended by the most common contaminants with the following criteria: peptide mass 
tolerance 10 ppm, MS/MS ion mass tolerance 0.8 Da, and up to two missed cleavages 
allowed. Only high confident peptides with a false discovery rate less than 0.01 were 
considered. 
 
2.2.5.5 Identification of crosslinked peptides 
The MS data of crosslinked peptides were analyzed with StavroX2.3.4.5 (Gotze et al., 2012). 
MS data in the Mascot generic file (mgf) format containing all MS/MS data of precursor ions 
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were loaded into the program. The following parameters were used for the StavroX analysis: 
(i) cleavage sites: C-terminal: K, R; N-terminal: D; (ii) number of missed cleavages = 2; (iii) 
variable modifications: oxidation of methionine; nitration of tyrosine; cysteine-to-cysteine 
acetamide; (iv) mass of crosslinker: -H2; (v) crosslinks only between two tyrosines; (vi) 
precision precursor comparison = 10 ppm. The false-positive rate was evaluated by decoy 
analysis using the reversed protein sequence. The frequency of occurrence of candidates 
from the data analysis and decoy analysis was compared for each sample. Only scores with 
decoy frequencies below 8 % of the data frequency were considered as possible crosslinks. 
The data were filtered for unique scans and each scan was considered only once with its 
highest score. Since multiple tyrosine residues are located on one and the same peptide, 
different combinations of crosslinked peptides with equal masses were possible. For each 
scan, the crosslinked tyrosine dimers were assigned according to the score calculated by the 
program based on the fragment ions series. 
 
2.2.6 Phenotypical characterization 
2.2.6.1 Spotting assay 
Growth of yeast strains on solid medium was analyzed by performing spotting assay. Cells 
were grown in selective SC medium supplemented with 2 % raffinose at 30 °C overnight. 
After normalizing the cells to equal densities (OD600 of 0.1), 10-fold dilutions series were 
prepared (10-1, 10-2, 10-3, 10-4) and spotted in a volume of 10 µL on selective SC agar plates 
supplemented with either 2 % glucose or 2 % galactose. The growth intensity was 
documented after two to three days incubation at 30 °C. 
 
2.2.6.2 Fluorescence microscopy 
For fluorescence microscopy cells were pre-grown in selective SC medium containing 2 % 
raffinose at 30 °C overnight and inoculated in 2 % galactose-containing SC medium to an 
OD600 of 0.1. αSyn expression was induced for five hours. 300 µL of the cells were subjected 
to fluorescence microscopy. Fluorescent images were obtained with 63x magnification using 
a Zeiss Axio Observer. Z1 microscope (Zeiss) equipped with a CSU-X1 A1 confocal scanner 
unit (Yokogawa), QuantEM:512SC digital camera (Photometrics) and SlideBook 6.0 software 
package (Intelligent Imaging Innovations GmbH). Depending on the fluorescent agent, 
ssGFP or sdRFP filter were applied. To quantify aggregation of αSyn, at least 300 cells were 
counted per strain and experiment and the number of cells displaying αSyn aggregation was 
referred to the total number of counted cells. 
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2.2.6.3 Mitochondrial staining   
To study mitochondrial morphology within live cells, the red-fluorescent dye MitoTracker® 
Red CMXRos-Special Packaging (Invitrogen) was used. MitoTracker Red accumulates in 
mitochondria depending on membrane potential. Cells were pre-grown in selective 
SC medium containing 2 % raffinose and inoculated in 2 % galactose-containing SC medium 
to an OD600 of 0.1. αSyn expression was induced for five hours. To label mitochondria, the 
cells were incubated for 45 minutes in the presence of 50 nM MitoTracker Red, washed once 
with fresh medium and imaged. 
 
2.2.6.4 Detection of reactive oxygen and nitrogen species  
Reactive oxygen species (ROS) in yeast cells were visualized by microscopy using 
dihydrorhodamine 123 (DHR123, Cayman Chemical). The nonfluorescent ROS indicator 
passively diffuses across cell membranes where it is oxidized to the highly fluorescent 
product rhodamine 123 (Crow, 1997). It has an excitation and emission wavelengths of 
500 and 536 nm, respectively. In order to test yeast for production of ROS, cells were pre-
grown in selective SC medium containing 2 % raffinose at 30 °C overnight and inoculated in 
2 % galactose-containing medium to an OD600 of 0.1. αSyn expression was induced for 
six hours. After washing the cells in 1 mL dH2O, DHR123 was added to a final concentration 
of 5 µg/mL to 300 µL cells resuspended in dH2O and incubated in the dark at 30 °C for 
1.5 hours. After washing, cells were re-suspended in dH2O and microscopy was performed 
using RFP filter. To test yeast for reactive nitrogene species (RNS) production, the sensitive 
fluorescent indicator DAF-2 diacetate (Genaxxon BioScience GmbH) was used (Kojima et 
al., 1998). Upon entry into the cell, DAF-2 diacetate is transformed into DAF-2 by cellular 
esterases, which reacts with nitric oxide in the presence of oxygen to yield the highly 
fluorescent triazolofluorescein. It has an excitation and emission wavelengths of 485 and 
538 nm, respectively. Cells pre-grown overnight in 2 % raffinose-containing SC medium were 
transferred to 2 % galactose-containing SC medium at OD600 of 0.1. After six hours induction 
of αSyn expression, cells were washed and diluted in PBS buffer [pH 7.5] (137 mM NaCl, 
8 mM Na2HPO4, 2 mM NaH2PO4) to OD600 of 0.1. DAF-2 diacetate was added to a final 
concentration of 25 µg/mL and cells were incubated in the dark at 30 °C for one hour. Before 
microscopy, the cells were washed in PBS buffer [pH 7.5] and RNS were visualized using 
GFP filter. 
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2.2.6.5 Flow cytometry 
For quantification of ROS and RNS stained by DHR123 and DAF-2 diacetate in yeast cells, 
flow cytometry was performed. This technique simultaneously measures and analyzes 
multiple physical characteristics of single particles, such as cells that flow in a fluid stream 
through a beam of light (Fulwyler, 1965). Cells were grown and treated with DHR123 or DAF-
2 diacetate as described in section 2.2.6.4. Before measuring, cells were resuspended in 
50 mM trisodium citrate buffer pH 7.0. Flow cytometry analysis was performed on a BD 
FACSCANTO II (Becton Dickinson). 100 000 events were counted for each experiment. Data 
analysis was performed using the BD FACSDIVATM software (Becton Dickinson). 
Representative examples were repeated at least three times. 
 
2.2.6.6 Cell integrity assay 
Yeast cell membrane integrity was analyzed with propidium iodide (PI) staining. After five 
hours induction of αSyn expression in 2 % galactose-containing SC medium, yeast cells with 
an OD600 of 0.3 were washed in 500 µL PBS and incubated with 12.5 µg/mL PI in 500 µL 
PBS for 30 minutes. As a positive control, cells were boiled for 10 minutes at 95 oC. Flow 
cytometry analysis was performed as described in section 2.2.6.5.  
 
2.2.6.7 Growth analysis in liquid culture 
For growth tests in liquid cultures, cells were pre-grown in 2 % raffinose-containing selective 
SC medium at 30 °C overnight and inoculated in 2 % galactose-containing SC medium to 
equal densities of OD600 of 0.1. Optical density measurements of 200 µL cell cultures were 
performed in triplicates in 96-well plates for 48 hours using a microplate reader (Infinite® 
M200, Tecan Group). Growth analyses under nitrative stress conditions were performed 
using 600 µM or 1 mM DETA-NONOate (Cayman Chemical) as NO donor. This compound 
releases NO radicals and thereby induces nitrative stress in the cells. For DETA-NONOate 
use, the induction 2 % galactose-containing SC medium was adjusted to pH 7.4 by 200 mM 
NaOH to avoid a fast release of the compound. Incubation without DETA-NONOate served 
as control.  
 
2.2.6.8 Promoter shut-off assay  
To study the ability of yeast cells to degrade αSyn, promoter shut-off analyses were 
performed. Yeast cells were pre-grown in selective SC medium containing 2 % raffinose 
overnight and shifted to 2 % galactose-containing selective SC medium to induce αSyn 
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expression for four hours. Afterwards, cells were transferred to selective SC medium 
containing 2 % glucose to shut-off the promoter. Four hours after promoter shut-off, cells 
were visualized by fluorescence microscopy and the reduction of number of cells displaying 
αSyn inclusions was recorded. To study the lysosome/vacuole degradation pathway 
(autophagy), 1 mM phenylmethanesulfonyl fluoride (PMSF, Carl Roth GmbH & CO. KG) 
dissolved in ethanol was applied to the cell suspension (Lee and Goldberg, 1996). As 
control, equal volume of ethanol was applied to the cells. For impairment of the proteasomal 
degradation system, Carbobenzoxyl-leucinylleucinyl-leucinal (MG132, Selleck Chemicals) 
dissolved in dimethyl sulfoxide (DMSO) was added to the cell suspension in a final 
concentration of 75 µM. In parallel, equal volume of DMSO was applied to the cells as a 
control. For drug treatment with MG132, induction-medium containing galactose and shut-off-
medium containing glucose was supplemented with 0.003 % (w/v) SDS and 0.1 % (w/v) 
proline (Liu et al., 2007). 
 
2.2.6.9 Agar diffusion assay 
To analyze the sensitivity of Saccharomyces cerevisiae strains to reactive oxygen species, 
agar diffusion assay was performed using hydrogen peroxide (H2O2). H2O2 is reduced to 
hydroxyl radical (OH•), which is one of the strongest oxidants in nature leading to oxidative 
stress. For testing sensitivity to oxidative stress, cells were grown in selective SC medium 
containing 2 % raffinose at 30 °C overnight and harvested by centrifugation at 3000 rpm for 
three minutes using the centrifuge 5804R (Eppendorf AG). After washing the cells in 1 mL 
dH2O, optical densities were normalized to OD600 of 1 in 1 mL dH2O. 100 µL of cell 
suspension was resolved in 10 mL liquid top agar (0.5 % (w/v)) and transferred on solid MV 
medium [pH 7.2] supplemented with 2 % galactose. Small Whatman paper disks were 
soaked with 10 µL 30 % H2O2 and placed in the middle of the agar plate. The size of the 
inhibition area was measured after two to three days incubation at 30 °C. 
  
2.2.6.10 Oxygen consumption rate assay 
Oxygen consumption rate (OCR) is an indicator of mitochondrial respiration, which was 
assessed using the XF24 Extracellular Flux Analyzer (Seahorse Bioscience). This device 
measures the oxygen concentration in the medium and concludes the oxygen consumption 
rate (OCR). Cells were pre-grown in selective SC medium containing 2 % raffinose at 30 °C 
overnight and inoculated in 2 % galactose-containing medium to an OD600 of 0.1. αSyn 
expression was induced for six hours. For the assay, cells were seeded in galactose-
containing selective SC medium with OD600 of 0.075. OCR was assessed at basal conditions, 
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as well as after sequential addition of 2 µM FCCP (protonophore), 20 µM oligomycin A (ATP 
synthase inhibitor) and 50 µM antimycin A (complex III inhibitor). Basal OCR was obtained 
after subtraction of non-mitochondrial respiration (difference between initial OCR and 
antimycin A OCR response). Bioenergetic parameters were calculated upon normalizing 
OCR values to the baseline. Measuring of OCR was performed in the Department of 
Neurodegeneration and Restorative Research of the University Medical Center Göttingen 
(Göttingen, Germany). 
 
2.2.7 Cell culture methods 
All experiments carried out in mammalian cell culture were performed by Diana F. Lázaro in 
the Department of Neurodegeneration and Restorative Research of the University Medical 
Center Göttingen (Göttingen, Germany).  
 
2.2.7.1 Transfection of H4 cells 
H4 neuroglioma cells were used to analyze aggregation propensity of αSyn in mammalian 
cells. H4 cells are tumor cells of human neuroglia. H4 cells were plated 24 hours prior to 
transfection in 12-well plates (Costar). Cells were transfected with FuGENE®6 Transfection 
Reagent (Promega) using equal amounts of plasmid DNA encoding for αSyn, synphilin-1 




For visualization of αSyn in H4 cells, immunocytochemistry was performed. This technique is 
based on the principle of specific binding of antibodies to antigens and is used to detect 
antigens in biological tissues. 48 hours after transfection, cells were washed with PBS and 
fixed with 4 % paraformaldehyde for 10 minutes at room temperature. After washing with 
PBS, cells were permeabilized with 0.5 % Triton X-100/PBS (Sigma-Aldrich) for 20 minutes 
at room temperature and blocked in 1.5 % normal goat serum (PAA)/PBS for one hour. Cells 
were incubated with a mouse anti-αSyn antibody (1:1000, BD Transduction Laboratory) 
overnight and then with a secondary antibody (Alexa Fluor 488 donkey anti-mouse IgG) for 
two hours at room temperature. Finally, cells were stained with Hoechst 33258 (1:5000 in 
PBS, Invitrogen) for five minutes and maintained in PBS prior to epifluorescence microscopy. 
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2.2.7.3 Quantification of α-synuclein inclusions in H4 cells 
Transfected cells were scored based on the αSyn inclusion pattern and classified into: cells 
without inclusions, less than ten inclusions (<10 inclusions), and more than ten inclusions 
(≥10 inclusions), as described (Lazaro et al., 2014). The total number of transfected cells was 
expressed in percentage, as the average from three independent experiments.  
 
2.2.7.4 Lactate dehydrogenase assay 
The lactate dehydrogenase (LDH) cytotoxicity assay (Roche Diagnostics) was performed 
according to the manufacturer’s instructions. Growth media from cells were applied in 
triplicates in a 96-well plate in a ratio 1:1 with the reaction mixture. The measurements were 
performed in a TECAN Infinite 200 Pro plate reader (Tecan Group) at 490 nm. The 
percentage of toxicity was calculated as indicated by the manufacturer. 
 
2.2.8 Statistical analysis 
Data were analyzed using GraphPad Prism 5 Software (San Diego, USA) and were 
presented as mean ± SEM of at least three independent experiments. The significance of 
differences was calculated using Students t-test, one-way ANOVA test with Bonferroni’s 
multiple comparison test or Dunnett’s multiple comparison test. P value < 0.05 was 




Misfolded oligomeric αSyn species have been hypothesized to be involved in the 
neurodegeneration process of PD and other synucleinopathies. In this study, ability of an 
eukaryotic cell to overcome misfolded and accumulated αSyn species was explored. 
Moreover, the impact of oxidative stresses on these molecular processes was addressed. 
Therefore, αSyn was heterologously expressed in Saccharomyces cerevisiae cells and the 
influence of nitration on αSyn-mediated cytotoxicity was examined. Thereby, aggregation 
propensity, growth impact, ROS/RNS accumulation, protein and mitochondrial analysis 
served as instruments to question, whether nitration affects αSyn-induced cytotoxicity. 
Moreover, it was investigated, whether there is an interplay between nitration and 
phosphorylation of αSyn on S129 as the predominant posttranslational modification found in 
LBs.  
 
3.1 α-synuclein forms dimers in vivo in yeast cells 
Exposure of αSyn to nitrating agents causes tyrosine nitration in vitro and leads to formation 
of covalently crosslinked αSyn dimers and inclusions (Hodara et al., 2004; Norris et al., 2003; 
Paxinou et al., 2001; Souza et al., 2000a; Takahashi et al., 2002). High levels of αSyn with 
C-terminal HIS6-tags were heterologously expressed in yeast cells to uncover how nitration 
influences in vivo αSyn toxicity and aggregate formation. The first approach was to examine, 
whether αSyn and A30P form dimers in vivo without additional exposure of the cells to 
nitrating or oxidative agents. αSyn and A30P expression was driven by the GAL1-promoter, 
which was repressed in the presence of glucose and induced when shifted to 2 % galactose-
containing medium for 12 hours. High copy number expression of the HIS6-tagged αSyn 
resulted in growth inhibition, whereas high expression of the A30P mutant resulted in a 
similar growth rate as the yeast control without any αSyn (Figure 6A). Similar results were 
previously reported with untagged or GFP-tagged αSyn and corroborate that the HIS6-tag 
does not interfere with the behavior of αSyn in yeast (Outeiro and Lindquist, 2003; Petroi et 
al., 2012).  
Next, αSyn proteins were enriched by Ni2+ pull-down under denaturing conditions in the 
presence of urea. Immunoblotting with anti-αSyn antibody revealed distinct bands, 
corresponding to monomeric (~17 kDa), dimeric (~35 kDa) and higher molecular weight αSyn 
species (oligomers), detected from in vivo samples (Figure 6B). This supports that αSyn and 
the A30P mutant form dimers and oligomers in vivo even without additional exposure of the 





Figure 6. αSyn forms dimers in vivo in yeast.  
(A) Spotting analysis of yeast cells expressing C-terminally HIS6-tagged αSyn and A30P 
αSyn on a high copy vector (2µ) driven by the inducible GAL1-promoter on non-inducing 
(´OFF`: glucose) and inducing (´ON`: galactose) SC-Ura medium after three days. Control 
cells expressed only the empty vector pME2795 (EV). (B) Immunoblotting of αSyn and A30P 
enriched from cell extracts by Ni2+ pull-down with anti-αSyn antibody. In vitro nitration was 
carried out with 15 µg of αSyn extracts using 1 µL peroxynitrite (PON) in the presence of 
1 µL 0.3 M HCl. (C) Quantification of dimers. Densitometric analysis of the immunodetection 
of αSyn and A30P dimers in vivo and in PON-treated samples. The amount of dimers is 
presented as percent of the total amount of αSyn detected per lane (monomer + dimer). 
Significance of differences was calculated with t-test (**, p < 0.01, n=4).  
 
Dimer and oligomer formation of αSyn in vivo was further analyzed by comparison to 
additional in vitro nitration (Souza et al., 2000a). PON (ONOO-) was applied as nitrating 
agent for αSyn tyrosine residues because it leads to the formation of stable αSyn oligomers. 
PON is formed by the reaction of superoxide (•O2-) with the free radical nitric oxide (•NO) and 
represents a major nitrating agent that causes tissue injury in several neurological disorders 
(Beckman, 1994; Beckman, 1996). αSyn and A30P proteins were expressed in yeast, pulled-
down using Ni2+-NTA and exposed to PON. Immunoblotting of the in vitro nitrated proteins 
revealed that the abundance of dimers and oligomers is significantly increased with the same 
pattern as for in vivo isolated αSyn species (Figure 6B). The major distinct band corresponds 
to the αSyn dimer species. Quantification of the dimer band intensities of in vivo isolated 
probes showed that A30P forms approximately twice as many dimers relative to monomers 
as wild-type αSyn (Figure 6C). In vitro nitration of αSyn and A30P increased the total amount 
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of dimers. However, the dimer to monomer ratios between αSyn and A30P were not changed 
when the in vivo samples were enhanced by additional in vitro nitration (Figure 6C). This 
result suggests that the high molecular weight variants of αSyn, which can be isolated from 
yeast cells and which withstand strong denaturing conditions during the pull-down (8 M Urea, 
2 % SDS), represent covalently crosslinked αSyn species. These data support the formation 
of αSyn dimers in living cells. A remarkable result is that the toxicity of αSyn, which correlates 
to a high protein aggregation rate (Petroi et al., 2012), results in a reduced amount of αSyn 
dimer relative to monomer. In contrast, the non-toxic A30P mutant that does not inhibit 
cellular growth (Figure 6A), and has a reduced aggregation rate (Petroi et al., 2012), 
produces twice as many dimers relative to monomers in comparison to wild-type αSyn. This 
suggests that αSyn dimer formation is a molecular mechanism which can be used by the cell 
as salvage pathway for detoxification. 
  
3.2 The C-terminus of α-synuclein is preferentially modified by nitration and 
di-tyrosine formation  
Liquid chromatography-mass spectrometry (LC-MS) analysis was performed to study αSyn 
and A30P nitration sites in vivo. Single trypsin or AspN digestions were employed and the 
resulting peptides were analyzed by LC-MS. In addition to single digestions, a combined 
proteolytic approach by double digestion of the proteins with trypsin and AspN was employed 
that enabled 100 % sequence coverage. The modifications of the tyrosine residues identified 
from fragment spectra are summarized in Table 15.  
 
Table 15. Determination of nitrated peptides from αSyn and A30P. 
                              in vivo                         in vitro (PON) 
  Y39 Y125 Y133 Y136 Y39 Y125 Y133 Y136 
αSyn monomers    3-NT   3-NT   3-NT   3-NT   3-NT   3-NT   3-NT  
αSyn dimers          3-NT        
A30P monomers    3-NT       3-NT   3-NT   3-NT    
A30P dimers          3-NT   3-NT   3-NT    
αSyn and A30P were enriched by Ni2+ pull-down from yeast crude extracts and separated by 
SDS-PAGE. Monomeric and dimeric αSyn stained with Coomassie were excised from the gel 
and digested with trypsin and AspN. Untreated (in vivo) and subsequent peroxynitrite (PON) 
treated (in vitro) αSyn and A30P protein samples were analyzed with LC-MS for tyrosine 
nitration. 3-NT (3-nitrotyrosine) indicates identified nitration sites, supported by at least two 
peptides and two independent experiments. 
 
As a positive control, αSyn was used, where nitration was enhanced after the pull-down by 
additional PON exposure. MS data revealed nitration of wild-type αSyn at all three C-terminal 
tyrosines (Y125, Y133, Y136). Nitration of A30P was restricted to Y125 and absent at Y133 
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or Y136. Nitration of the additional tyrosine residue Y39 in the N-terminal domain of αSyn 
could not be identified from any in vivo samples by LS-MS. Additional PON exposure, 
however, resulted in Y39 nitration in all samples. This suggests that Y39 is not a primary in 
vivo nitration target within cells. Additional PON-exposure after pull-down also revealed that 
the αSyn dimers can be potentially nitrated in vitro. The increased in vitro PON-mediated 
nitration of the A30P in comparison to wild-type could be due to the higher amounts of the 
dimer in this mutant strain. Beyond nitration, also phosphorylation of αSyn as well as of A30P 
at S129, Y125 or Y133 was identified but not at Y39 or Y136 (Table 16).  
 
Table 16. Phospho-peptides identified by MS/MS. 
Position Modification PTM Score αSyn PTM Score A30P Sequence Motif 
Y39 Phospho 0 1.5 KEGVLyVGSKT 
Y125 Phospho 9.7 8 PDNEAyEMPSE 
S129 Phospho 100 100 AYEMPsEEGYQ 
Y133 Phospho 99.8 100 PSEEGyQDYEP 
Y136 Phospho 0 0 EGYQDyEPEA 
Posttranslational modification (PTM) scores were calculated with phosphoRS algorithm and 
represent the probability for phosphorylation modification. The corresponding amino acid is 
indicated by a small letter code in the sequence motif. Number of peptide sequence 
matches: αSyn = 332; A30P = 414. 
 
The probabilities for possible phosphorylation sites were calculated with the phophoRS 
algorithm (Taus et al., 2011). Phosphorylation of Y125 was identified with only low probability 
scores (Table 16). In contrast, S129 and Y133 were almost completely co-phosphorylated 
with scores of 100 % for S129 and 99 % for Y133, respectively. 
The LC-MS spectra of αSyn and A30P migrating in SDS-PAGE with the size of the dimer 
band were analyzed to assess whether di-tyrosines cause dimer formation of αSyn or A30P. 
The presence of di-tyrosine peptide crosslinks was validated using StavroX2.3.4.5 software 
(Gotze et al., 2012). This software compares the masses of all potential crosslinked peptides 
with the precursor ion masses, calculates b- and y-type ions for all possible crosslinks and 
compares them to MS2 data of the precursor ion. Different combinations of crosslinked 
peptides with an identical mass are possible when multiple tyrosine residues are located on 
one and the same peptide. The crosslinked tyrosine pairs were assigned according to the 
scores calculated by StavroX based on the fragment ion series of the MS2 spectra. The MS 
data analysis verified that αSyn dimers are crosslinked by tyrosine residues. The detected 
combinations of crosslinked tyrosines are depicted in Table 17. The results indicate a strong 
preference for crosslinking of defined combinations of tyrosines (Table 17, Figure 7, 8). 
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Table 17. Number of verified crosslinks (in vivo). 
 Y39 Y125 Y133 Y136 
Y39 
    
Y125 
    
Y133 
    
Y136 
    
Determination of crosslinked peptides from αSyn and A30P. Exemplary heat map diagram of 
the number (N) of identified di-tyrosine crosslinked peptides of the non-treated αSyn 
samples.  
 
The most frequent combinations for either wild-type αSyn or A30P are Y125-Y136 and Y133-
Y136 dimers which are all located in the C-terminus. Only the C-terminal tyrosine residues 
can mutually interact. Only a small fraction of Y39-Y39 dimers were found and there are no 
tyrosine dimers between the N-terminal Y39 and the C-terminal tyrosines of αSyn or A30P.  
 
 
Figure 7. Analysis of di-tyrosine dimers from αSyn.  
(A) Distribution of all identified di-tyrosine peptides for untreated (in vivo) αSyn (left diagram) 
and A30P (right diagram) protein samples. Identified combinations of crosslinked peptides 
are presented as percentage of n (n = total number of MS2 spectra verified as crosslinked 
peptides). (B) Distribution of all identified di-tyrosine peptides for peroxynitrite (PON) treated 






Figure 8. MS2 analysis of crosslinked peptides. 
(A) Exemplary fragment ion MS2 spectrum of the crosslink between Y133 and Y136 of αSyn 
dimers. y-ions of the crosslinked peptides are represented in blue, while b-ions are 
represented in red. Fragmentation sites are indicated in the amino acid sequence. (B) 






These data suggest that the C-terminus of αSyn or A30P has an increased susceptibility for 
nitration and di-tyrosine formation compared to the N-terminus. Only Y125 is a major nitration 
site of A30P. In contrast, all three C-terminal tyrosines Y125, Y133 and Y136 of the wild-type 
αSyn are putative targets for nitration. Y133 is an additional strong and Y125 a weak 
phosphorylation site, respectively. Dimer formation through di-tyrosine follows a specific 
pattern for both tested αSyn proteins with predominant forms including Y136 interacting 
either with Y125 (Y125-Y136) or with Y133 (Y133-136). 
 
3.3 Tyrosine residues contribute to α-synuclein cytotoxicity and aggregate 
formation  
The codons for the four tyrosine sites of αSyn and A30P (Y39, Y125, Y133 and Y136) were 
replaced in the corresponding genes by phenylalanine codons (4(Y/F)) to analyze the role of 
the tyrosine residues on αSyn dimer formation, cytotoxicity or aggregation. Fusion genes with 
GFP- or HIS6-tags were constructed and expressed. Here, it was assessed whether the 
quadruple Y to F replacements influence the dimerization of αSyn and A30P. Expression of 
αSyn and A30P as well as their 4(Y/F) mutants was induced for 12 hours. Tagged proteins 
were enriched by Ni2+ pull-down under denaturing conditions. Immunoblotting using αSyn 
antibodies as well as antibodies that specifically recognize di-tyrosines revealed that 4(Y/F) 
mutants of αSyn or A30P had lost the potential to form dimers in vivo (Figure 9A). 
Additional in vitro nitration with PON did also not result in any dimer or oligomer formation 
and served as control (Figure 9A). Immunoblotting analysis was carried out to determine in 
vivo nitrated αSyn using 3-nitrotyrosine specific antibodies (Figure 9B). The results 
demonstrated that the 4(Y/F) variants of wild-type αSyn or A30P did not result in any nitration 
signal even after additional PON treatment. This is in contrast to wild-type αSyn with its four 
original tyrosine residues as control, where nitration is present in vivo and can be further 




Figure 9. Mutation of tyrosines of αSyn prevents dimerization and nitration of αSyn. 
(A) Expression of αSyn, A30P, 4(Y/F) and A30P/4(Y/F) αSyn was induced for 12 hours in 
galactose-containing medium and the proteins were enriched by Ni2+ pull-down from yeast 
cell extracts. For in vitro nitration, 1 µL peroxynitrite (PON) was mixed with 15 µg of αSyn 
extracts in the presence of 1 µL 0.3 M HCl. Immunoblotting with di-tyrosine antibody reveals 
a major band at about 36 kDa, corresponding to dimers. Additional bands with lower 
molecular weights are probably due to intramolecular di-tyrosine crosslinking. The same 
membrane was stripped and re-probed with αSyn antibody. (B) Immunoblotting using 3-
nitrotyrosine antibody (3-NT). Phenylalanine codon substitutions eliminate immunoreactivity. 
The same membrane was stripped and re-probed with αSyn antibody.  
 
The growth impact of wild-type αSyn or the A30P variant were compared with that of the 
additional 4(Y/F) substitutions by spotting analysis and in liquid medium, respectively 
(Figure 10). Substitutions of the four tyrosine residues in wild-type αSyn significantly 
improved growth on solid medium, whereas A30P αSyn growth was similar with tyrosine or 
instead with phenylalanine residues (Figure 10A). Growth in liquid medium resulted in similar 
effects, revealing significantly reduced growth inhibition of the 4(Y/F) mutant strain in 
comparison to wild-type αSyn (Figure 10B), whereas A30P and its A30P/4(Y/F) derivative 




Figure 10. Blocking of αSyn tyrosine nitration decreases cytotoxicity.  
(A) Spotting analysis of yeast cells expressing GAL1-driven αSyn, A30P, 4(Y/F), A30P/4(Y/F) 
αSyn and GFP (control). Yeast cells were spotted in 10-fold dilutions on SC-Ura plates 
containing glucose (αSyn ‘OFF’) or galactose (αSyn ‘ON’). (B) Cell growth analysis of yeast 
cells expressing αSyn, 4(Y/F) and GFP (control) in galactose-containing SC-Ura medium for 
40 hours. Error bars represent standard deviations of three independent experiments. (C) 
Cell growth analysis of yeast cells expressing A30P, A30P/4(Y/F) αSyn and GFP (control), in 
galactose-containing SC-Ura medium for 40 hours. Error bars represent standard deviations 
of three independent experiments.  
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It was assessed, whether the decrease in wild-type αSyn toxicity was related to the formation 
of αSyn inclusions (Figure 11A, B). No change in inclusion formation could be monitored 
when A30P was compared to A30P/4(Y/F). However, yeast cells expressing the 4(Y/F) αSyn 
variant formed less inclusions in comparison to wild-type αSyn (Figure 11A, B). 
Immunoblotting with αSyn antibody revealed that the protein levels of the different αSyn 
variants were similar (Figure 11C), excluding that reduction of aggregates results from lower 
αSyn expression levels.  
 
 
Figure 11. Blocking of αSyn tyrosine nitration decreases aggregation.  
(A) Fluorescence microscopy of yeast cells, expressing indicated αSyn-GFP variants after six 
hours of induction in galactose-containing medium. Scale bar: 1 μm. (B) Quantification of the 
percentage of cells displaying aggregates after six hours induction in galactose-containing 
medium. Significance of differences was calculated with t-test (*, p < 0.05, n=6). (C) 
Immunoblotting of protein crude extracts of GFP-tagged αSyn, 4(Y/F), A30P and 
A30P/4(Y/F) αSyn after six hours induction in galactose-containing medium. GAPDH 
antibody was used as loading control. 
 
Taken together, only tyrosine replacements by phenylalanine in case of wild-type αSyn but 
not in case of an additional A30P substitution reduce αSyn-induced toxicity and inclusion 
formation. Accordingly, there is only growth improvement in the absence of an A30P 
substitution that correlates with decrease of intracellular accumulations of αSyn fluorescent 
foci. This supports that tyrosine residues that are responsible for nitration of αSyn contribute 
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to the cytotoxic effect and inclusion formation of αSyn in yeast. This tyrosine-dependent 
effect is significantly less pronounced in the presence of an A30P codon mutation suggesting 
that A30P suppresses the tyrosine effect, which can be observed in wild-type αSyn. The 
presence of tyrosine residues in wild-type αSyn favor nitration and di-tyrosine crosslinking 
but offer only a minor contribution to inclusion formation. 
 
3.4 The nitric oxide oxidoreductase Yhb1 reduces A30P aggregation and 
toxicity 
The effect of nitrative stress on the toxicity and aggregation of wild-type and A30P mutant 
αSyn was examined. A yeast strain carrying a deletion in the yeast flavohemoglobin gene 
(YHB1), responsible for stress signaling, was used for enhancement of nitrative stress. Yhb1 
is a nitric oxide oxidoreductase, which protects against nitration of cellular targets and 
against cell growth inhibition under aerobic or anaerobic conditions (Liu et al., 2000). 
Deletion of YHB1 abolishes the nitric oxide (NO) consuming activity of yeast cells (Liu et al., 
2000). The compound DETA-NONOate causes nitrative stress by acting as a NO donor.  
The absence of the flavohemoglobin results in a growth impairment of the hypersensitive 
yhb1 deletion strain in comparison to wild-type under NO nitrative stress conditions 
(Figure 12A). The genes encoding wild-type or A30P αSyn, or GFP as a control, were 
expressed in ∆yhb1 or the isogenic wild-type background. Cell growth was compared in the 
absence of nitrative stress by spotting assays (Figure 12B). Wild-type αSyn was as well 
cytotoxic in the presence or absence of YHB1. This was different for A30P, where no 
cytotoxicity was observed in the presence of YHB1. However, expression of A30P in ∆yhb1 
cells inhibited cell growth. This effect was verified by low copy plasmid expression of YHB1. 
Cells rescued with YHB1 showed the same growth phenotype as the original A30P or the 






Figure 12. The nitric oxide oxidoreductase Yhb1 reduces A30P toxicity. 
(A) Cell growth comparison of wild-type YHB1 and mutant ∆yhb1 yeast cells in the presence 
of the NO stress-mediating drug DETA-NONOate (1 mM) in liquid galactose-containing SC-
Ura medium. Error bars indicate standard deviations of three independent experiments. (B) 
Spotting analysis of YHB1 and ∆yhb1 yeast cells expressing αSyn (upper boxes) or A30P 
(lower boxes) compared to GFP and empty vector (EV) as control on non-inducing and 
galactose-inducing SC-Ura medium after three days. 
 
The correlation between growth inhibition and aggregate formation of αSyn variants was 
examined. Cells expressing αSyn or A30P were imaged by fluorescence microscopy and the 
cells displaying aggregates were counted. Deletion of YHB1 resulted in an increased 
percentage of cells with A30P inclusions, whereas no significant difference was observed in 
cell expressing wild-type αSyn (Figure 13A). In agreement with the growth analyses, the 
complementation of the ∆yhb1 deletion by YHB1 rescued the lower aggregation potential of 




Figure 13. The nitric oxide oxidoreductase Yhb1 reduces A30P aggregation.  
(A) Quantification of the percentage of cells displaying αSyn aggregates after six hours 
induction in galactose-containing medium. Significance of differences was calculated with t-
test (**, p < 0.01, n=6). (B) Immunoblotting of protein crude extracts of αSyn and A30P 
expressed in YHB1 and ∆yhb1 yeast after six hours induction in galactose-containing 
medium. GAPDH antibody was used as loading control. (C) Quantification of αSyn and A30P 
levels in YHB1 and ∆yhb1 yeast cells. Densitometric analysis of the immunodetection of 
αSyn and A30P relative to the intensity obtained for GAPDH (n=3). 
 
αSyn toxicity is dependent on the expression levels (Outeiro and Lindquist, 2003; Petroi et 
al., 2012). Thus, it was tested whether the A30P expression level is equal in Δyhb1 mutant 
compared to YHB1 yeast. Immunoblot analysis revealed that the A30P variant is expressed 
at similar levels in both yeast backgrounds six hours after induction of gene expression 
(Figure 13B, C), excluding that differences in toxicity are due to different A30P expression 
levels. 
 
3.5 Overexpression of YHB1 impairs growth of Saccharomyces cerevisiae 
As previous results of this study have shown, YHB1 is a repressor of A30P aggregation and 
toxicity. To test whether this protein generally diminishes αSyn-induced toxicity and whether 
increasing the putative repressive function by overexpression leads to reduction of toxicity, 
YHB1 was cloned into a high copy vector and overexpressed with wild-type αSyn and A30P 
in wild-type yeast. Growth analysis on solid medium shows that expression of YHB1 with 
either empty vector or GFP inhibits growth of yeast cells (Figure 14A), indicating that 
overexpression of YHB1 triggers cell processes that harm the cells. In yeast, Yhb1 detoxifies 
cell targets from nitric oxide (NO) (Liu et al., 2000). NO is a free radical that reacts with 
superoxide to form peroxynitrite. This oxidant harms the cell by damaging proteins, lipids and 
Results 
63 
DNA leading to dysfunction of important cell processes and cell death (Beckman, 1996). 
However, peroxynitrite was shown to have an important role for various cell signaling 
transduction pathways, due to its ability to nitrate tyrosine residues and thereby affecting 
phosphotyrosine-dependent signalling processes (Gow et al., 1996; Kong et al., 1996). 
Moreover, studies have found that peroxynitrite influences the activity of various kinases and 
phosphatases leading to up- or downregulation of signalling cascades (Kang et al., 2002; 
Klotz et al., 2000). Such examples of function variety demonstrate which dramatic influences 
the misbalance of peroxynitrite may induce in the cell. Overexpression of YHB1 changes the 
peroxynitrite levels, which may lead to misregulation of signalling pathways causing growth 
inhibition or cell death.  
 
Figure 14. Overexpression of YHB1 impairs growth of Saccharomyces cerevisiae. 
(A) Spotting assay of wild-type yeast cells expressing αSyn, A30P and GFP (control) with 
either empty vector (pME2792) as control or high copy of YHB1 on non-inducing and 
galactose-inducing SC-Ura medium after three days. (B) Quantification of the percentage of 
cells displaying αSyn and A30P aggregates after six hours induction in galactose-containing 
medium. Significance of differences was calculated with t-test (**, p < 0.01, n=3). 
 
When overexpressing wild-type αSyn together with YHB1, growth inhibition of the cells is 
severely enhanced. In contrast, co-expressing A30P with YHB1 only slightly inhibited growth 
similar to the control strains expressing the empty vector or GFP (Figure 14A). This suggests 
that the strong growth inhibition of wild-type αSyn and YHB1 expressing cells is an additive 
impact of coincidently overexpression of two genes causing cytotoxicity. Analysis of 
aggregation of wild-type αSyn and A30P co-expressing YHB1 demonstrated that strong 
growth inhibition induced by wild-type αSyn is accompanied by increase of aggregate 
formation (Figure 14B). However, aggregation of A30P was not significantly changed by 
YHB1 overexpression. The molecular target of Yhb1 is the small molecule nitric oxide. This 
free radical is the main source of nitrative stress but is also required as an endogenous 
signalling molecule involved in the regulation of different physiological processes. The 
observed growth inhibition of cells overexpressing YHB1 may result from disturbance of NO-
mediated cell processes.   
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3.6 Yhb1 decreases sensitivity of A30P expressing cells to nitrative stress 
Deletion of YHB1 constitutes an internal stress signal. The effect of nitrative stress on A30P 
was further investigated by adding external nitrative stress conditions. Growth tests in liquid 
culture were performed using DETA-NONOate, which reduces growth of the ∆yhb1 mutant 
but not of the wild-type strain (Figure 15A).  
 
 
Figure 15. Yhb1 decreases sensitivity of A30P expressing cells to nitrative stress.  
(A) Cell growth analysis of YHB1 and ∆yhb1 yeast cells expressing αSyn, A30P, 4(Y/F), 
A30P/4(Y/F) and GFP (control) after 40 hours induction in galactose-containing SC-Ura 
medium without DETA-NONOate. Error bars show standard deviations of three independent 
experiments. (B) Cell growth analysis of YHB1 and ∆yhb1 yeast cells expressing αSyn, 
A30P, 4(Y/F), A30P/4(Y/F) and GFP (control) with 600 µM DETA-NONOate. 
 
Cells expressing A30P αSyn grew uninhibited in the YHB1 wild-type background, whereas 
∆yhb1 cells expressing A30P were less inhibited than αSyn, thus recapitulating the growth 
phenotype on solid medium (Figure 12B, 15A). In contrast, ∆yhb1 cells expressing both αSyn 
variants were equally impaired in growth under nitrative stress conditions (Figure 15B). This 
indicates that increase in nitrative stress changes A30P to a toxic protein in yeast cells 
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comparable to wild-type αSyn. These results suggest a specific suppressive function of the 
nitric oxide oxidoreductase Yhb1 on A30P-induced aggregate formation and growth inhibition 
in yeast. 
 
3.7 α-synuclein expression does not affect the sensitivity of yeast cells to 
H2O2 
In addition to nitrative stress, oxidative stress was shown to be involved in the degeneration 
of dopaminergic neurons in PD. Increased levels of oxidized lipids, proteins and DNA was 
found in the substantia nigra of PD patients (Alam et al., 1997a; Alam et al., 1997b; Bosco et 
al., 2006). Moreover, in vitro studies showed that oxidative stress induces aggregation of 
αSyn when incubating with the reactive oxygen specie hydrogen peroxide (H2O2). Therefore, 
the sensitivity of αSyn expressing wild-type and Δyhb1 yeast cells to oxidative stress was 
analyzed by exposing the cells to H2O2 (Figure 16A). Sensitivity of yeast cells to H2O2 was 
concluded from the measured size of the growth inhibition area of cells grown on the surface 
of agar plates in the presence of a disc containing H2O2 (Figure 16B).  
 
Figure 16. αSyn expression does not affect sensitivity of yeast cells to H2O2.  
(A) Halo assay of YHB1 and ∆yhb1 yeast cells expressing αSyn or A30P compared to empty 
vector (EV) as control on galactose-inducing SC-Ura medium in the presence of a Whatman 
paper disc containing 10 µL 30 % H2O2 after three days. (B) Quantification of the inhibition 
area shown as cm2 after three days induction on galactose-containing medium. Significance 
of differences was calculated with t-test (n=2). 
 
αSyn and A30P expressing wild-type cells exhibit an equal inhibition area as the control cells 
expressing the empty vector (Figure 16) suggesting that expression of both αSyn variants 
does not change sensitivity of the yeast cells to H2O2. Moreover, the inhibition area of Δyhb1 
cells was similar to that of wild-type yeast cells, indicating that deletion of YHB1 does not 
affect the susceptibility of yeast to oxidative stress. This result revealed that αSyn expressing 
cells exhibit low sensitivity to H2O2 under the used experimental conditions, which is not 
influenced by increased nitrative stress levels in YHB1 deletion yeast.    
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3.8 Blockage of tyrosine nitration protects against A30P toxicity and 
aggregate formation under nitrative stress  
The removal of the four tyrosines of αSyn as possible cellular nitration sites (4(Y/F)) might 
affect αSyn toxicity in yeast when the intracellular nitrative stress level is increased using the 
∆yhb1 strain defective in stress protection. This was examined by comparing αSyn, A30P 
and their tyrosine to phenylalanine replacement derivatives (4(Y/F)), which were expressed 
in yeast with wild-type YHB1 or ∆yhb1 deletion background. Growth was analyzed by 
spotting analysis and in liquid medium (Figure 17A, B).  
 
Figure 17. C-terminal tyrosine replacements of A30P decrease toxicity in ∆yhb1.  
(A) Spotting analysis of αSyn, A30P, 4(Y/F) αSyn, A30P/4(Y/F) and GFP (control) expressed 
in YHB1 and ∆yhb1 yeast on non-inducing and galactose-inducing SC-Ura plates after three 
days of growth. (B) Cell growth analysis of YHB1 and ∆yhb1 yeast expressing αSyn, A30P, 
4(Y/F), A30P/4(Y/F) and GFP (control) at time point 20 hours. Significance of differences 
was calculated with t-test (*, p < 0.05; **, p < 0.01, n=3). (C) Quantification of the percentage 
of cells displaying αSyn aggregates after six hours induction in galactose-containing SC-Ura 
medium. Significance of differences was calculated with t-test (*, p < 0.05, **, p < 0.01, n=6). 
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Expression of 4(Y/F) αSyn with an intact YHB1 gene resulted in improved growth, whereas 
A30P toxicity was not affected (Figure 10, 17A, B). In the absence of the YHB1 gene, A30P 
delayed growth. However, 4(Y/F) A30P grew similar to the GFP control. A30P-mediated 
toxicity was related to the formation of inclusions (Figure 17C). These results corroborate 
that increased nitrative stress contributes to A30P toxicity by nitration of tyrosine residues. 
Nitration-deficient wild-type or A30P αSyn were less toxic and aggregated less, whereas an 
increase of intracellular nitrative stress resulted in growth retardation and increased 
aggregate formation of A30P variant only when tyrosine resides were present. 
 
3.9 Yhb1 reduces the accumulation of reactive nitrogen species in A30P 
expressing cells 
Oxidative and nitrative stresses are implicated in the pathogenesis of PD (Danielson and 
Andersen, 2008; Dias et al., 2013). These stresses emerge from the accumulation of reactive 
intermediates such as ROS and RNS. ROS and RNS production was visualized in yeast 
cells. αSyn and A30P expression was induced for six hours and ROS and RNS specific dyes 
were applied to compare the production of the reactive species in YHB1 and ∆yhb1 cells by 
fluorescence microscopy and flow cytometry. Dihydrorhodamine 123 (DHR123) was used for 
ROS detection. The dye accumulates in cells, where it is oxidized by free radicals to the 
bright red fluorescent product rhodamine 123 (Figure 18A, B). Expression of A30P and its 
derivative A30P/4(Y/F) did not significantly increase the number of cells accumulating ROS 
(Figure 18C). In contrast, expression of wild-type αSyn as well as its 4(Y/F) derivative 
strongly increased the number of cells that accumulate red fluorescence indicative for ROS. 
No difference in ROS accumulation was observed between the YHB1 wild-type and the 




Figure 18. Expression of αSyn increases accumulation of ROS.  
(A) αSyn and A30P were induced in galactose-containing medium for six hours in YHB1 wild-
type or ∆yhb1 deletion yeast strains. Cells were incubated with 5 μg/mL dihydrorhodamine 
123 (DHR123) as an indicator of high intracellular ROS accumulation for 1.5 hours and 
analyzed by live-cell fluorescence microscopy. Scale bar = 5 μm. (B) Fluorescent intensity of 
cells from (A), assessed with flow cytometry analysis. Forward scatter (FSC) and DHR123 
fluorescence of cells after six hours induction of αSyn expression. (C) Quantification of αSyn 
and A30P expressing cells displaying ROS stained by DHR123 using flow cytometry. The 
percentage of the sub-population of yeast cells with higher fluorescent intensities (P1) than 
the background is presented.  
 
DAF-2 DA (4,5-Diaminofluorescein diacetate) dye was used as a sensitive and highly 
specific fluorescent indicator for detection of NO (Figure 19A, B). Expression of both αSyn 
and A30P induced accumulation of reactive nitrogen species (Figure 19C). Interestingly, 
deletion of YHB1 significantly increased the number of cells exhibiting RNS when A30P 
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variant was expressed. This effect was dependent on tyrosine residues since RNS 
accumulation in cells expressing A30P/4(Y/F) did not differ from empty vector control. 
  
 
Figure 19. Δyhb1 increases accumulation of reactive nitrogen species (RNS) in A30P 
expressing cells.  
(A) Microscopy analysis of RNS stained cells. αSyn and A30P were induced in galactose-
containing SC-Ura medium for six hours in YHB1 and ∆yhb1 yeast strains. Cells were 
incubated with 25 μg/mL DAF-2 DA for one hour at 30 °C for visualization of RNS and 
analyzed by live-cell fluorescence microscopy. Scale bar = 5 μm. (B) Fluorescent intensity of 
cells from (A), assessed with flow cytometry analysis. Forward scatter (FSC) and DAF-2 DA 
fluorescence of cells after six hours induction of αSyn expression. (C) Quantification of αSyn 
and A30P expressing cells displaying RNS stained by DAF-2 DA using flow cytometry. The 
percentage of the sub-population of yeast cells with higher fluorescent intensities (P1) than 
the background is presented. Significance of differences was calculated with t-test (**, p < 




The results show that toxic wild-type αSyn expression induces significantly more ROS 
accumulation in yeast cells than non-toxic A30P. Accumulation of ROS species was not 
dependent on the presence of tyrosine residues or YHB1 gene. In contrast, both αSyn as 
well as A30P induce the accumulation of RNS for nitrative stress in yeast cells. The levels of 
RNS in A30P but not wild-type αSyn expressing cells are dependent on the presence of 
tyrosine residues and YHB1. The results suggest that Yhb1 attenuates the accumulation of 
RNS of A30P expressing cells.  
 
3.10 Yhb1 protects mitochondria from A30P toxicity 
Overexpression of αSyn and A30P leads to increased levels of RNS and higher sensitivity to 
NO stress in ∆yhb1 yeast. The Yhb1 protein is translocated into yeast mitochondria under 
hypoxic conditions where it detoxifies NO (Cassanova et al., 2005). Mitochondria are a major 
source of free radicals in the cells. Yhb1 is consuming NO, which inhibits mitochondrial 
respiration and thus increases the level of ROS. αSyn toxicity results in mitochondrial 
dysfunction and generation of ROS (Su et al., 2010). Overexpression of αSyn in mammalian 
cells results in mitochondrial fragmentation and involves a direct interaction of αSyn with 
mitochondrial membranes (Nakamura et al., 2011).  
It was examined, whether deletion of YHB1 influences the mitochondrial morphology in αSyn 
and A30P αSyn expressing yeast cells. αSyn expression in the wild-type and Δyhb1 
background was induced for six hours in galactose medium and the mitochondria were 
visualized with a mitochondrial specific dye (MitoTracker Red). Yeast cells overexpressing 
GFP served as a control (Figure 20A). Co-localization of αSyn with mitochondria was not 
observed, which suggests that the described mitochondrial fraction of the protein might be 
small (Nakamura et al., 2011). The mitochondrial morphology was classified as tubular, 
partially fragmented or fully fragmented. In the control cells, the mitochondria revealed a 
ribbon-like tubular architecture, typical for healthy mitochondria. Cells expressing αSyn 
showed a dramatic increase in the percentage of cells with fully fragmented mitochondria 




Figure 20. Yhb1 protects mitochondria from A30P toxicity.  
(A) Live-cell fluorescence microscopy of YHB1 compared to Δyhb1 yeast cells expressing 
GFP (control), αSyn or A30P after six hours induction in galactose-containing medium. 
MitoTracker Red was used to visualize mitochondria in the cells (MT panel). αSyn expressing 
cells with plasma membrane localization (PM) and with aggregates are visualized. Scale bar 
= 1 μM. (B) Quantification of yeast cells with tubular mitochondrial network. GFP: percentage 
of all cells with tubular mitochondria; αSyn* and A30P*: percentage of cells with aggregates, 
showing tubular mitochondria. At least 50 cells were counted per cell type and experiment. 
Significance of differences was calculated with t-test (*, p < 0.05, n=4). (C) Quantification of 
yeast cells with tubular mitochondrial network for rescue of A30P phenotype. A30P with 
empty vector (EV) in YHB1 and Δyhb1 strain and A30P co-transformed with YHB1 on low-
copy vector in Δyhb1 strain. A30P*: percentage of cells with aggregates, showing tubular 
mitochondria. Significance of differences was calculated with t-test (**, p < 0.01, n=3). 
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Cells with and without inclusions were considered separately for statistical evaluation. Cells 
with plasma-membrane localization of the GFP-signal, typical αSyn localization for early 
stages of expression or lower expression levels, revealed partially fragmented mitochondrial 
architecture. αSyn expressing cells with aggregates had fully fragmented mitochondria. In 
contrast to αSyn, A30P expressing cells with aggregates had mainly tubular mitochondria, 
similar to the control cells (Figure 20A). Deletion of YHB1 increased the percentage of cells 
with fully fragmented mitochondria almost two-fold (Figure 20B). Thus, the disrupted 
mitochondrial morphology in Δyhb1 correlates with the increased levels of RNS (Figure 19) 
and diminished growth behavior of A30P expressing cells (Figure 12B). Complementation of 
the Δyhb1 phenotype in A30P expressing cells rescued the defect (Figure 20C), as 
mitochondrial morphology was recovered by expression of YHB1 on a low-copy vector. The 
result suggests that Yhb1 protects against A30P-induced cytotoxicity by preventing the 
mitochondrial fragmentation.  
  
3.11 Mitochondrial functionality is not affected by Yhb1 in A30P expressing 
yeast cells  
Analysis of mitochondrial morphology revealed an YHB1-dependent mitochondrial 
fragmentation upon A30P expression. In the next step, it was investigated how mitochondrial 
functionality is affected by YHB1 deletion. Mitochondrial respiration was assessed by 
measuring the oxygen consumption rate (OCR) under mitochondrial stress conditions by 
applying the mitochondrial inhibitors oligomycin A and antimycin A and the mitochondrial 
uncoupler fluoro-carbonyl cyanide phenylhydrazone (FCCP). After six hours induction of 
αSyn or A30P expression in YHB1 yeast cells, no significant differences in the basal 
respiration could be detected (Figure 21A). However, expression of αSyn and A30P in Δyhb1 
diminished basal respiration of the cells.  
Interestingly, under stimulating conditions increased OCR was observed in Δyhb1 cells 
expressing A30P compared to YHB1 yeast, suggesting that these cells have higher reserve 
capacity (Figure 21B). Addition of oligomycin A, which is an inhibitor of the mitochondrial 
ATP synthase, had only a moderate inhibitory effect on OCR. It is known that the yeast ATP 
synthase is less sensitive to oligomycin A than the animal mitochondrial ATP synthase. The 
gene YOR1 (Yeast Oligomycin Resistance) is responsible for the tolerance to this drug 
(Katzmann et al., 1995). Addition of antimycin A strongly inhibited respiration in all strains. 
The reported severe effect of antimycin A on yeast mitochondrial respiration is in agreement 
with earlier investigations (Ocampo et al., 2012). The remaining oxygen consumption reveals 
the extent of non-mitochondrial sources of oxygen consumption in the cells (Figure 21C).  
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Non-mitochondrial respiration results from oxygen consumption of cytosolic oxidase 
enzymes. The formation of reactive oxygen and nitrogen species was shown to increase 




Figure 21. Mitochondrial functionality is not affected by Yhb1 in A30P expressing 
yeast cells.  
(A) Measurement of basal oxygen consumption rate (OCR) of YHB1 and Δyhb1 strains 
expressing αSyn, A30P and GFP (control) after six hours induction in galactose-containing 
SC-Ura medium. OCR is shown as absolute values in picomoles per minute after subtraction 
of non-mitochondrial respiration. Significance of differences was calculated with t-test (***, p 
< 0.001 versus GFP control; n=9). (B) Shown is OCR of YHB1 and Δyhb1 strains expressing 
αSyn, A30P and GFP (control) after six hours induction in galactose-containing SC-Ura 
medium normalized to basal respiration. OCR was measured after consecutive application of 
2 µM fluoro-carbonyl cyanide phenylhydrazone (FCCP), 20 µM oligomycin A and 50 µM 
antimycin A. OCR is shown as ratio normalized to basal respiration. Significance of 
differences was calculated with t-test (*, p < 0.05, n=9). (C) Shown is the non-mitochondrial 
respiration of YHB1 and Δyhb1 strains expressing αSyn, A30P and GFP (control) after six 
hours αSyn induction as ratio of OCR of antimycin A (50 µM) treated cells to basal OCR. 




In wild-type yeast, no differences in non-mitochondrial respiration were observed between 
control cells expressing GFP and cells expressing the two αSyn variants (Figure 21C). 
However, Δyhb1 cells expressing wild-type αSyn revealed increased non-mitochondrial 
respiration, which might be due to enhanced oxygen consumption by cytosolic oxidases or 
increased formation of of reactive oxygen and nitrogen species. These results indicate that 
αSyn-induced mitochondrial fragmentation does not compromise the bioenergetics of 
mitochondria when αSyn is overexpressed in yeast. However, non-mitochondrial oxygen 
consumption is varied in Δyhb1 cells expressing wild-type αSyn. 
 
3.12 Human neuroglobin protects against α-synuclein aggregate formation in 
yeast and in mammalian cells  
A BLAST search for human genes corresponding to yeast YHB1 revealed 49 % similarities of 
the YHB1 globin domain to the gene for human neuroglobin (NGB) as a putative homolog. It 
was analyzed analyzed whether the human counterpart of yeast YHB1 can affect αSyn 
aggregation. Neuroglobins are oxygen-binding proteins that are highly conserved among 
vertebrates and are expressed in the central and peripheral nervous system. They provide 
protection against hypoxic induced cell injury in the brain, which is associated with ROS and 
RNS accumulation (Greenberg et al., 2008). Both Yhb1 and neuroglobin contain a globin 
domain and are members of the globin gene family. NGB was shown to diminish beta-
amyloid-induced neurotoxicity in vitro and to attenuate the phenotypes in a transgenic mouse 
model of Alzheimer`s disease (Khan et al., 2007). NGB acts as an oxidative stress-
responsive sensor for neuroprotection (Watanabe et al., 2012).  
It was examined, whether human NGB affects αSyn or A30P growth and aggregate 
formation in yeast. Growth and aggregation of αSyn was not changed by the expression of 
the human NGB (Figure 22A, B). However, NGB expression in ∆yhb1 deletion strain rescued 
A30P yeast growth (Figure 22A) and reduced the number of cells with A30P aggregates 
(Figure 22C). The effect of NGB in yeast is similar to the impact of YHB1 on αSyn and A30P 





Figure 22. The human NGB gene for neuroglobin complements A30P growth in YHB1 
deletion yeast.  
(A) Spotting analysis of YHB1 and ∆yhb1 yeast cells co-expressing αSyn and GFP (control) 
(upper panel) or A30P and GFP (lower panel) with either empty vector as control or YHB1 
and NGB, respectively on non-inducing and galactose-inducing SC-Ura medium after three 
days. (B) Quantification of the percentage of cells displaying αSyn aggregates after six hours 
induction in galactose-containing medium (n=3). (C) Quantification of the percentage of cells 
displaying A30P aggregates after six hours induction in galactose-containing medium. 
Significance of differences was calculated with t-test (**, p < 0.01, n=3). 
 
It was examined, whether NGB has not only a protective role against αSyn aggregate 
formation in yeast but also in mammalian cells. Human Neuroglioma cells (H4) served as 
established αSyn aggregation model, where aggregation of αSyn is induced by co-
expressing C-terminally modified αSyn (SynT) and synphilin-1, αSyn-interacting protein that 
was also found in LBs (Engelender et al., 1999; Lazaro et al., 2014). H4 cells were co-
transfected with SynT, Synphilin-1 and NGB or empty vector and aggregate formation of 
SynT was monitored (Figure 23).  
Expression of NGB reduced the number of cells with aggregates almost two-fold in 
comparison to the control and reduced the number of aggregates per cell (Figure 23A, B). 
These results support that similar to its yeast counterpart YHB1, the stress response gene 





Figure 23. The human NGB gene for neuroglobin alters αSyn aggregation in 
mammalian cells.  
(A) Fluorescence microscopy of H4 cells co-expressing SynT, Synphilin-1 and pcDNA 
(control) or NGB-mCherry. Nuclei are stained with Hoechst dye (blue). Scale bar = 30 μm. 
(B) Quantification of the percentage of H4 cells displaying αSyn inclusions after 48 hours 
after transfection. Cells were classified into three groups according to the number of αSyn-
immunoreactive inclusions observed: cells with 10 inclusions, cells with less than 
10 inclusions and cells without inclusions. Significance of differences was calculated with 
one-way ANOVA (*, p < 0.05, n=3). (C) Lactate dehydrogenase (LDH) activity measurements 
support that NGB is non-toxic for H4 cells. H4 cells transfected with empty mammalian 
expression vector pcDNA3.1, with empty pcDNA3.1 or pcDNA3.1 encoding neuroglobin-
mCherry (NGB) together with SynT and symphilin-1 (SynT+Synphilin-1) were analyzed. 
Media from indicated H4 cells were collected and the secretion of lactate LDH was 
determined as a measure of cytotoxicity. Significance of differences were calculated with t-





Lactate dehydrogenase (LDH) measurements were performed to determine, whether there is 
an effect of NGB on cell toxicity. LDH is released into the cell culture medium upon damage 
of the plasma membrane and is, therefore, a widely used marker in cytotoxicity studies. LDH 
measurements were similar for all tested H4 cells (Figure 23C). The results support that the 
stress response gene NGB does act as suppressor of αSyn aggregation without significantly 
affecting the cytotoxicity.  
 
3.13 Yhb1 affects nitration but not dimerization level of A30P 
It was assessed, whether the different cytotoxicity of αSyn and A30P in yeast correlates with 
different nitration levels of the two variants in wild-type yeast background and under 
increased nitrative stress in ∆yhb1 strain. Immunoblotting performed with two specific 
antibodies against nitrotyrosine (3-nitrotyrosine and nitro-Y39 αSyn) showed that αSyn and 
A30P are nitrated in the YHB1 as well as in Δyhb1 yeast (Figure 24A).  
 
 
Figure 24. Yhb1 affects nitration of A30P.  
(A) Immunoblotting of 3-nitrotyrosine using 3-nitrotyrosine antibody (3-NT, left) and nitro-Y39 
αSyn antibody (Y39-3-NT, right). Protein expression was induced for 12 hours in galactose-
containing SC-Ura medium. Concentrated protein extracts of Ni2+ pull down-enriched αSyn 
and A30P αSyn from YHB1 and ∆yhb1 yeast cells were applied. Cells expressing empty 
vector (EV) served as control. The same membranes were stripped and re-probed with αSyn 
antibody. (B) Quantification of αSyn and A30P nitration levels in YHB1 and ∆yhb1 yeast 
cells. Densitometric analysis of the immunodetection of nitrated αSyn and A30P relative to 
the intensity obtained for αSyn. Significance of differences was calculated with one-way 
ANOVA with Bonferroni’s multiple comparison test (*, p < 0.05; ****, p < 0.0001; n=3).  
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Quantification of band intensities of both nitrated αSyn variants revealed significantly higher 
nitration level of αSyn in comparison to A30P. Deletion of YHB1 resulted in increase of A30P 
nitration level, whereas αSyn nitration level was not affected (Figure 24B).  
 
 
Figure 25. Yhb1 affects nitration but not dimerization of αSyn and A30P.  
(A) Immunoblotting of αSyn enriched by Ni2+ pull-down with αSyn antibody. (B) Ratio of 
dimers relative to the sum of monomers and dimers. Densitometric analysis of the 
immunodetection of αSyn and A30P αSyn dimers, presented as percent of the total amount 
of αSyn detected per lane (monomer + dimer). Significance of differences was calculated 
with one-way ANOVA (**, p < 0.01; n=4). 
 
The increased nitration level does not correlate with an increased dimerization level of both 
αSyn variants. The dimerization was not influenced by nitrative stress enhancement (Figure 
25A, B). The results suggest that nitration of αSyn contributes to the cytotoxicity of the 
protein, whereas dimer formation is in reverse correlation to toxicity. 
 
3.14 Tyrosine 133 is required for phosphorylation of α-synuclein at serine 129 
Phosphorylation of Y125 is required in vitro as a priming event for efficient phosphorylation of 
S129 by casein kinase CK1 (Kosten et al., 2014). Phosphorylation of S129 is the major PTM 
of αSyn, found in 90 % of the aggregated protein in neuronal inclusions of PD patients 
(Anderson et al., 2006). αSyn and A30P are phosphorylated at S129 in yeast by endogenous 
kinases and phosphorylation has a protective role against αSyn-induced toxicity and 
aggregate formation (Shahpasandzadeh et al., 2014; Tenreiro et al., 2014b). Given the 
importance of these PTM and the close proximity of serine and tyrosine residues at the C-
terminus, it was assessed whether there is a cross-talk between modifications of tyrosine 
residues and phosphorylation of αSyn at S129 in vivo. Immunoblotting with an antibody that 
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specifically recognizes αSyn phosphorylated at Y133 showed that both αSyn and A30P are 




Figure 26. αSyn has a higher S129 phosphorylation level than A30P.  
(A) Immunoblotting of αSyn and A30P expressed in YHB1 and ∆yhb1 yeast enriched by Ni2+ 
pull-down, using Y133 phosphorylation-specific αSyn antibody (pY133) and S129 
phosphorylation-specific αSyn antibody (pS129). The same membrane was stripped and re-
probed with αSyn antibody. (B) Quantification of αSyn and A30P Y133- and S129-
phosphorylation levels in YHB1 and ∆yhb1 yeast cells. Densitometric analysis of the 
immunodetection of pY133, pS129 αSyn and A30P relative to the intensity obtained for 
αSyn. Significance of differences was calculated with one-way ANOVA test (**, p < 0.01; 
n=4).  
 
Quantification of Y133 phosphorylation revealed similar phosphorylation level of αSyn and 
A30P variant both in presence and absence of Yhb1 (Figure 26A, B). Next, it was analyzed 
whether there is a difference between S129 phosphorylation level of αSyn and A30P. S129 
phosphorylation level of αSyn was much higher than that of A30P (Figure 26A, B).  
Tyrosine to phenylalanine (Y/F) substitutions were analyzed for their effects on the 
phosphorylation level at S129. Y/F mutation of the N-terminal tyrosine 39 as well as of the C-
terminal Y125 and Y136 did not affect the phosphorylation status of S129 (Figure 27A). In 
contrast, mutation of Y133 had a drastic impact and resulted in complete loss of 
phosphorylation at S129. Yeast growth was compared in spotting assay as well as in liquid 
culture between yeast cells, expressing Y/F single mutants and S129A phosphorylation 
deficient mutant (Figure 27B, C). Yeast growth was measured after 20 hours induction of 
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protein expression. Expression of Y133F resulted in significant growth inhibition in 
comparison with αSyn and other tyrosine mutants. S129A showed slight growth inhibition 




Figure 27. Tyrosine 133 is required for phosphorylation of αSyn at serine 129.  
(A) Immunoblotting of crude extracts from yeast cells, expressing different αSyn variants 
after six hours induction of protein expression using S129 phosphorylation-specific αSyn 
antibody (pS129) and αSyn antibody. Cells expressing S129A mutant served as control. (B) 
Spotting analysis of αSyn and indicated mutant strains driven by the inducible GAL1-
promoter on non-inducing (´OFF`: glucose) and inducing (´ON`: galactose) SC-Ura medium 
after three days. Yeast cells overexpressing GFP served as control. (C) Cell growth analysis 
of cells expressing different αSyn variants and GFP (control) after 20 hours induction of 
expression in galactose-containing SC-Ura medium. Significance of differences was 
calculated with one-way ANOVA (****, p < 0.0001) or Dunnett’s multiple comparison test (#, p 
< 0.05; ###, p < 0.001, n=4). (D) Quantification of the percentage of cells displaying αSyn 
aggregates after six hours induction in galactose-containing SC-Ura medium. Significance of 
differences was calculated with one-way ANOVA (***, p < 0.001) or Dunnett’s multiple 
comparison test (#, p < 0.05, ##, p < 0.01 versus αSyn; n=6). 
 
In addition to growth analysis, membrane integrity of the Y/F single mutants and S129A 
phosphorylation deficient mutant was examined to assess the cell viability of the mutants 
(Figure 28). Propidium iodide (PI) staining was used after 20 hours of protein induction as a 




Figure 28. Y133F and S129A mutations increase αSyn-mediated cytotoxicity.  
(A) Forward scatter (FSC) of cells assessed with flow cytometry analysis. Cells expressing 
different αSyn variants and GFP (control) after 20 hours induction of expression were stained 
with 12.5 μg/mL PI for 30 minutes. Shown is one representative result from at least four 
independent experiments. (B) Quantification of cells expressing different αSyn variants and 
GFP (control) displaying Propidium Iodide (PI) fluorescence after 20 hours induction of αSyn 
expression, assessed by flow cytometry. The percentage of PI-positive yeast cells with 
higher fluorescent intensities (P1) than the background is presented. Significance of 
differences was calculated with one-way ANOVA (****, p < 0.0001) or Dunnett’s multiple 
comparison test (#, p < 0.05; ###, p < 0.001 versus αSyn; n=4). 
 
Expression of Y133F and S129A significantly diminished membrane integrity, corroborating 
that expression of these mutants result in increased cytotoxicity. Flow cytometry 
measurements were performed to determine the accumulation of ROS and RNS in yeast 
cells, expressing the single mutants. DHR123 was used for detection of ROS (Figure 29A, C) 




Figure 29. Tyrosine 133 mutation does not alter the accumulation of reactive oxygen 
and nitrogen species.  
Quantification of cells expressing different αSyn variants displaying ROS (A) and RNS (B) 
assessed with flow cytometry analysis. αSyn expression was induced for six hours and the 
cells were stained for 1.5 hours with DHR123 to visualize ROS (A) and for 1.5 hours with 
DAF-2 DA to visualize RNS (B). Presented is the percentage of the sub-populations of yeast 
cells with higher fluorescent intensities (P1) than the background. Significance of differences 
was calculated with one-way ANOVA (****, p < 0.0001; n=4). (C, D) Forward scatter (FSC) of 
cells expressing different αSyn variants displaying DHR123 (C) and DAF-2 DA (D) 
fluorescence assessed with flow cytometry analysis. Shown is one representative result from 
at least four independent experiments.  
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Expression of all mutants revealed a significant increase in the levels of ROS and RNS in 
comparison with the control, however, no significant differences were observed between the 
single mutants revealing that the enhanced toxicity of Y133F and S129A mutant is not due to 
higher accumulation of ROS or RNS. These results indicate that Y133 is required for the 
protective effect of αSyn S129 phosphorylation in vivo. Expression of Y133F was more toxic 
than expression of the S129A phosphorylation deficient αSyn variant, suggesting additional 
protective contribution of Y133 modifications against αSyn cytotoxicity. The data support a 
complex cross-talk between nitration and phosphorylation of the C-terminal tyrosine residues 
and S129 phosphorylation of αSyn and A30P. 
 
3.15 C-terminal α-synuclein modifications promote autophagy clearance of α-
synuclein aggregates  
GAL1-promoter shut-off experiments were performed to study the role of αSyn PTMs on 
autophagy/vacuole and proteasome-mediated aggregate clearance of αSyn. The impact of 
blocking these systems by drug treatments was examined. Expression of αSyn was induced 
for four hours in galactose-containing medium and the cells were then shifted to glucose-
containing medium in order to repress the promoter. Cells were imaged four hours after 
promoter shut-off and the percentage of cells with inclusions was determined. Shut-off 
studies were performed with wild-type αSyn and the mutants 4(Y/F), S129A and Y133F. 
PMSF was used as an inhibitor of autophagy/vacuole to study the contribution of this 
pathway for aggregate clearance (Petroi et al., 2012). PMSF impairs the activity of many 
vacuolar serine proteases without interfering with proteasome function (Dubiel et al., 1992; 
Jones, 2002). Inhibition of autophagy resulted in inefficient aggregate clearance of αSyn, as 
shown previously (Petroi et al., 2012; Shahpasandzadeh et al., 2014). Mutations of the 
codons for the four tyrosines as well as the S129 and Y133 single exchanges resulted in 
similar aggregate clearance by inhibition of the autophagic proteases as in the control cells 
without drug (ethanol) (Figure 30A). This suggests that autophagy is less involved in 
aggregate clearance of these mutants and shows that autophagy-mediated aggregate 
clearance requires modifications of the tyrosines and S129.  
The contribution of the proteasome on 4(Y/F), S129A and Y133F αSyn aggregate clearance 
was analyzed by applying the proteasome inhibitor MG132 (Lee and Goldberg, 1998). In 
contrast to autophagy impairment, cells expressing 4(Y/F) and S129A αSyn cleared 





Figure 30. αSyn aggregate clearance after promoter shut-off.  
(A, C) Quantification of cells displaying aggregates of αSyn (A) and A30P (C) upon inhibition 
of autophagy by PMSF. Cells expressing αSyn (A) or A30P (C) and its 4(Y/F), S129A and 
Y133F variants were incubated in 2 % galactose-containing media for four hours and shifted 
to 2 % glucose-containing media supplemented with 1 mM PMSF dissolved in EtOH and only 
EtOH as a control. Cells with aggregates were counted after four hours GAL1-promoter shut-
off and presented as ratio to the control (EtOH). Significance of differences was calculated 
with one-way ANOVA (*, p < 0.05; **, p < 0.01) or Dunnett’s multiple comparison test (#, p < 
0.05; ##, p < 0.01 versus αSyn; n=4). (B, D) Quantification of cells displaying aggregates of 
αSyn (B) and A30P (D) upon inhibition of the proteasome by MG132. Cells expressing αSyn 
(B) or A30P (D) and the indicated 4(Y/F), S129A and Y133F variants were incubated in 2 % 
galactose-containing media for four hours and shifted to glucose medium, supplemented with 
75 μM MG132 dissolved in DMSO or only DMSO as a control. Cells with aggregates were 
counted after four hours GAL1-promoter shut-off and presented as ratio to the control 
(DMSO). Significance of differences was calculated with one-way ANOVA (***, p < 0.001) or 
Dunnett’s multiple comparison test (#, p < 0.05; ##, p < 0.01 versus αSyn; n=4). 
 
 
These results corroborate previous findings showing a minor contribution of proteasome-
dependent clearance of αSyn aggregates (Petroi et al., 2012). However, cells expressing the 
Y133F mutant were unable to clear inclusions in a same manner as the wild-type, 4(Y/F) and 
S129A αSyn. This indicates that αSyn, which is not modified at Y133, is degraded by the 
proteasomal pathway. The results suggest that PTMs of tyrosine residues and S129 promote 
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the autophagy mediated aggregate clearance, whereas non-modified Y133 residue is a key 
determinant for the targeting of the protein to the proteasome. Inhibition of autophagy of 
A30P expressing cells revealed diminished clearance of aggregates of A30P as well as the 
A30P/4(Y/F) mutant indicating that degradation of the A30P/4(Y/F) aggregates depends on 
the autophagy/vacuole system similarly to wild-type αSyn and A30P (Figure 30C). 
A30P/S129A and A30P/Y133F mutants were able to degrade aggregates efficiently upon 
autophagy inhibition, similar to S129A and Y133F. Proteasome impairment resulted in 
inefficient clearance of the A30P/Y133F mutant (Figure 30D). However, this impact was not 
as strong as in the αSyn Y133F mutant, confirming that the wild-type αSyn is strongly 





In industrialized countries, better nutrition, growing health awareness and less heavy 
physical work result in improved quality of life. In addition, medical advances such as novel 
drugs, novel ways of diagnostic, preventive medicine and technological progress lead to 
increased life expectancy. However, extended life span correlates with an elevated risk for 
neurodegenerative disorders resulting in physical or mental impairments and a long period of 
suffering. Up to now, no curative therapies are available because most of the pathogenic 
causes are unknown. Therefore, study of human neurodegenerative diseases such as 
Parkinson´s disease (PD) is becoming increasingly important.  
The small neuronal protein αSyn is thought to be one of the most crucial factors in the 
pathogenesis of PD. αSyn is an intrinsically unfolded brain protein of 140 amino acids which 
is present in high concentration at presynaptic terminals as soluble or membrane-associated 
fractions. It is the major component of the fibrillary intracellular protein inclusions termed 
Lewy bodies that are associated with selective loss of dopamine-producing neurons in the 
substantia nigra in PD. Among other factors, posttranslational modifications were observed 
to alter the aggregation propensities of αSyn.  
In this study, Saccharomyces cerevisiae was used as reference cell to study the function of 
posttranslational modifications such as nitration or phosphorylation on the toxicity of αSyn. 
Apart from understanding the behavior of αSyn in PD, this model system is also used for 
identification of new therapeutic strategies. When expressed in yeast, αSyn associates with 
the plasma membrane in a highly selective manner, before forming cytoplasmic inclusions 
through a concentration-dependent process (Outeiro and Lindquist, 2003; Petroi et al., 
2012). αSyn accumulations, further referred to as aggregates, cause vesicle traffic defects, 
proteasome dysfunction, mitochondrial activity impairment and damage to cellular 
membranes. These cellular disorders in yeast are reminiscent to αSyn-related effects of PD 
(Chen et al., 2005; Outeiro and Lindquist, 2003).  
Chemical reactive molecules such as reactive oxygen species (ROS) and reactive nitrogen 
species (RNS) are formed that damage the cell by causing oxidative and nitrative stress. 
Both cellular stresses are implicated in the pathogenesis of PD. Previous studies indicated 
that oxidative injury of αSyn, specifically nitration of tyrosine residues, contributes directly to 
the pathology of PD. However, the toxic mechanism involved in nitrative stress-induced 





4.1 Role of tyrosine nitration on α-synuclein cytotoxicity 
In αSyn four tyrosines sites were discovered that serve as targets of nitration (Sevcsik et al., 
2011). One is located in the membrane binding N-terminus at residue 39, and three near the 
C-terminus at residues 125, 133 and 136. All four tyrosines can be nitrated in the presence of 
oxidizing agents such as peroxynitrite (PON). These modifications lead to the accumulation 
of stable oligomers originating from covalent crosslinking through the formation of di-tyrosine 
species (Souza et al., 2000a).  
Several examples in the literature indicate a contribution of αSyn nitration in aggregation and 
αSyn-related neuronal vulnerability and suggest an implication of nitrative stress in the 
pathogenic mechanism of PD (Giasson et al., 2000; Jenner and Olanow, 1996; McCormack 
et al., 2012; Olanow, 1990; Souza et al., 2000a; Yao et al., 2004). Nitrated αSyn was 
detected in LBs from post mortem brain tissue using 3-nitrotyrosine antibodies (Giasson et 
al., 2000). It has been observed that nitrated αSyn can be toxic to dopaminergic neurons in 
vitro as well as in vivo (Yu et al., 2010). Neuroinflammation followed by nitration of αSyn 
causes accumulation of αSyn aggregates and neurodegeneration in mice (Gao et al., 2008). 
Nitrated αSyn was observed to induce adaptive immune responses that exacerbate PD 
pathology in the MPTP mouse model (Benner et al., 2008). Increased nitrated αSyn levels 
were detected in peripheral blood mononuclear cells of idiopathic PD patients compared to 
healthy individuals (Prigione et al., 2010). There might be a direct link between nitrative 
damage and the onset and progression of neurodegenerative synucleinopathies, but the 
precise molecular mechanism that leads to the formation of pathological inclusions is still 
elusive. Concluding these evidences, oxidative and nitrative stress plays an important role in 
αSyn induced cytotoxicity and consequently in the pathogenesis of PD.  
Phosphorylation at serine residue S129 represents the major protective phosphorylation site 
of αSyn, which is conserved from man to the baker’s yeast as a eukaryotic Morbus Parkinson 
cell model. The effect of nitrative modifications of αSyn and their contribution towards αSyn-
induced cytotoxicity was investigated. A complex interplay was discovered between 
modifications of the C-terminal tyrosine residues and S129 phosphorylation (Figure 31). 
These tyrosine residues of αSyn can be phosphorylated or nitrated with drastic 
consequences for cellular growth. There is a strong preference of the C-terminus of αSyn for 
nitration or di-tyrosine formation. Nitration interferes with protective phosphorylation of S129, 







Figure 31. αSyn posttranslational modifications and nitrative stress in yeast.  
Enhanced intracellular nitrative stress increases the protein nitration level and influences 
yeast growth and aggregation. The nitration of tyrosine residues acts as trigger for αSyn and 
A30P toxicity. Wild-type αSyn, which is highly nitrated, inhibits growth and shows a high 
aggregation rate. A30P is weakly nitrated and therefore, does not inhibit yeast growth and 
has a low aggregation propensity. Yhb1 and its human homolog NGB protect the cells 
against accumulation of nitrative species and diminish the aggregate formation. Increased 
aggregation contributes to ROS/RNS accumulation and mitochondrial fragmentation. Di-
tyrosine crosslinked dimers are formed in reverse correlation to cytotoxicity and do not 
depend on Yhb1. A30P forms twice as many dimers as the toxic αSyn variant, suggesting 
that the di-tyrosine crosslinked dimers are not toxic species and are presumably part of a 
cellular detoxification pathway, sequestering the protein off-pathway of αSyn nucleation. The 
C-terminal tyrosine modifications have dual effect on the toxicity of the protein. Y133, which 
is nitrated and phosphorylated, is required for the protective phosphorylation at S129 and for 
the autophagy degradation of αSyn aggregates. Non-modified Y133 promotes the 
proteasomal degradation of αSyn aggregates. N: nitration; P: phosphorylation.  
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Expression of αSyn in yeast induces a number of cellular defects and efficiently mimics the 
αSyn-related effects of PD (Chen et al., 2005; Outeiro and Lindquist, 2003; Zabrocki et al., 
2005). Among others, chemically reactive molecules such as ROS and RNS are formed that 
damage the cell by causing oxidative and nitrative stress which in turn contributes to cell 
death (Flower et al., 2005). Nitration reduces the binding affinity of αSyn to lipid vesicles and 
therefore disrupts αSyn-membrane interaction (Sevcsik et al., 2011). Hodora and colleagues 
concluded that nitration hinders αSyn to bind membrane lipids leading to increased unbound 
αSyn, which results in enhance of intracellular aggregates (Hodara et al., 2004).  
Oxidative injury of αSyn, specifically nitration of tyrosine residues, has been widely discussed 
to contribute directly to the pathology of PD. Nitrative stress was proposed to induce αSyn 
aggregation as well as αSyn-induced pathology (Benner et al., 2008; Giasson et al., 2000; 
Liu et al., 2011; Paxinou et al., 2001; Ulrih et al., 2008; Yu et al., 2010). However, also 
opposing influence of nitrated αSyn has been shown (Uversky et al., 2005; Yamin et al., 
2003b). Thus, the effect of nitrative αSyn modifications and their influence on the toxicity and 
aggregation of αSyn is still controversial. In this study, it was shown that PTMs on αSyn 
tyrosine residues have a dual impact on αSyn mediated growth inhibition of yeast cells 
(Figure 31). Previous studies suggested that nitration of αSyn might be responsible for the 
formation of the proteinaceous inclusions observed in PD brains and for the neuronal loss in 
the substantia nigra (Giasson et al., 2000; Yu et al., 2010). Here, it was shown that nitration 
increases the growth defect induced by αSyn in yeast cells. Tyrosine nitration increases 
aggregation, mitochondrial fragmentation and growth inhibition. A correlation between the 
growth impairment, mediated by αSyn and A30P and their nitration level was demonstrated. 
αSyn, which inhibits yeast growth and has a high aggregation level, is strongly nitrated. In 
contrast, A30P, which is not toxic to yeast and aggregates to a lesser extent, is weakly 
nitrated. Increased nitration of A30P as a consequence of YHB1 deletion leads to A30P-
induced toxicity in yeast cells, which indicates that nitration is able to convert a non-toxic to 
toxic specie.  
 
4.2 Role of Yhb1 and neuroglobin on α-synuclein cytotoxicity 
Expression of A30P in yeast has different toxicity properties from wild-type αSyn (Outeiro 
and Lindquist, 2003; Petroi et al., 2012). A30P is located in the cytoplasm, whereas αSyn is 
delivered to the plasma membrane. Overexpression from a high-copy number plasmid 
results in formation of A30P fluorescent foci, however, the aggregation is transient and yeast 
cell growth is not affected. In Saccharomyces cerevisiae, the gene YHB1 (yeast 
flavohemoglobin) was identified to be implicated in oxidative and nitrative stress response 
(Cassanova et al., 2005). This gene encodes a nitric oxide oxidoreductase that belongs to 
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the globin family. Yhb1 protects against nitration of cellular targets by NO detoxification (Liu 
et al., 2000) and was also shown to be involved in the control of ferric reductase activity and 
modulation of NO signaling pathways (Lewinska and Bartosz, 2006; Martinez-Ruiz and 
Lamas, 2009; Schildknecht and Ullrich, 2009). Using the ∆yhb1 mutant lacking the 
flavohemoglobin Yhb1, this study could demonstrate that nitration plays also a role for A30P 
and confirmed that nitration increases aggregation and growth inhibition (Figure 31). Yhb1 
decreases the nitration level of the A30P variant of αSyn by reducing the accumulation of 
reactive nitrogen species, with the result that yeast cells can tolerate increased levels of this 
αSyn variant without significant growth inhibition. Deletion of the YHB1 yeast gene results in 
deficient cellular detoxification machinery towards NO and makes A30P as toxic as wild-type 
αSyn. This shows that the A30P nitration level is a crucial factor for gaining toxicity. 
Consequently, elimination of its putative NO-detoxifier Yhb1 results in stronger formation of 
toxic αSyn aggregates. Yhb1 reduced the level of nitrative stress in A30P expressing cells. 
Moreover, Yhb1 protected the A30P-expressing cells from mitochondrial fragmentation. 
αSyn-induced fragmentation of mitochondrial structure caused by direct interaction of αSyn 
with the mitochondrial membranes was already demonstrated (Nakamura et al., 2011). It was 
proposed that ROS accumulation induced by αSyn expression is an indirect effect due to 
mitochondrial dysfunction (Su et al., 2010). A connection between increased nitrative stress 
and mitochondrial fragmentation was found. This suggests a mechanistic model based on 
the specific ability of αSyn and A30P to form aggregates and damage mitochondria induced 
by nitrative stress.  
A protein BLAST search for human homologues of yeast YHB1 identified similarity of Yhb1 to 




Figure 32. Putative conserved domain of Yhb1 and NGB. 
Yhb1 amino acid sequence was used as query sequence (seq.) and analyzed by the blastp 
tool using UniProtKB/Swiss-Prot as database. The human neuroglobin (NGB) was identified 
as a hit with a score of 60.1 bits and an E value of 5e-11, 28% identity and 49 % similarities 
in the globin domain of Yhb1.  
 
 
Analysis of neuroglobin (NGB), the human homologue of YHB1, in human cell lines (H4 
cells) confirmed that this protein modulates αSyn aggregation. Expression of neuroglobin in 
mammalian cells reduced the number inclusions per cell. The yeast nitric oxidoreductase 
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Yhb1 as well as its related human protein neuroglobin play protective roles against αSyn 
aggregation. Similar as Yhb1, NGB is a member of the globin family. In general, 
neuroglobins play a role as regulators of ROS, reservoir for oxygen, facilitator for oxygen 
transport and also acts as scavenger of nitric oxide. In human, neuroglobin is expressed 
primarily in neurons and protects against hypoxic neuronal death and ischemic brain injury 
(Wang et al., 2008). Furthermore, expression of neuroglobin protects against beta-amyloid-
induced neurotoxicity in transgenic mice in vivo (Khan et al., 2007). Increased neuroglobin 
levels were observed in brain tissue of patients with early and moderately advanced 
Alzheimer´s disease (AD) (Sun et al., 2013). Recent reports revealed that overexpression of 
neuroglobin prevents tau hyperphosphorylation at multiple AD-related sites (Chen et al., 
2012). These data support our findings and imply NGB as a new therapeutic target in PD and 
other neurodegenerative diseases. 
 
4.3 Dimerization of α-synuclein by covalent di-tyrosine crosslinking 
Beside nitration, the reaction between tyrosine and RNS can result in the formation of di-
tyrosine bonds, leading to the formation of stable αSyn oligomers, including dimers and 
higher oligomeric structures. At low peroxynitrite level, di-tyrosine formation outcompetes the 
reaction of tyrosine nitration (Pfeiffer et al., 2000; Schildknecht et al., 2013) indicating a 
forced reaction to tyrosine nitration under nitrative stress. This study observed formation of 
dimers and oligomers in vivo without exposure of yeast cells to nitrating agents; therefore, 
they represent the consequence of endogenous nitrative stress. Previous studies already 
demonstrated nitration-induced oligomerization of αSyn (Norris et al., 2003; Souza et al., 
2000a). There, treatment with nitrating agent resulted in the formation of αSyn dimers and 
oligomers crosslinked by di-tyrosine bonds. Using MS, this study characterized the tyrosine 
residues involved in covalent dimer formation and nitration and identified to what extend the 
different tyrosine residues are involved in the di-tyrosine formation and what are the precise 
positions of the respective tyrosines. This data is the first characterization of αSyn dimer 
species, formed in vivo and without additional exposure to nitrative agents.  
The LC-MS results reveal strong preference of the C-terminal tyrosine residues for dimer 
formation with predominant forms including Y136 interacting either with Y125 (Y125-Y136) or 
with Y133 (Y133-136). Y39 was hardly involved in dimer formation under physiological 
conditions in yeast or in vitro after PON treatment. Recently, in vitro studies on αSyn 
oligomerization and di-tyrosine formation upon treatment with tetranitromethane (TMN) 
demonstrate a predominant formation of di-tyrosine dimers when Y39 is not available for 
nitration (Y39F) and suggest that the N-terminal region of αSyn plays a role in TMN-induced 
di-tyrosine formation of higher order oligomers (Burai et al., 2015). Previous studies 
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described an increase of nitration at Y39 of αSyn in an oxidative cellular model of PD 
(Danielson et al., 2009), whereas data of this study reveal resistance of Y39 to 3-NT 
modification in comparison to the C-terminal tyrosine residues which are nitrated in vitro as 
well as in vivo. These results are corroborated by previous findings, where treatment of 
purified αSyn with PON did not result in nitration of Y39; however, all C-terminal residues 
were nitrated (Schildknecht et al., 2011).  
Higher nitration levels of αSyn compared to A30P were also detected by LC-MS data 
confirming the results from immunoblot analyses. There, only one tyrosine residue is nitrated 
in A30P, whereas three αSyn residues are nitrated. These data reveal that αSyn dimers 
originating from di-tyrosine crosslinking are non-toxic species in contrast to nitrated αSyn 
(Figure 31). Covalent bonding of the di-tyrosines stabilizes the dimeric structures and 
consequently removes αSyn molecules from aggregation to toxic aggregates. αSyn protein 
lacking all four tyrosine residues forms less aggregates, however, the aggregate formation is 
not prevented. This indicates that tyrosine residues are not crucial for in vivo assembly of the 
protein to aggregates and suggests an independent pathogenic mechanism of αSyn 
aggregation. Similarly, nitration of αSyn was shown to promote formation of stable off-
pathway oligomeric species that inhibit αSyn fibrillation (Uversky et al., 2005; Yamin et al., 
2003b). Thus, the formation of stable oligomers under oxidative stress conditions redirects 
the monomers to oligomers that do not contribute to fibril formation.  
 
4.4 Interplay between tyrosine nitration and serine 129 phosphorylation of α-
synuclein in yeast 
This study revealed that C-terminal tyrosine 133 is required for the protective 
phosphorylation of αSyn at S129. αSyn C-terminal tyrosines Y125, Y133 and Y136 are in 
close proximity to S129, which raises the question whether there is an interplay between 
different PTMs at these residues. S129-phosphorylated αSyn is abundantly found in LBs 
(Anderson et al., 2006; Fujiwara et al., 2002). This phosphorylation site is conserved in yeast 
and can be used by several endogenous kinases (Wang et al., 2012). The effects of S129 
phosphorylation are complex and the role of this modification on αSyn-induced toxicity and 
aggregation is still controversial (Tenreiro et al., 2014a). Phosphorylation of S129 was shown 
to play a role in the regulation of αSyn localization, aggregation and toxicity. Several 
mammalian models of PD have demonstrated a protective role of S129 phosphorylation on 
neuronal dysfunction (Gorbatyuk et al., 2008; Kuwahara et al., 2012). Contrary, neurotoxicity 
tests in rats revealed no protective role of S129 phosphorylation on αSyn toxicity (McFarland 
et al., 2009). Even a pathogenic effect of αSyn S129 phosphorylation was observed (Chen 
and Feany, 2005).  
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In yeast, S129 phosphorylation has a protective role against growth impairment and 
aggregate formation (Popova et al., 2015; Shahpasandzadeh et al., 2014; Tenreiro et al., 
2014b). Moreover, increased phosphorylation of αSyn mediated by PLK2 leads to aggregate 
clearance by the autophagy-vacuole system and suppresses cytotoxicity (Oueslati et al., 
2013). Further yeast studies revealed that autophagy-dependent clearance of αSyn 
aggregates is stimulated by sumoylation of αSyn (Shahpasandzadeh et al., 2014). Inhibition 
of sumoylation results in increased toxicity, impaired autophagic clearance as well as in 
redirection of the αSyn aggregates to the proteasome. Expression of the human kinase 
GRK5 in yeast results in increased phosphorylation and ubiquitination of non-sumoylated 
αSyn, which promotes the autophagy- and proteasome-mediated clearance of αSyn 
aggregates. Further studies in yeast showed downregulation of αSyn aggregate clearance 
and increased toxicity by inhibition of S129 phosphorylation using the S129A mutant of αSyn 
(Tenreiro et al., 2014b). 
Phosphorylation of the tyrosine residues of αSyn is less explored and the effects of this 
modification are still unclear, varying from protective to no impact on neurotoxicity and 
oligomerization (Chen et al., 2009; Ellis et al., 2001; Kosten et al., 2014; Nakamura et al., 
2002; Nakamura et al., 2001; Negro et al., 2002; Papay et al., 2002). This study shows for 
the first time that tyrosine 133 is strictly required for phosphorylation at S129 in yeast. 
Tyrosine 133 can be nitrated or phosphorylated, as demonstrated by immunoblot analysis 
and MS analysis. These two PTMs might have opposing roles on the cellular toxicity of the 
protein. Phosphorylation might prevent tyrosine residues from nitration and vice versa. In this 
study, tyrosine to phenylalanine exchanges that abolishes both phosphorylation and nitration 
were used. There are no protective mechanisms exist in the cell, which do not depend on 
aggregate formation but support cellular survival. This suggests an even more complicated 
interplay between different αSyn modifications.  
Recently, the role of site-specific nitration of αSyn was investigated using site-specifically 
nitrated synthetic proteins at Y39 and Y125 (Burai et al., 2015). The authors assessed the 
influence of nitration at Y125 and Y39 on PLK3-mediated in vitro phosphorylation at S129 
and showed that tyrosine nitration does not prevent recognition of the protein by PLK3 and 
the subsequent phosphorylation at S129. These results strengthen the link between the C-
terminal tyrosine and serine modifications, revealing a complex cross-talk between PTMs 
with different contributions to the cytotoxicity of αSyn (Figure 31).  
Previously, it was shown that autophagy is the major pathway for aggregate clearance in 
yeast (Petroi et al., 2012). The phosphorylation state of αSyn influences the clearance 
mechanism of the protein. Blocking of S129 phosphorylation in yeast leads to impaired 
aggregate clearance by autophagy (Tenreiro et al., 2014b). Increased levels of S129 
phosphorylation can suppress the defect of impaired αSyn sumoylation by rescuing the 
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autophagic aggregate clearance and promoting the proteasomal clearance of αSyn 
(Shahpasandzadeh et al., 2014).  
In this study, it was shown that posttranslational modifications of the four tyrosine residues, 
similar to S129 phosphorylation, promote the autophagic clearance of αSyn aggregates. 
Inhibition of autophagy rendered yeast cells unable to clear αSyn aggregates, however had 
no effect on the clearance of S129A, 4(Y/F) and Y133F mutants. Interestingly, Y133F mutant 
could not be degraded upon inhibition of the proteasome. Therefore, Y133 represents a key 
determinant for the degradation fate of αSyn. Phospho- and nitro-modifications at Y133 
promote the autophagic clearance of the aggregates, whereas the non-modified Y133 protein 
is directed to the proteasomenatural amino acids that mimic the phosphorylation or nitration 
state of the tyrosine residue, thus restricting the investigation of the contribution of a single 
posttranslational modification at one and the same tyrosine residue in vivo. These results 
reveal Y133 as major tyrosine phosphorylation site in yeast, and only insignificant 
phosphorylation at Y125 was observed. This study reveals a correlation between tyrosine 
nitration and the cellular S129 phosphorylation level (Figure 31).  
The wild-type αSyn has significantly higher nitration levels as well as increased protein 
populations with S129 phosphorylation but similar levels of Y133 phosphorylation when 
compared to its A30P variant. These results suggest that rather nitration than 
phosphorylation at Y133 promotes S129 phosphorylation in yeast. Alternatively, nitration at 
Y133 might change the protein conformation and make S129 more accessible for protein 
kinases. The protective effect of Y133 was not accompanied with changes in the potential to 
form aggregates. The discrepancy between the clear protective effect of Y133 on yeast 
growth without significant effect on inclusion formation suggests that additional yet elusive 
protective mechanisms exist in the cell, which do not depend on aggregate formation but 
support cellular survival. This suggests an even more complicated interplay between different 
αSyn modifications.  
 
4.5 C-terminal tyrosine residue modifications modulate α-synuclein toxicity in 
yeast as unicellular model for Parkinson´s disease  
The main goal in today´s PD research is the discovery of the pathogenic mechanism causing 
PD which may help to find a cure for the disease. αSyn aggregation and formation of αSyn 
oligomeric species have been prososed as one of the pathophysiological mechanisms that 
participates in neurodegeneration. Therefore, studies uncovering the conditions leading to 
αSyn aggregation and toxicity are urgently required. In this study, nitration and 
phosphorylation of αSyn were analyzed. It was demonstrated that tyrosine nitration is not 
required for aggregate formation but is neccessary for covalently crosslinking of dimers and 
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oligomers. The data reveal that nitration rather that dimer formation correlates with increased 
toxicity leading to mitochondrial fragmentation. Moreover, this study discloses a complex 
interplay between nitration and phosphorylation of αSyn C-terminal residues, deeply 
interconnected with nitrative stress, which determines the aggregate clearance by autophagy 
or ubiquitin-dependent 26S proteasome pathways. The proposed model derived from yeast 
as unicellular eukaryotic cell provides interesting hints and insights for the study of αSyn 
posttranslational communications as it happens in the human brain and its connection to 
oligomer or aggregate formation and clearance (Figure 31). Furthermore, this study suggests 
the human NGB as a modulator of αSyn aggregation, which can be used to gain a deeper 




Abeliovich, A., Schmitz, Y., Farinas, I., Choi-Lundberg, D., Ho, W.H., Castillo, P.E., Shinsky, 
N., Verdugo, J.M., Armanini, M., Ryan, A., Hynes, M., Phillips, H., Sulzer, D. and Rosenthal, 
A. (2000) Mice lacking alpha-synuclein display functional deficits in the nigrostriatal 
dopamine system. Neuron, 25, 239-252. 
Ahn, B.H., Rhim, H., Kim, S.Y., Sung, Y.M., Lee, M.Y., Choi, J.Y., Wolozin, B., Chang, J.S., 
Lee, Y.H., Kwon, T.K., Chung, K.C., Yoon, S.H., Hahn, S.J., Kim, M.S., Jo, Y.H. and Min, 
D.S. (2002) alpha-Synuclein interacts with phospholipase D isozymes and inhibits 
pervanadate-induced phospholipase D activation in human embryonic kidney-293 cells. J 
Biol Chem, 277, 12334-12342. 
Ahn, M., Kim, S., Kang, M., Ryu, Y. and Kim, T.D. (2006) Chaperone-like activities of alpha-
synuclein: alpha-synuclein assists enzyme activities of esterases. Biochem Biophys Res 
Commun, 346, 1142-1149. 
Alam, Z.I., Daniel, S.E., Lees, A.J., Marsden, D.C., Jenner, P. and Halliwell, B. (1997a) A 
generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy 
body disease. J Neurochem, 69, 1326-1329. 
Alam, Z.I., Jenner, A., Daniel, S.E., Lees, A.J., Cairns, N., Marsden, C.D., Jenner, P. and 
Halliwell, B. (1997b) Oxidative DNA damage in the parkinsonian brain: an apparent selective 
increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem, 69, 1196-1203. 
Anderson, J.P., Walker, D.E., Goldstein, J.M., de Laat, R., Banducci, K., Caccavello, R.J., 
Barbour, R., Huang, J., Kling, K., Lee, M., Diep, L., Keim, P.S., Shen, X., Chataway, T., 
Schlossmacher, M.G., Seubert, P., Schenk, D., Sinha, S., Gai, W.P. and Chilcote, T.J. 
(2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-
synuclein in familial and sporadic Lewy body disease. J Biol Chem, 281, 29739-29752. 
Appel-Cresswell, S., Vilarino-Guell, C., Encarnacion, M., Sherman, H., Yu, I., Shah, B., Weir, 
D., Thompson, C., Szu-Tu, C., Trinh, J., Aasly, J.O., Rajput, A., Rajput, A.H., Jon Stoessl, A. 
and Farrer, M.J. (2013) Alpha-synuclein p.H50Q, a novel pathogenic mutation for 
Parkinson's disease. Mov Disord, 28, 811-813. 
Arawaka, S., Wada, M., Goto, S., Karube, H., Sakamoto, M., Ren, C.H., Koyama, S., 
Nagasawa, H., Kimura, H., Kawanami, T., Kurita, K., Tajima, K., Daimon, M., Baba, M., Kido, 
T., Saino, S., Goto, K., Asao, H., Kitanaka, C., Takashita, E., Hongo, S., Nakamura, T., 
Kayama, T., Suzuki, Y., Kobayashi, K., Katagiri, T., Kurokawa, K., Kurimura, M., Toyoshima, 
I., Niizato, K., Tsuchiya, K., Iwatsubo, T., Muramatsu, M., Matsumine, H. and Kato, T. (2006) 
The role of G-protein-coupled receptor kinase 5 in pathogenesis of sporadic Parkinson's 
disease. J Neurosci, 26, 9227-9238. 
Athanassiadou, A., Voutsinas, G., Psiouri, L., Leroy, E., Polymeropoulos, M.H., Ilias, A., 
Maniatis, G.M. and Papapetropoulos, T. (1999) Genetic analysis of families with Parkinson 
disease that carry the Ala53Thr mutation in the gene encoding alpha-synuclein. Am J Hum 
Genet, 65, 555-558. 
Auluck, P.K., Caraveo, G. and Lindquist, S. (2010) alpha-Synuclein: membrane interactions 
and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol, 26, 211-233. 
Baba, M., Nakajo, S., Tu, P.H., Tomita, T., Nakaya, K., Lee, V.M., Trojanowski, J.Q. and 
Iwatsubo, T. (1998) Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's 
disease and dementia with Lewy bodies. Am J Pathol, 152, 879-884. 
References 
97 
Bartels, T., Choi, J.G. and Selkoe, D.J. (2011) alpha-Synuclein occurs physiologically as a 
helically folded tetramer that resists aggregation. Nature, 477, 107-110. 
Bartels, T., Kim, N.C., Luth, E.S. and Selkoe, D.J. (2014) N-alpha-acetylation of alpha-
synuclein increases its helical folding propensity, GM1 binding specificity and resistance to 
aggregation. PLoS One, 9, e103727. 
Beckman, J.S. (1994) Peroxynitrite versus hydroxyl radical: the role of nitric oxide in 
superoxide-dependent cerebral injury. Ann N Y Acad Sci, 738, 69-75. 
Beckman, J.S. (1996) Oxidative damage and tyrosine nitration from peroxynitrite. Chem Res 
Toxicol, 9, 836-844. 
Benner, E.J., Banerjee, R., Reynolds, A.D., Sherman, S., Pisarev, V.M., Tsiperson, V., 
Nemachek, C., Ciborowski, P., Przedborski, S., Mosley, R.L. and Gendelman, H.E. (2008) 
Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. 
PLoS One, 3, e1376. 
Bennett, M.C., Bishop, J.F., Leng, Y., Chock, P.B., Chase, T.N. and Mouradian, M.M. (1999) 
Degradation of alpha-synuclein by proteasome. J Biol Chem, 274, 33855-33858. 
Bertani, G. (1951) Studies on lysogenesis. I. The mode of phage liberation by lysogenic 
Escherichia coli. J Bacteriol, 62, 293-300. 
Blum, H., Beier, H. and Gross, H.J. (1987) Improved silver staining of plant proteins, RNA 
and DNA in polyacrylamide gels. Electrophoresis, 8, 93-99. 
Bonifacino, J.S. and Glick, B.S. (2004) The mechanisms of vesicle budding and fusion. Cell, 
116, 153-166. 
Bonifati, V., Rizzu, P., Squitieri, F., Krieger, E., Vanacore, N., van Swieten, J.C., Brice, A., 
van Duijn, C.M., Oostra, B., Meco, G. and Heutink, P. (2003) DJ-1(PARK7), a novel gene for 
autosomal recessive, early onset parkinsonism. Neurol Sci, 24, 159-160. 
Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., Abbruzzese, G. 
and Tabaton, M. (2000) Full length alpha-synuclein is present in cerebrospinal fluid from 
Parkinson's disease and normal subjects. Neurosci Lett, 287, 65-67. 
Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., Wentworth, P., Jr., Lerner, 
R.A. and Kelly, J.W. (2006) Elevated levels of oxidized cholesterol metabolites in Lewy body 
disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol, 2, 249-253. 
Botstein, D., Chervitz, S.A. and Cherry, J.M. (1997) Yeast as a model organism. Science, 
277, 1259-1260. 
Braak, H., Del Tredici, K., Rub, U., de Vos, R.A., Jansen Steur, E.N. and Braak, E. (2003) 
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-
211. 
Bradford, M.M. (1976) A rapid and sensitive method for the quantitation of microgram 
quantities of protein utilizing the principle of protein-dye binding. Anal Biochem, 72, 248-254. 
Brodsky, J.L. and Skach, W.R. (2011) Protein folding and quality control in the endoplasmic 




Burai, R., Ait-Bouziad, N., Chiki, A. and Lashuel, H.A. (2015) Elucidating the Role of Site-
Specific Nitration of alpha-Synuclein in the Pathogenesis of Parkinson's Disease via Protein 
Semisynthesis and Mutagenesis. J Am Chem Soc, 137, 5041-5052. 
Burre, J., Sharma, M., Tsetsenis, T., Buchman, V., Etherton, M.R. and Sudhof, T.C. (2010) 
Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science, 329, 
1663-1667. 
Campion, D., Martin, C., Heilig, R., Charbonnier, F., Moreau, V., Flaman, J.M., Petit, J.L., 
Hannequin, D., Brice, A. and Frebourg, T. (1995) The NACP/synuclein gene: chromosomal 
assignment and screening for alterations in Alzheimer disease. Genomics, 26, 254-257. 
Cassanova, N., O'Brien, K.M., Stahl, B.T., McClure, T. and Poyton, R.O. (2005) Yeast 
flavohemoglobin, a nitric oxide oxidoreductase, is located in both the cytosol and the 
mitochondrial matrix: effects of respiration, anoxia, and the mitochondrial genome on its 
intracellular level and distribution. J Biol Chem, 280, 7645-7653. 
Chacko, B.K., Kramer, P.A., Ravi, S., Benavides, G.A., Mitchell, T., Dranka, B.P., Ferrick, D., 
Singal, A.K., Ballinger, S.W., Bailey, S.M., Hardy, R.W., Zhang, J., Zhi, D. and Darley-Usmar, 
V.M. (2014) The Bioenergetic Health Index: a new concept in mitochondrial translational 
research. Clin Sci (Lond), 127, 367-373. 
Chandra, S., Chen, X., Rizo, J., Jahn, R. and Sudhof, T.C. (2003) A broken alpha-helix in 
folded alpha-Synuclein. J Biol Chem, 278, 15313-15318. 
Chandra, S., Fornai, F., Kwon, H.B., Yazdani, U., Atasoy, D., Liu, X., Hammer, R.E., 
Battaglia, G., German, D.C., Castillo, P.E. and Sudhof, T.C. (2004) Double-knockout mice for 
alpha- and beta-synucleins: effect on synaptic functions. Proc Natl Acad Sci U S A, 101, 
14966-14971. 
Chartier-Harlin, M.C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., 
Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., Waucquier, N., Defebvre, L., Amouyel, 
P., Farrer, M. and Destee, A. (2004) Alpha-synuclein locus duplication as a cause of familial 
Parkinson's disease. Lancet, 364, 1167-1169. 
Chaudhuri, K.R., Healy, D.G. and Schapira, A.H. (2006) Non-motor symptoms of Parkinson's 
disease: diagnosis and management. Lancet Neurol, 5, 235-245. 
Chen, L. and Feany, M.B. (2005) Alpha-synuclein phosphorylation controls neurotoxicity and 
inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci, 8, 657-663. 
Chen, L., Jin, J., Davis, J., Zhou, Y., Wang, Y., Liu, J., Lockhart, P.J. and Zhang, J. (2007) 
Oligomeric alpha-synuclein inhibits tubulin polymerization. Biochem Biophys Res Commun, 
356, 548-553. 
Chen, L., Periquet, M., Wang, X., Negro, A., McLean, P.J., Hyman, B.T. and Feany, M.B. 
(2009) Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on 
neurotoxicity and soluble oligomer formation. J Clin Invest, 119, 3257-3265. 
Chen, L.M., Xiong, Y.S., Kong, F.L., Qu, M., Wang, Q., Chen, X.Q., Wang, J.Z. and Zhu, 
L.Q. (2012) Neuroglobin attenuates Alzheimer-like tau hyperphosphorylation by activating 
Akt signaling. J Neurochem, 120, 157-164. 
Chen, Q., Thorpe, J. and Keller, J.N. (2005) Alpha-synuclein alters proteasome function, 
protein synthesis, and stationary phase viability. J Biol Chem, 280, 30009-30017. 
References 
99 
Chen, X., de Silva, H.A., Pettenati, M.J., Rao, P.N., St George-Hyslop, P., Roses, A.D., Xia, 
Y., Horsburgh, K., Ueda, K. and Saitoh, T. (1995) The human NACP/alpha-synuclein gene: 
chromosome assignment to 4q21.3-q22 and TaqI RFLP analysis. Genomics, 26, 425-427. 
Cherry, J.M., Hong, E.L., Amundsen, C., Balakrishnan, R., Binkley, G., Chan, E.T., Christie, 
K.R., Costanzo, M.C., Dwight, S.S., Engel, S.R., Fisk, D.G., Hirschman, J.E., Hitz, B.C., 
Karra, K., Krieger, C.J., Miyasato, S.R., Nash, R.S., Park, J., Skrzypek, M.S., Simison, M., 
Weng, S. and Wong, E.D. (2012) Saccharomyces Genome Database: the genomics 
resource of budding yeast. Nucleic Acids Res, 40, D700-705. 
Chinta, S.J., Mallajosyula, J.K., Rane, A. and Andersen, J.K. (2010) Mitochondrial alpha-
synuclein accumulation impairs complex I function in dopaminergic neurons and results in 
increased mitophagy in vivo. Neurosci Lett, 486, 235-239. 
Choi, B.K., Choi, M.G., Kim, J.Y., Yang, Y., Lai, Y., Kweon, D.H., Lee, N.K. and Shin, Y.K. 
(2013) Large alpha-synuclein oligomers inhibit neuronal SNARE-mediated vesicle docking. 
Proc Natl Acad Sci U S A, 110, 4087-4092. 
Clayton, D.F. and George, J.M. (1998) The synucleins: a family of proteins involved in 
synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci, 21, 249-254. 
Conway, K.A., Harper, J.D. and Lansbury, P.T. (1998) Accelerated in vitro fibril formation by 
a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med, 4, 1318-1320. 
Conway, K.A., Harper, J.D. and Lansbury, P.T., Jr. (2000) Fibrils formed in vitro from alpha-
synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. 
Biochemistry, 39, 2552-2563. 
Cooper, A.A., Gitler, A.D., Cashikar, A., Haynes, C.M., Hill, K.J., Bhullar, B., Liu, K., Xu, K., 
Strathearn, K.E., Liu, F., Cao, S., Caldwell, K.A., Caldwell, G.A., Marsischky, G., Kolodner, 
R.D., Labaer, J., Rochet, J.C., Bonini, N.M. and Lindquist, S. (2006) Alpha-synuclein blocks 
ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science, 313, 324-
328. 
Corpet, F. (1988) Multiple sequence alignment with hierarchical clustering. Nucleic Acids 
Res, 16, 10881-10890. 
Crawford, M.J., Sherman, D.R. and Goldberg, D.E. (1995) Regulation of Saccharomyces 
cerevisiae flavohemoglobin gene expression. J Biol Chem, 270, 6991-6996. 
Crow, J.P. (1997) Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive 
indicators of peroxynitrite in vitro: implications for intracellular measurement of reactive 
nitrogen and oxygen species. Nitric Oxide, 1, 145-157. 
Danielson, S.R. and Andersen, J.K. (2008) Oxidative and nitrative protein modifications in 
Parkinson's disease. Free Radic Biol Med, 44, 1787-1794. 
Danielson, S.R., Held, J.M., Schilling, B., Oo, M., Gibson, B.W. and Andersen, J.K. (2009) 
Preferentially increased nitration of alpha-synuclein at tyrosine-39 in a cellular oxidative 
model of Parkinson's disease. Anal Chem, 81, 7823-7828. 
Davidson, W.S., Jonas, A., Clayton, D.F. and George, J.M. (1998) Stabilization of alpha-
synuclein secondary structure upon binding to synthetic membranes. J Biol Chem, 273, 
9443-9449. 




de Rijk, M.C., Launer, L.J., Berger, K., Breteler, M.M., Dartigues, J.F., Baldereschi, M., 
Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C. and Hofman, A. (2000) 
Prevalence of Parkinson's disease in Europe: A collaborative study of population-based 
cohorts. Neurologic Diseases in the Elderly Research Group. Neurology, 54, S21-23. 
Desplats, P., Lee, H.J., Bae, E.J., Patrick, C., Rockenstein, E., Crews, L., Spencer, B., 
Masliah, E. and Lee, S.J. (2009) Inclusion formation and neuronal cell death through neuron-
to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci U S A, 106, 13010-13015. 
Devi, L., Raghavendran, V., Prabhu, B.M., Avadhani, N.G. and Anandatheerthavarada, H.K. 
(2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human 
dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem, 283, 9089-9100. 
Dexter, D.T. and Jenner, P. (2013) Parkinson disease: from pathology to molecular disease 
mechanisms. Free Radic Biol Med, 62, 132-144. 
Di Fonzo, A., Chien, H.F., Socal, M., Giraudo, S., Tassorelli, C., Iliceto, G., Fabbrini, G., 
Marconi, R., Fincati, E., Abbruzzese, G., Marini, P., Squitieri, F., Horstink, M.W., Montagna, 
P., Libera, A.D., Stocchi, F., Goldwurm, S., Ferreira, J.J., Meco, G., Martignoni, E., Lopiano, 
L., Jardim, L.B., Oostra, B.A., Barbosa, E.R. and Bonifati, V. (2007) ATP13A2 missense 
mutations in juvenile parkinsonism and young onset Parkinson disease. Neurology, 68, 
1557-1562. 
Dias, V., Junn, E. and Mouradian, M.M. (2013) The role of oxidative stress in Parkinson's 
disease. J Parkinsons Dis, 3, 461-491. 
Dixon, C., Mathias, N., Zweig, R.M., Davis, D.A. and Gross, D.S. (2005) Alpha-synuclein 
targets the plasma membrane via the secretory pathway and induces toxicity in yeast. 
Genetics, 170, 47-59. 
Dorval, V. and Fraser, P.E. (2006) Small ubiquitin-like modifier (SUMO) modification of 
natively unfolded proteins tau and alpha-synuclein. J Biol Chem, 281, 9919-9924. 
Dranka, B.P., Hill, B.G. and Darley-Usmar, V.M. (2010) Mitochondrial reserve capacity in 
endothelial cells: The impact of nitric oxide and reactive oxygen species. Free Radic Biol 
Med, 48, 905-914. 
Dubiel, W., Ferrell, K., Pratt, G. and Rechsteiner, M. (1992) Subunit 4 of the 26 S protease is 
a member of a novel eukaryotic ATPase family. J Biol Chem, 267, 22699-22702. 
Duda, J.E., Giasson, B.I., Chen, Q., Gur, T.L., Hurtig, H.I., Stern, M.B., Gollomp, S.M., 
Ischiropoulos, H., Lee, V.M. and Trojanowski, J.Q. (2000) Widespread nitration of 
pathological inclusions in neurodegenerative synucleinopathies. Am J Pathol, 157, 1439-
1445. 
Ebrahimi-Fakhari, D., Cantuti-Castelvetri, I., Fan, Z., Rockenstein, E., Masliah, E., Hyman, 
B.T., McLean, P.J. and Unni, V.K. (2011) Distinct roles in vivo for the ubiquitin-proteasome 
system and the autophagy-lysosomal pathway in the degradation of alpha-synuclein. J 
Neurosci, 31, 14508-14520. 
El-Agnaf, O.M., Salem, S.A., Paleologou, K.E., Cooper, L.J., Fullwood, N.J., Gibson, M.J., 
Curran, M.D., Court, J.A., Mann, D.M., Ikeda, S., Cookson, M.R., Hardy, J. and Allsop, D. 
(2003) Alpha-synuclein implicated in Parkinson's disease is present in extracellular biological 
fluids, including human plasma. FASEB J, 17, 1945-1947. 
References 
101 
Ellis, C.E., Schwartzberg, P.L., Grider, T.L., Fink, D.W. and Nussbaum, R.L. (2001) alpha-
synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases. J Biol 
Chem, 276, 3879-3884. 
Emmanouilidou, E., Stefanis, L. and Vekrellis, K. (2010) Cell-produced alpha-synuclein 
oligomers are targeted to, and impair, the 26S proteasome. Neurobiol Aging, 31, 953-968. 
Engelender, S., Kaminsky, Z., Guo, X., Sharp, A.H., Amaravi, R.K., Kleiderlein, J.J., 
Margolis, R.L., Troncoso, J.C., Lanahan, A.A., Worley, P.F., Dawson, V.L., Dawson, T.M. 
and Ross, C.A. (1999) Synphilin-1 associates with alpha-synuclein and promotes the 
formation of cytosolic inclusions. Nat Genet, 22, 110-114. 
Fairbanks, G., Steck, T.L. and Wallach, D.F. (1971) Electrophoretic analysis of the major 
polypeptides of the human erythrocyte membrane. Biochemistry, 10, 2606-2617. 
Fearnley, J.M. and Lees, A.J. (1991) Ageing and Parkinson's disease: substantia nigra 
regional selectivity. Brain, 114, 2283-2301. 
Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P. and Double, K.L. (2005) 
Neuromelanin in human dopamine neurons: comparison with peripheral melanins and 
relevance to Parkinson's disease. Prog Neurobiol, 75, 109-124. 
Flower, T.R., Chesnokova, L.S., Froelich, C.A., Dixon, C. and Witt, S.N. (2005) Heat shock 
prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol 
Biol, 351, 1081-1100. 
Foulds, P.G., Mitchell, J.D., Parker, A., Turner, R., Green, G., Diggle, P., Hasegawa, M., 
Taylor, M., Mann, D. and Allsop, D. (2011) Phosphorylated alpha-synuclein can be detected 
in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB J, 25, 
4127-4137. 
Franssens, V., Boelen, E., Anandhakumar, J., Vanhelmont, T., Buttner, S. and Winderickx, J. 
(2010) Yeast unfolds the road map toward alpha-synuclein-induced cell death. Cell Death 
Differ, 17, 746-753. 
Frein, D., Schildknecht, S., Bachschmid, M. and Ullrich, V. (2005) Redox regulation: a new 
challenge for pharmacology. Biochem Pharmacol, 70, 811-823. 
Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M.S., 
Shen, J., Takio, K. and Iwatsubo, T. (2002) alpha-Synuclein is phosphorylated in 
synucleinopathy lesions. Nat Cell Biol, 4, 160-164. 
Fulwyler, M.J. (1965) Electronic separation of biological cells by volume. Science, 150, 910-
911. 
Galvin, J.E., Lee, V.M. and Trojanowski, J.Q. (2001) Synucleinopathies: clinical and 
pathological implications. Arch Neurol, 58, 186-190. 
Gao, H.M., Kotzbauer, P.T., Uryu, K., Leight, S., Trojanowski, J.Q. and Lee, V.M. (2008) 
Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic 
neurodegeneration. J Neurosci, 28, 7687-7698. 
German, D.C., Manaye, K., Smith, W.K., Woodward, D.J. and Saper, C.B. (1989) Midbrain 




German, D.C., Manaye, K.F., Sonsalla, P.K. and Brooks, B.A. (1992) Midbrain dopaminergic 
cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-
containing cells. Ann N Y Acad Sci, 648, 42-62. 
Giasson, B.I., Duda, J.E., Murray, I.V., Chen, Q., Souza, J.M., Hurtig, H.I., Ischiropoulos, H., 
Trojanowski, J.Q. and Lee, V.M. (2000) Oxidative damage linked to neurodegeneration by 
selective alpha-synuclein nitration in synucleinopathy lesions. Science, 290, 985-989. 
Giasson, B.I., Murray, I.V., Trojanowski, J.Q. and Lee, V.M. (2001) A hydrophobic stretch of 
12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J 
Biol Chem, 276, 2380-2386. 
Gibb, W.R. and Lees, A.J. (1988) The relevance of the Lewy body to the pathogenesis of 
idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry, 51, 745-752. 
Gibb, W.R. and Lees, A.J. (1991) Anatomy, pigmentation, ventral and dorsal subpopulations 
of the substantia nigra, and differential cell death in Parkinson's disease. J Neurol Neurosurg 
Psychiatry, 54, 388-396. 
Gitler, A.D., Bevis, B.J., Shorter, J., Strathearn, K.E., Hamamichi, S., Su, L.J., Caldwell, K.A., 
Caldwell, G.A., Rochet, J.C., McCaffery, J.M., Barlowe, C. and Lindquist, S. (2008) The 
Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl 
Acad Sci U S A, 105, 145-150. 
Gitler, A.D., Chesi, A., Geddie, M.L., Strathearn, K.E., Hamamichi, S., Hill, K.J., Caldwell, 
K.A., Caldwell, G.A., Cooper, A.A., Rochet, J.C. and Lindquist, S. (2009) Alpha-synuclein is 
part of a diverse and highly conserved interaction network that includes PARK9 and 
manganese toxicity. Nat Genet, 41, 308-315. 
Giupponi, G., Pycha, R., Erfurth, A., Hausmann, A. and Conca, A. (2008) [Depressive 
symptoms and the Idiopathic Parkinson's Syndrome (IPS): a review]. Neuropsychiatr, 22, 71-
82. 
Goers, J., Manning-Bog, A.B., McCormack, A.L., Millett, I.S., Doniach, S., Di Monte, D.A., 
Uversky, V.N. and Fink, A.L. (2003) Nuclear localization of alpha-synuclein and its interaction 
with histones. Biochemistry, 42, 8465-8471. 
Goffeau, A., Barrell, B.G., Bussey, H., Davis, R.W., Dujon, B., Feldmann, H., Galibert, F., 
Hoheisel, J.D., Jacq, C., Johnston, M., Louis, E.J., Mewes, H.W., Murakami, Y., Philippsen, 
P., Tettelin, H. and Oliver, S.G. (1996) Life with 6000 genes. Science, 274, 546, 563-547. 
Goldberg, A.L. (2003) Protein degradation and protection against misfolded or damaged 
proteins. Nature, 426, 895-899. 
Golovko, M.Y., Barcelo-Coblijn, G., Castagnet, P.I., Austin, S., Combs, C.K. and Murphy, 
E.J. (2009) The role of alpha-synuclein in brain lipid metabolism: a downstream impact on 
brain inflammatory response. Mol Cell Biochem, 326, 55-66. 
Goncalves, S. and Outeiro, T.F. (2013) Assessing the subcellular dynamics of alpha-
synuclein using photoactivation microscopy. Mol Neurobiol, 47, 1081-1092. 
Gorbatyuk, O.S., Li, S., Sullivan, L.F., Chen, W., Kondrikova, G., Manfredsson, F.P., Mandel, 
R.J. and Muzyczka, N. (2008) The phosphorylation state of Ser-129 in human alpha-
synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad 
Sci U S A, 105, 763-768. 
References 
103 
Gotze, M., Pettelkau, J., Schaks, S., Bosse, K., Ihling, C.H., Krauth, F., Fritzsche, R., Kuhn, 
U. and Sinz, A. (2012) StavroX--a software for analyzing crosslinked products in protein 
interaction studies. J Am Soc Mass Spectrom, 23, 76-87. 
Gow, A.J., Duran, D., Malcolm, S. and Ischiropoulos, H. (1996) Effects of peroxynitrite-
induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett, 385, 
63-66. 
Greenbaum, E.A., Graves, C.L., Mishizen-Eberz, A.J., Lupoli, M.A., Lynch, D.R., Englander, 
S.W., Axelsen, P.H. and Giasson, B.I. (2005) The E46K mutation in alpha-synuclein 
increases amyloid fibril formation. J Biol Chem, 280, 7800-7807. 
Greenberg, D.A., Jin, K. and Khan, A.A. (2008) Neuroglobin: an endogenous 
neuroprotectant. Curr Opin Pharmacol, 8, 20-24. 
Guerrero, E., Vasudevaraju, P., Hegde, M.L., Britton, G.B. and Rao, K.S. (2013) Recent 
advances in alpha-synuclein functions, advanced glycation, and toxicity: implications for 
Parkinson's disease. Mol Neurobiol, 47, 525-536. 
Guthrie, C. and Fink, G.F. (1991) Guide to yeast genetics and molecular biology. Methods 
Enzymol, 194, 1-863. 
Hardy, J., Cai, H., Cookson, M.R., Gwinn-Hardy, K. and Singleton, A. (2006) Genetics of 
Parkinson's disease and parkinsonism. Ann Neurol, 60, 389-398. 
Hartwell, L.H. (2002) Nobel Lecture. Yeast and cancer. Biosci Rep, 22, 373-394. 
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V.M., 
Trojanowski, J.Q., Mann, D. and Iwatsubo, T. (2002) Phosphorylated alpha-synuclein is 
ubiquitinated in alpha-synucleinopathy lesions. J Biol Chem, 277, 49071-49076. 
Hashimoto, M., Hsu, L.J., Xia, Y., Takeda, A., Sisk, A., Sundsmo, M. and Masliah, E. (1999) 
Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. 
Neuroreport, 10, 717-721. 
Hashimoto, M. and Masliah, E. (1999) Alpha-synuclein in Lewy body disease and 
Alzheimer's disease. Brain Pathol, 9, 707-720. 
Hill, B.G., Benavides, G.A., Lancaster, J.R., Jr., Ballinger, S., Dell'Italia, L., Jianhua, Z. and 
Darley-Usmar, V.M. (2012) Integration of cellular bioenergetics with mitochondrial quality 
control and autophagy. Biol Chem, 393, 1485-1512. 
Hodara, R., Norris, E.H., Giasson, B.I., Mishizen-Eberz, A.J., Lynch, D.R., Lee, V.M. and 
Ischiropoulos, H. (2004) Functional consequences of alpha-synuclein tyrosine nitration: 
diminished binding to lipid vesicles and increased fibril formation. J Biol Chem, 279, 47746-
47753. 
Hoffman, C.S. and Winston, F. (1987) A ten-minute DNA preparation from yeast efficiently 
releases autonomous plasmids for transformation of Escherichia coli. Gene, 57, 267-272. 
Hornykiewicz, O. (2001) Chemical neuroanatomy of the basal ganglia--normal and in 
Parkinson's disease. J Chem Neuroanat, 22, 3-12. 
Hsu, L.J., Sagara, Y., Arroyo, A., Rockenstein, E., Sisk, A., Mallory, M., Wong, J., 
Takenouchi, T., Hashimoto, M. and Masliah, E. (2000) alpha-synuclein promotes 
mitochondrial deficit and oxidative stress. Am J Pathol, 157, 401-410. 
References 
104 
Huang, Z., Xu, Z., Wu, Y. and Zhou, Y. (2011) Determining nuclear localization of alpha-
synuclein in mouse brains. Neuroscience, 199, 318-332. 
Hughes, T.R. (2002) Yeast and drug discovery. Funct Integr Genomics, 2, 199-211. 
Inoue, H., Nojima, H. and Okayama, H. (1990) High efficiency transformation of Escherichia 
coli with plasmids. Gene, 96, 23-28. 
Ischiropoulos, H. (1998) Biological tyrosine nitration: a pathophysiological function of nitric 
oxide and reactive oxygen species. Arch Biochem Biophys, 356, 1-11. 
Ito, H., Fukuda, Y., Murata, K. and Kimura, A. (1983) Transformation of intact yeast cells 
treated with alkali cations. J Bacteriol, 153, 163-168. 
Jakes, R., Spillantini, M.G. and Goedert, M. (1994) Identification of two distinct synucleins 
from human brain. FEBS Lett, 345, 27-32. 
Jankovic, J. (2008) Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg 
Psychiatry, 79, 368-376. 
Jenner, P. and Olanow, C.W. (1996) Oxidative stress and the pathogenesis of Parkinson's 
disease. Neurology, 47, S161-170. 
Jensen, P.H., Nielsen, M.S., Jakes, R., Dotti, C.G. and Goedert, M. (1998) Binding of alpha-
synuclein to brain vesicles is abolished by familial Parkinson's disease mutation. J Biol 
Chem, 273, 26292-26294. 
Jo, E., Fuller, N., Rand, R.P., St George-Hyslop, P. and Fraser, P.E. (2002) Defective 
membrane interactions of familial Parkinson's disease mutant A30P alpha-synuclein. J Mol 
Biol, 315, 799-807. 
Jones, E.W. (2002) Vacuolar proteases and proteolytic artifacts in Saccharomyces 
cerevisiae. Methods Enzymol, 351, 127-150. 
Junn, E. and Mouradian, M.M. (2002) Human alpha-synuclein over-expression increases 
intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett, 
320, 146-150. 
Kang, K.W., Choi, S.H. and Kim, S.G. (2002) Peroxynitrite activates NF-E2-related factor 
2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the 
role of nitric oxide synthase in rat glutathione S-transferase A2 induction. Nitric Oxide, 7, 
244-253. 
Karpinar, D.P., Balija, M.B., Kugler, S., Opazo, F., Rezaei-Ghaleh, N., Wender, N., Kim, 
H.Y., Taschenberger, G., Falkenburger, B.H., Heise, H., Kumar, A., Riedel, D., Fichtner, L., 
Voigt, A., Braus, G.H., Giller, K., Becker, S., Herzig, A., Baldus, M., Jackle, H., Eimer, S., 
Schulz, J.B., Griesinger, C. and Zweckstetter, M. (2009) Pre-fibrillar alpha-synuclein variants 
with impaired beta-structure increase neurotoxicity in Parkinson's disease models. Embo J, 
28, 3256-3268. 
Karube, H., Sakamoto, M., Arawaka, S., Hara, S., Sato, H., Ren, C.H., Goto, S., Koyama, S., 
Wada, M., Kawanami, T., Kurita, K. and Kato, T. (2008) N-terminal region of alpha-synuclein 
is essential for the fatty acid-induced oligomerization of the molecules. FEBS Lett, 582, 3693-
3700. 
Katzmann, D.J., Hallstrom, T.C., Voet, M., Wysock, W., Golin, J., Volckaert, G. and Moye-
Rowley, W.S. (1995) Expression of an ATP-binding cassette transporter-encoding gene 
References 
105 
(YOR1) is required for oligomycin resistance in Saccharomyces cerevisiae. Mol Cell Biol, 15, 
6875-6883. 
Khan, A.A., Mao, X.O., Banwait, S., Jin, K. and Greenberg, D.A. (2007) Neuroglobin 
attenuates beta-amyloid neurotoxicity in vitro and transgenic Alzheimer phenotype in vivo. 
Proc Natl Acad Sci U S A, 104, 19114-19119. 
Kiely, A.P., Asi, Y.T., Kara, E., Limousin, P., Ling, H., Lewis, P., Proukakis, C., Quinn, N., 
Lees, A.J., Hardy, J., Revesz, T., Houlden, H. and Holton, J.L. (2013) alpha-Synucleinopathy 
associated with G51D SNCA mutation: a link between Parkinson's disease and multiple 
system atrophy? Acta Neuropathol, 125, 753-769. 
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, 
M., Mizuno, Y. and Shimizu, N. (1998) Mutations in the parkin gene cause autosomal 
recessive juvenile parkinsonism. Nature, 392, 605-608. 
Klionsky, D.J. and Emr, S.D. (2000) Autophagy as a regulated pathway of cellular 
degradation. Science, 290, 1717-1721. 
Klotz, L.O., Schieke, S.M., Sies, H. and Holbrook, N.J. (2000) Peroxynitrite activates the 
phosphoinositide 3-kinase/Akt pathway in human skin primary fibroblasts. Biochem J, 352 Pt 
1, 219-225. 
Kojima, H., Sakurai, K., Kikuchi, K., Kawahara, S., Kirino, Y., Nagoshi, H., Hirata, Y. and 
Nagano, T. (1998) Development of a fluorescent indicator for nitric oxide based on the 
fluorescein chromophore. Chem Pharm Bull (Tokyo), 46, 373-375. 
Kong, S.K., Yim, M.B., Stadtman, E.R. and Chock, P.B. (1996) Peroxynitrite disables the 
tyrosine phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to 
phosphorylate nitrated cdc2(6-20)NH2 peptide. Proc Natl Acad Sci U S A, 93, 3377-3382. 
Kontopoulos, E., Parvin, J.D. and Feany, M.B. (2006) Alpha-synuclein acts in the nucleus to 
inhibit histone acetylation and promote neurotoxicity. Hum Mol Genet, 15, 3012-3023. 
Kosten, J., Binolfi, A., Stuiver, M., Verzini, S., Theillet, F.X., Bekei, B., van Rossum, M. and 
Selenko, P. (2014) Efficient modification of alpha-synuclein serine 129 by protein kinase CK1 
requires phosphorylation of tyrosine 125 as a priming event. ACS Chem Neurosci, 5, 1203-
1208. 
Kowall, N.W., Hantraye, P., Brouillet, E., Beal, M.F., McKee, A.C. and Ferrante, R.J. (2000) 
MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport, 
11, 211-213. 
Kruger, R., Kuhn, W., Muller, T., Woitalla, D., Graeber, M., Kosel, S., Przuntek, H., Epplen, 
J.T., Schols, L. and Riess, O. (1998) Ala30Pro mutation in the gene encoding alpha-
synuclein in Parkinson's disease. Nat Genet, 18, 106-108. 
Kuwahara, T., Tonegawa, R., Ito, G., Mitani, S. and Iwatsubo, T. (2012) Phosphorylation of 
alpha-synuclein protein at Ser-129 reduces neuronal dysfunction by lowering its membrane 
binding property in Caenorhabditis elegans. J Biol Chem, 287, 7098-7109. 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature, 227, 680-685. 
Lavedan, C. (1998) The synuclein family. Genome Res, 8, 871-880. 
References 
106 
Lazaro, D.F., Rodrigues, E.F., Langohr, R., Shahpasandzadeh, H., Ribeiro, T., Guerreiro, P., 
Gerhardt, E., Krohnert, K., Klucken, J., Pereira, M.D., Popova, B., Kruse, N., Mollenhauer, 
B., Rizzoli, S.O., Braus, G.H., Danzer, K.M. and Outeiro, T.F. (2014) Systematic comparison 
of the effects of alpha-synuclein mutations on its oligomerization and aggregation. PLoS 
Genet, 10, e1004741. 
Lee, D.H. and Goldberg, A.L. (1996) Selective inhibitors of the proteasome-dependent and 
vacuolar pathways of protein degradation in Saccharomyces cerevisiae. J Biol Chem, 271, 
27280-27284. 
Lee, D.H. and Goldberg, A.L. (1998) Proteasome inhibitors: valuable new tools for cell 
biologists. Trends Cell Biol, 8, 397-403. 
Lee, H.J., Khoshaghideh, F., Patel, S. and Lee, S.J. (2004) Clearance of alpha-synuclein 
oligomeric intermediates via the lysosomal degradation pathway. J Neurosci, 24, 1888-1896. 
Lee, H.J., Shin, S.Y., Choi, C., Lee, Y.H. and Lee, S.J. (2002) Formation and removal of 
alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J Biol Chem, 277, 
5411-5417. 
Lee, P.Y., Costumbrado, J., Hsu, C.Y. and Kim, Y.H. (2012) Agarose gel electrophoresis for 
the separation of DNA fragments. J Vis Exp, 20, 3923. 
Lesage, S., Anheim, M., Letournel, F., Bousset, L., Honore, A., Rozas, N., Pieri, L., Madiona, 
K., Durr, A., Melki, R., Verny, C. and Brice, A. (2013) G51D alpha-synuclein mutation causes 
a novel parkinsonian-pyramidal syndrome. Ann Neurol, 73, 459-471. 
Lewinska, A. and Bartosz, G. (2006) Yeast flavohemoglobin protects against nitrosative 
stress and controls ferric reductase activity. Redox Rep, 11, 231-239. 
Li, J., Uversky, V.N. and Fink, A.L. (2001) Effect of familial Parkinson's disease point 
mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human 
alpha-synuclein. Biochemistry, 40, 11604-11613. 
Liu, C., Apodaca, J., Davis, L.E. and Rao, H. (2007) Proteasome inhibition in wild-type yeast 
Saccharomyces cerevisiae cells. Biotechniques, 42, 158, 160, 162. 
Liu, L., Zeng, M., Hausladen, A., Heitman, J. and Stamler, J.S. (2000) Protection from 
nitrosative stress by yeast flavohemoglobin. Proc Natl Acad Sci U S A, 97, 4672-4676. 
Liu, Y., Qiang, M., Wei, Y. and He, R. (2011) A novel molecular mechanism for nitrated 
{alpha}-synuclein-induced cell death. J Mol Cell Biol, 3, 239-249. 
Lorenzen, N., Lemminger, L., Pedersen, J.N., Nielsen, S.B. and Otzen, D.E. (2014) The N-
terminus of alpha-synuclein is essential for both monomeric and oligomeric interactions with 
membranes. FEBS Lett, 588, 497-502. 
Luk, K.C., Kehm, V., Carroll, J., Zhang, B., O'Brien, P., Trojanowski, J.Q. and Lee, V.M. 
(2012a) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration 
in nontransgenic mice. Science, 338, 949-953. 
Luk, K.C., Kehm, V.M., Zhang, B., O'Brien, P., Trojanowski, J.Q. and Lee, V.M. (2012b) 
Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive 
neurodegenerative alpha-synucleinopathy in mice. J Exp Med, 209, 975-986. 
References 
107 
Lundblad, M., Decressac, M., Mattsson, B. and Bjorklund, A. (2012) Impaired 
neurotransmission caused by overexpression of alpha-synuclein in nigral dopamine neurons. 
Proc Natl Acad Sci U S A, 109, 3213-3219. 
Lymar, S.V. and Hurst, J.K. (1998) Radical nature of peroxynitrite reactivity. Chem Res 
Toxicol, 11, 714-715. 
Machiya, Y., Hara, S., Arawaka, S., Fukushima, S., Sato, H., Sakamoto, M., Koyama, S. and 
Kato, T. (2010) Phosphorylated alpha-synuclein at Ser-129 is targeted to the proteasome 
pathway in a ubiquitin-independent manner. J Biol Chem, 285, 40732-40744. 
Mager, W.H. and Winderickx, J. (2005) Yeast as a model for medical and medicinal 
research. Trends Pharmacol Sci, 26, 265-273. 
Mahul-Mellier, A.L., Fauvet, B., Gysbers, A., Dikiy, I., Oueslati, A., Georgeon, S., 
Lamontanara, A.J., Bisquertt, A., Eliezer, D., Masliah, E., Halliday, G., Hantschel, O. and 
Lashuel, H.A. (2014) c-Abl phosphorylates alpha-synuclein and regulates its degradation: 
implication for alpha-synuclein clearance and contribution to the pathogenesis of Parkinson's 
disease. Hum Mol Genet, 23, 2858-2879. 
Maroteaux, L., Campanelli, J.T. and Scheller, R.H. (1988) Synuclein: a neuron-specific 
protein localized to the nucleus and presynaptic nerve terminal. J Neurosci, 8, 2804-2815. 
Maroteaux, L. and Scheller, R.H. (1991) The rat brain synucleins; family of proteins 
transiently associated with neuronal membrane. Brain Res Mol Brain Res, 11, 335-343. 
Martinez-Ruiz, A. and Lamas, S. (2009) Two decades of new concepts in nitric oxide 
signaling: from the discovery of a gas messenger to the mediation of nonenzymatic 
posttranslational modifications. IUBMB Life, 61, 91-98. 
Martinez-Vicente, M., Talloczy, Z., Kaushik, S., Massey, A.C., Mazzulli, J., Mosharov, E.V., 
Hodara, R., Fredenburg, R., Wu, D.C., Follenzi, A., Dauer, W., Przedborski, S., 
Ischiropoulos, H., Lansbury, P.T., Sulzer, D. and Cuervo, A.M. (2008) Dopamine-modified 
alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest, 118, 777-788. 
Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, 
D.M. and Hasegawa, M. (2013) Prion-like spreading of pathological alpha-synuclein in brain. 
Brain, 136, 1128-1138. 
McCormack, A.L., Mak, S.K. and Di Monte, D.A. (2012) Increased alpha-synuclein 
phosphorylation and nitration in the aging primate substantia nigra. Cell Death Dis, 3, e315. 
McFarland, N.R., Fan, Z., Xu, K., Schwarzschild, M.A., Feany, M.B., Hyman, B.T. and 
McLean, P.J. (2009) Alpha-synuclein S129 phosphorylation mutants do not alter nigrostriatal 
toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol, 68, 515-524. 
McLean, P.J., Kawamata, H. and Hyman, B.T. (2001) Alpha-synuclein-enhanced green 
fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. 
Neuroscience, 104, 901-912. 
Meselson, M. and Yuan, R. (1968) DNA restriction enzyme from E. coli. Nature, 217, 1110-
1114. 




Mumberg, D., Muller, R. and Funk, M. (1994) Regulatable promoters of Saccharomyces 
cerevisiae: comparison of transcriptional activity and their use for heterologous expression. 
Nucleic Acids Res, 22, 5767-5768. 
Munoz, A.J., Wanichthanarak, K., Meza, E. and Petranovic, D. (2012) Systems biology of 
yeast cell death. FEMS Yeast Res, 12, 249-265. 
Nakamura, K., Nemani, V.M., Azarbal, F., Skibinski, G., Levy, J.M., Egami, K., Munishkina, 
L., Zhang, J., Gardner, B., Wakabayashi, J., Sesaki, H., Cheng, Y., Finkbeiner, S., 
Nussbaum, R.L., Masliah, E. and Edwards, R.H. (2011) Direct membrane association drives 
mitochondrial fission by the Parkinson disease-associated protein alpha-synuclein. J Biol 
Chem, 286, 20710-20726. 
Nakamura, T., Yamashita, H., Nagano, Y., Takahashi, T., Avraham, S., Avraham, H., 
Matsumoto, M. and Nakamura, S. (2002) Activation of Pyk2/RAFTK induces tyrosine 
phosphorylation of alpha-synuclein via Src-family kinases. FEBS Lett, 521, 190-194. 
Nakamura, T., Yamashita, H., Takahashi, T. and Nakamura, S. (2001) Activated Fyn 
phosphorylates alpha-synuclein at tyrosine residue 125. Biochem Biophys Res Commun, 
280, 1085-1092. 
Negro, A., Brunati, A.M., Donella-Deana, A., Massimino, M.L. and Pinna, L.A. (2002) Multiple 
phosphorylation of alpha-synuclein by protein tyrosine kinase Syk prevents eosin-induced 
aggregation. FASEB J, 16, 210-212. 
Norris, E.H., Giasson, B.I., Ischiropoulos, H. and Lee, V.M. (2003) Effects of oxidative and 
nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein 
modifications. J Biol Chem, 278, 27230-27240. 
Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Arbizu, J. and Gimenez-Amaya, J.M. 
(2002) The basal ganglia and disorders of movement: pathophysiological mechanisms. News 
Physiol Sci, 17, 51-55. 
Ocampo, A., Liu, J., Schroeder, E.A., Shadel, G.S. and Barrientos, A. (2012) Mitochondrial 
respiratory thresholds regulate yeast chronological life span and its extension by caloric 
restriction. Cell Metab, 16, 55-67. 
Olanow, C.W. (1990) Oxidation reactions in Parkinson's disease. Neurology, 40, suppl 32-37; 
discussion 37-39. 
Oliveira, L.M., Falomir-Lockhart, L.J., Botelho, M.G., Lin, K.H., Wales, P., Koch, J.C., 
Gerhardt, E., Taschenberger, H., Outeiro, T.F., Lingor, P., Schule, B., Arndt-Jovin, D.J. and 
Jovin, T.M. (2015) Elevated alpha-synuclein caused by SNCA gene triplication impairs 
neuronal differentiation and maturation in Parkinson's patient-derived induced pluripotent 
stem cells. Cell Death Dis, 6, e1994. 
Oueslati, A., Fournier, M. and Lashuel, H.A. (2010) Role of post-translational modifications in 
modulating the structure, function and toxicity of alpha-synuclein: implications for Parkinson's 
disease pathogenesis and therapies. Prog Brain Res, 183, 115-145. 
Oueslati, A., Schneider, B.L., Aebischer, P. and Lashuel, H.A. (2013) Polo-like kinase 2 
regulates selective autophagic alpha-synuclein clearance and suppresses its toxicity in vivo. 
Proc Natl Acad Sci U S A, 110, E3945-3954. 
Outeiro, T.F. and Lindquist, S. (2003) Yeast cells provide insight into alpha-synuclein biology 
and pathobiology. Science, 302, 1772-1775. 
References 
109 
Paleologou, K.E., Oueslati, A., Shakked, G., Rospigliosi, C.C., Kim, H.Y., Lamberto, G.R., 
Fernandez, C.O., Schmid, A., Chegini, F., Gai, W.P., Chiappe, D., Moniatte, M., Schneider, 
B.L., Aebischer, P., Eliezer, D., Zweckstetter, M., Masliah, E. and Lashuel, H.A. (2010) 
Phosphorylation at S87 is enhanced in synucleinopathies, inhibits alpha-synuclein 
oligomerization, and influences synuclein-membrane interactions. J Neurosci, 30, 3184-
3198. 
Papay, R., Zuscik, M.J., Ross, S.A., Yun, J., McCune, D.F., Gonzalez-Cabrera, P., Gaivin, 
R., Drazba, J. and Perez, D.M. (2002) Mice expressing the alpha(1B)-adrenergic receptor 
induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation. J 
Neurochem, 83, 623-634. 
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M. and Ghafourifar, P. (2008) Mitochondrial 
association of alpha-synuclein causes oxidative stress. Cell Mol Life Sci, 65, 1272-1284. 
Parihar, M.S., Parihar, A., Fujita, M., Hashimoto, M. and Ghafourifar, P. (2009) Alpha-
synuclein overexpression and aggregation exacerbates impairment of mitochondrial 
functions by augmenting oxidative stress in human neuroblastoma cells. Int J Biochem Cell 
Biol, 41, 2015-2024. 
Parkinson, J. (2002) An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci, 
14, 223-236; discussion 222. 
Paxinou, E., Chen, Q., Weisse, M., Giasson, B.I., Norris, E.H., Rueter, S.M., Trojanowski, 
J.Q., Lee, V.M. and Ischiropoulos, H. (2001) Induction of alpha-synuclein aggregation by 
intracellular nitrative insult. J Neurosci, 21, 8053-8061. 
Petroi, D., Popova, B., Taheri-Talesh, N., Irniger, S., Shahpasandzadeh, H., Zweckstetter, 
M., Outeiro, T.F. and Braus, G.H. (2012) Aggregate clearance of alpha-synuclein in 
Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on 
the proteasome. J Biol Chem, 287, 27567-27579. 
Pfeiffer, S., Schmidt, K. and Mayer, B. (2000) Dityrosine formation outcompetes tyrosine 
nitration at low steady-state concentrations of peroxynitrite. Implications for tyrosine 
modification by nitric oxide/superoxide in vivo. J Biol Chem, 275, 6346-6352. 
Pillon, B., Dubois, B., Cusimano, G., Bonnet, A.M., Lhermitte, F. and Agid, Y. (1989) Does 
cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol 
Neurosurg Psychiatry, 52, 201-206. 
Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., Pike, B., 
Root, H., Rubenstein, J., Boyer, R., Stenroos, E.S., Chandrasekharappa, S., Athanassiadou, 
A., Papapetropoulos, T., Johnson, W.G., Lazzarini, A.M., Duvoisin, R.C., Di Iorio, G., Golbe, 
L.I. and Nussbaum, R.L. (1997) Mutation in the alpha-synuclein gene identified in families 
with Parkinson's disease. Science, 276, 2045-2047. 
Popova, B., Kleinknecht, A. and Braus, G.H. (2015) Posttranslational Modifications and 
Clearing of alpha-Synuclein Aggregates in Yeast. Biomolecules, 5, 617-634. 
Porath, J., Carlsson, J., Olsson, I. and Belfrage, G. (1975) Metal chelate affinity 
chromatography, a new approach to protein fractionation. Nature, 258, 598-599. 
Prigione, A., Piazza, F., Brighina, L., Begni, B., Galbussera, A., Difrancesco, J.C., Andreoni, 
S., Piolti, R. and Ferrarese, C. (2010) Alpha-synuclein nitration and autophagy response are 




Pronin, A.N., Morris, A.J., Surguchov, A. and Benovic, J.L. (2000) Synucleins are a novel 
class of substrates for G protein-coupled receptor kinases. J Biol Chem, 275, 26515-26522. 
Qing, H., Wong, W., McGeer, E.G. and McGeer, P.L. (2009) Lrrk2 phosphorylates alpha 
synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun, 
387, 149-152. 
Radi, R. (2004) Nitric oxide, oxidants, and protein tyrosine nitration. Proc Natl Acad Sci U S 
A, 101, 4003-4008. 
Radi, R. (2012) Protein tyrosine nitration: biochemical mechanisms and structural basis of 
functional effects. Acc Chem Res, 46, 550-559. 
Rappsilber, J., Mann, M. and Ishihama, Y. (2007) Protocol for micro-purification, enrichment, 
pre-fractionation and storage of peptides for proteomics using StageTips. Nat Protoc, 2, 
1896-1906. 
Recasens, A., Dehay, B., Bove, J., Carballo-Carbajal, I., Dovero, S., Perez-Villalba, A., 
Fernagut, P.O., Blesa, J., Parent, A., Perier, C., Farinas, I., Obeso, J.A., Bezard, E. and Vila, 
M. (2014) Lewy body extracts from Parkinson disease brains trigger alpha-synuclein 
pathology and neurodegeneration in mice and monkeys. Ann Neurol, 75, 351-362. 
Recchia, A., Debetto, P., Negro, A., Guidolin, D., Skaper, S.D. and Giusti, P. (2004) Alpha-
synuclein and Parkinson's disease. FASEB J, 18, 617-626. 
Rott, R., Szargel, R., Haskin, J., Bandopadhyay, R., Lees, A.J., Shani, V. and Engelender, S. 
(2011) alpha-Synuclein fate is determined by USP9X-regulated monoubiquitination. Proc 
Natl Acad Sci U S A, 108, 18666-18671. 
Sacino, A.N., Brooks, M., Thomas, M.A., McKinney, A.B., Lee, S., Regenhardt, R.W., 
McGarvey, N.H., Ayers, J.I., Notterpek, L., Borchelt, D.R., Golde, T.E. and Giasson, B.I. 
(2014) Intramuscular injection of alpha-synuclein induces CNS alpha-synuclein pathology 
and a rapid-onset motor phenotype in transgenic mice. Proc Natl Acad Sci U S A, 111, 
10732-10737. 
Sahay, S., Ghosh, D., Dwivedi, S., Anoop, A., Mohite, G.M., Kombrabail, M., 
Krishnamoorthy, G. and Maji, S.K. (2015) Familial Parkinson disease-associated mutations 
alter the site-specific microenvironment and dynamics of alpha-synuclein. J Biol Chem, 290, 
7804-7822. 
Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. and 
Erlich, H.A. (1988) Primer-directed enzymatic amplification of DNA with a thermostable DNA 
polymerase. Science, 239, 487-491. 
Sancenon, V., Lee, S.A., Patrick, C., Griffith, J., Paulino, A., Outeiro, T.F., Reggiori, F., 
Masliah, E. and Muchowski, P.J. (2012) Suppression of alpha-synuclein toxicity and vesicle 
trafficking defects by phosphorylation at S129 in yeast depends on genetic context. Hum Mol 
Genet, 21, 2432-2449. 
Sanger, F., Nicklen, S. and Coulson, A.R. (1992) DNA sequencing with chain-terminating 
inhibitors. 1977. Biotechnology, 24, 104-108. 
Schildknecht, S., Gerding, H.R., Karreman, C., Drescher, M., Lashuel, H.A., Outeiro, T.F., Di 
Monte, D.A. and Leist, M. (2013) Oxidative and nitrative alpha-synuclein modifications and 
proteostatic stress: implications for disease mechanisms and interventions in 
synucleinopathies. J Neurochem, 125, 491-511. 
References 
111 
Schildknecht, S., Pape, R., Muller, N., Robotta, M., Marquardt, A., Burkle, A., Drescher, M. 
and Leist, M. (2011) Neuroprotection by minocycline caused by direct and specific 
scavenging of peroxynitrite. J Biol Chem, 286, 4991-5002. 
Schildknecht, S. and Ullrich, V. (2009) Peroxynitrite as regulator of vascular prostanoid 
synthesis. Arch Biochem Biophys, 484, 183-189. 
Schmid, A.W., Fauvet, B., Moniatte, M. and Lashuel, H.A. (2013) Alpha-synuclein post-
translational modifications as potential biomarkers for Parkinson disease and other 
synucleinopathies. Mol Cell Proteomics, 12, 3543-3558. 
Sekiyama, K., Takamatsu, Y., Waragai, M. and Hashimoto, M. (2014) Role of genomics in 
translational research for Parkinson's disease. Biochem Biophys Res Commun, 452, 226-
235. 
Sevcsik, E., Trexler, A.J., Dunn, J.M. and Rhoades, E. (2011) Allostery in a disordered 
protein: oxidative modifications to alpha-synuclein act distally to regulate membrane binding. 
J Am Chem Soc, 133, 7152-7158. 
Shahpasandzadeh, H., Popova, B., Kleinknecht, A., Fraser, P.E., Outeiro, T.F. and Braus, 
G.H. (2014) Interplay between sumoylation and phosphorylation for protection against alpha-
synuclein inclusions. J Biol Chem, 289, 31224-31240. 
Sharma, N., Brandis, K.A., Herrera, S.K., Johnson, B.E., Vaidya, T., Shrestha, R. and 
Debburman, S.K. (2006) alpha-Synuclein budding yeast model: toxicity enhanced by 
impaired proteasome and oxidative stress. J Mol Neurosci, 28, 161-178. 
Sharon, R., Goldberg, M.S., Bar-Josef, I., Betensky, R.A., Shen, J. and Selkoe, D.J. (2001) 
alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and 
shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A, 98, 9110-9115. 
Shevchenko, A., Wilm, M., Vorm, O. and Mann, M. (1996) Mass spectrometric sequencing of 
proteins silver-stained polyacrylamide gels. Anal Chem, 68, 850-858. 
Shimura, H., Schlossmacher, M.G., Hattori, N., Frosch, M.P., Trockenbacher, A., Schneider, 
R., Mizuno, Y., Kosik, K.S. and Selkoe, D.J. (2001) Ubiquitination of a new form of alpha-
synuclein by parkin from human brain: implications for Parkinson's disease. Science, 293, 
263-269. 
Singleton, A.B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., 
Peuralinna, T., Dutra, A., Nussbaum, R., Lincoln, S., Crawley, A., Hanson, M., Maraganore, 
D., Adler, C., Cookson, M.R., Muenter, M., Baptista, M., Miller, D., Blancato, J., Hardy, J. and 
Gwinn-Hardy, K. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. 
Science, 302, 841. 
Sivaraman, T., Kumar, T.K., Jayaraman, G. and Yu, C. (1997) The mechanism of 2,2,2-
trichloroacetic acid-induced protein precipitation. J Protein Chem, 16, 291-297. 
Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A. and Wolozin, B. (2003) 
Aggregated and monomeric alpha-synuclein bind to the S6' proteasomal protein and inhibit 
proteasomal function. J Biol Chem, 278, 11753-11759. 
Soper, J.H., Roy, S., Stieber, A., Lee, E., Wilson, R.B., Trojanowski, J.Q., Burd, C.G. and 
Lee, V.M. (2008) Alpha-synuclein-induced aggregation of cytoplasmic vesicles in 
Saccharomyces cerevisiae. Mol Biol Cell, 19, 1093-1103. 
References 
112 
Souza, J.M., Giasson, B.I., Chen, Q., Lee, V.M. and Ischiropoulos, H. (2000a) Dityrosine 
cross-linking promotes formation of stable alpha -synuclein polymers. Implication of nitrative 
and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol 
Chem, 275, 18344-18349. 
Souza, J.M., Giasson, B.I., Lee, V.M. and Ischiropoulos, H. (2000b) Chaperone-like activity 
of synucleins. FEBS Lett, 474, 116-119. 
Specht, C.G., Tigaret, C.M., Rast, G.F., Thalhammer, A., Rudhard, Y. and Schoepfer, R. 
(2005) Subcellular localisation of recombinant alpha- and gamma-synuclein. Mol Cell 
Neurosci, 28, 326-334. 
Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. and Goedert, M. (1998) alpha-
Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia 
with lewy bodies. Proc Natl Acad Sci U S A, 95, 6469-6473. 
Spillantini, M.G. and Goedert, M. (2000) The alpha-synucleinopathies: Parkinson's disease, 
dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci, 920, 16-27. 
Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. and Goedert, M. 
(1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840. 
Su, L.J., Auluck, P.K., Outeiro, T.F., Yeger-Lotem, E., Kritzer, J.A., Tardiff, D.F., Strathearn, 
K.E., Liu, F., Cao, S., Hamamichi, S., Hill, K.J., Caldwell, K.A., Bell, G.W., Fraenkel, E., 
Cooper, A.A., Caldwell, G.A., McCaffery, J.M., Rochet, J.C. and Lindquist, S. (2010) 
Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects 
and mitochondrial dysfunction in Parkinson's disease models. Dis Model Mech, 3, 194-208. 
Sun, F., Mao, X., Xie, L., Greenberg, D.A. and Jin, K. (2013) Neuroglobin protein is 
upregulated in Alzheimer's disease. J Alzheimers Dis, 36, 659-663. 
Sung, V.W. and Nicholas, A.P. (2013) Nonmotor symptoms in Parkinson's disease: 
expanding the view of Parkinson's disease beyond a pure motor, pure dopaminergic 
problem. Neurol Clin, 31, S1-16. 
Takahashi, T., Yamashita, H., Nakamura, T., Nagano, Y. and Nakamura, S. (2002) Tyrosine 
125 of alpha-synuclein plays a critical role for dimerization following nitrative stress. Brain 
Res, 938, 73-80. 
Taus, T., Kocher, T., Pichler, P., Paschke, C., Schmidt, A., Henrich, C. and Mechtler, K. 
(2011) Universal and confident phosphorylation site localization using phosphoRS. J 
Proteome Res, 10, 5354-5362. 
Tenreiro, S., Eckermann, K. and Outeiro, T.F. (2014a) Protein phosphorylation in 
neurodegeneration: friend or foe? Front Mol Neurosci, 7, 42. 
Tenreiro, S., Munder, M.C., Alberti, S. and Outeiro, T.F. (2013) Harnessing the power of 
yeast to unravel the molecular basis of neurodegeneration. J Neurochem, 127, 438-452. 
Tenreiro, S., Reimao-Pinto, M.M., Antas, P., Rino, J., Wawrzycka, D., Macedo, D., Rosado-
Ramos, R., Amen, T., Waiss, M., Magalhaes, F., Gomes, A., Santos, C.N., Kaganovich, D. 
and Outeiro, T.F. (2014b) Phosphorylation modulates clearance of alpha-synuclein 
inclusions in a yeast model of Parkinson's disease. PLoS Genet, 10, e1004302. 
Thayanidhi, N., Helm, J.R., Nycz, D.C., Bentley, M., Liang, Y. and Hay, J.C. (2010) Alpha-
synuclein delays endoplasmic reticulum (ER)-to-Golgi transport in mammalian cells by 
antagonizing ER/Golgi SNAREs. Mol Biol Cell, 21, 1850-1863. 
References 
113 
Tofaris, G.K., Layfield, R. and Spillantini, M.G. (2001) alpha-synuclein metabolism and 
aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett, 
509, 22-26. 
Totterdell, S. and Meredith, G.E. (2005) Localization of alpha-synuclein to identified fibers 
and synapses in the normal mouse brain. Neuroscience, 135, 907-913. 
Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl 
Acad Sci U S A, 76, 4350-4354. 
Ulrih, N.P., Barry, C.H. and Fink, A.L. (2008) Impact of Tyr to Ala mutations on alpha-
synuclein fibrillation and structural properties. Biochim Biophys Acta, 1782, 581-585. 
Uversky, V.N., Li, J. and Fink, A.L. (2001) Metal-triggered structural transformations, 
aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between 
Parkinson's disease and heavy metal exposure. J Biol Chem, 276, 44284-44296. 
Uversky, V.N., Yamin, G., Munishkina, L.A., Karymov, M.A., Millett, I.S., Doniach, S., 
Lyubchenko, Y.L. and Fink, A.L. (2005) Effects of nitration on the structure and aggregation 
of alpha-synuclein. Brain Res Mol Brain Res, 134, 84-102. 
Valente, E.M., Bentivoglio, A.R., Dixon, P.H., Ferraris, A., Ialongo, T., Frontali, M., Albanese, 
A. and Wood, N.W. (2001) Localization of a novel locus for autosomal recessive early-onset 
parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet, 68, 895-900. 
Vamvaca, K., Volles, M.J. and Lansbury, P.T., Jr. (2009) The first N-terminal amino acids of 
alpha-synuclein are essential for alpha-helical structure formation in vitro and membrane 
binding in yeast. J Mol Biol, 389, 413-424. 
van Rooijen, B.D., Claessens, M.M. and Subramaniam, V. (2009) Lipid bilayer disruption by 
oligomeric alpha-synuclein depends on bilayer charge and accessibility of the hydrophobic 
core. Biochim Biophys Acta, 1788, 1271-1278. 
Vila, M., Vukosavic, S., Jackson-Lewis, V., Neystat, M., Jakowec, M. and Przedborski, S. 
(2000) Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following 
administration of the parkinsonian toxin MPTP. J Neurochem, 74, 721-729. 
Vilchez, D., Saez, I. and Dillin, A. (2014) The role of protein clearance mechanisms in 
organismal ageing and age-related diseases. Nat Commun, 5, 5659. 
Visanji, N.P., Wislet-Gendebien, S., Oschipok, L.W., Zhang, G., Aubert, I., Fraser, P.E. and 
Tandon, A. (2011) Effect of Ser-129 phosphorylation on interaction of alpha-synuclein with 
synaptic and cellular membranes. J Biol Chem, 286, 35863-35873. 
Wang, S., Xu, B., Liou, L.C., Ren, Q., Huang, S., Luo, Y., Zhang, Z. and Witt, S.N. (2012) 
alpha-Synuclein disrupts stress signaling by inhibiting polo-like kinase Cdc5/Plk2. Proc Natl 
Acad Sci U S A, 109, 16119-16124. 
Wang, W. and Malcolm, B.A. (1999) Two-stage PCR protocol allowing introduction of 
multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis. 
Biotechniques, 26, 680-682. 
Wang, X., Liu, J., Zhu, H., Tejima, E., Tsuji, K., Murata, Y., Atochin, D.N., Huang, P.L., 
Zhang, C. and Lo, E.H. (2008) Effects of neuroglobin overexpression on acute brain injury 
and long-term outcomes after focal cerebral ischemia. Stroke, 39, 1869-1874. 
References 
114 
Watanabe, S., Takahashi, N., Uchida, H. and Wakasugi, K. (2012) Human neuroglobin 
functions as an oxidative stress-responsive sensor for neuroprotection. J Biol Chem, 287, 
30128-30138. 
Waxman, E.A. and Giasson, B.I. (2008) Specificity and regulation of casein kinase-mediated 
phosphorylation of alpha-synuclein. J Neuropathol Exp Neurol, 67, 402-416. 
Waxman, E.A., Mazzulli, J.R. and Giasson, B.I. (2009) Characterization of hydrophobic 
residue requirements for alpha-synuclein fibrillization. Biochemistry, 48, 9427-9436. 
Webb, J.L., Ravikumar, B., Atkins, J., Skepper, J.N. and Rubinsztein, D.C. (2003) Alpha-
Synuclein is degraded by both autophagy and the proteasome. J Biol Chem, 278, 25009-
25013. 
Weinreb, P.H., Zhen, W., Poon, A.W., Conway, K.A. and Lansbury, P.T., Jr. (1996) NACP, a 
protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 35, 
13709-13715. 
Winner, B., Jappelli, R., Maji, S.K., Desplats, P.A., Boyer, L., Aigner, S., Hetzer, C., Loher, 
T., Vilar, M., Campioni, S., Tzitzilonis, C., Soragni, A., Jessberger, S., Mira, H., Consiglio, A., 
Pham, E., Masliah, E., Gage, F.H. and Riek, R. (2011) In vivo demonstration that alpha-
synuclein oligomers are toxic. Proc Natl Acad Sci U S A, 108, 4194-4199. 
Witt, S.N. and Flower, T.R. (2006) alpha-Synuclein, oxidative stress and apoptosis from the 
perspective of a yeast model of Parkinson's disease. FEMS Yeast Res, 6, 1107-1116. 
Woodcock, D.M., Crowther, P.J., Doherty, J., Jefferson, S., DeCruz, E., Noyer-Weidner, M., 
Smith, S.S., Michael, M.Z. and Graham, M.W. (1989) Quantitative evaluation of Escherichia 
coli host strains for tolerance to cytosine methylation in plasmid and phage recombinants. 
Nucleic Acids Res, 17, 3469-3478. 
Xu, S., Zhou, M., Yu, S., Cai, Y., Zhang, A., Ueda, K. and Chan, P. (2006) Oxidative stress 
induces nuclear translocation of C-terminus of alpha-synuclein in dopaminergic cells. 
Biochem Biophys Res Commun, 342, 330-335. 
Yamin, G., Glaser, C.B., Uversky, V.N. and Fink, A.L. (2003a) Certain metals trigger 
fibrillation of methionine-oxidized alpha-synuclein. J Biol Chem, 278, 27630-27635. 
Yamin, G., Uversky, V.N. and Fink, A.L. (2003b) Nitration inhibits fibrillation of human alpha-
synuclein in vitro by formation of soluble oligomers. FEBS Lett, 542, 147-152. 
Yao, D., Gu, Z., Nakamura, T., Shi, Z.Q., Ma, Y., Gaston, B., Palmer, L.A., Rockenstein, 
E.M., Zhang, Z., Masliah, E., Uehara, T. and Lipton, S.A. (2004) Nitrosative stress linked to 
sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase 
activity. Proc Natl Acad Sci U S A, 101, 10810-10814. 
Yu, S., Li, X., Liu, G., Han, J., Zhang, C., Li, Y., Xu, S., Liu, C., Gao, Y., Yang, H., Ueda, K. 
and Chan, P. (2007) Extensive nuclear localization of alpha-synuclein in normal rat brain 
neurons revealed by a novel monoclonal antibody. Neuroscience, 145, 539-555. 
Yu, Z., Xu, X., Xiang, Z., Zhou, J., Zhang, Z., Hu, C. and He, C. (2010) Nitrated alpha-
synuclein induces the loss of dopaminergic neurons in the substantia nigra of rats. PLoS 
One, 5, e9956. 
Zabrocki, P., Bastiaens, I., Delay, C., Bammens, T., Ghillebert, R., Pellens, K., De Virgilio, 
C., Van Leuven, F. and Winderickx, J. (2008) Phosphorylation, lipid raft interaction and traffic 
of alpha-synuclein in a yeast model for Parkinson. Biochim Biophys Acta, 1783, 1767-1780. 
References 
115 
Zabrocki, P., Pellens, K., Vanhelmont, T., Vandebroek, T., Griffioen, G., Wera, S., Van 
Leuven, F. and Winderickx, J. (2005) Characterization of alpha-synuclein aggregation and 
synergistic toxicity with protein tau in yeast. Febs J, 272, 1386-1400. 
Zarranz, J.J., Alegre, J., Gomez-Esteban, J.C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., 
Hoenicka, J., Rodriguez, O., Atares, B., Llorens, V., Gomez Tortosa, E., del Ser, T., Munoz, 
D.G. and de Yebenes, J.G. (2004) The new mutation, E46K, of alpha-synuclein causes 
Parkinson and Lewy body dementia. Ann Neurol, 55, 164-173. 
Zhao, X.J., Raitt, D., P, V.B., Clewell, A.S., Kwast, K.E. and Poyton, R.O. (1996) Function 
and expression of flavohemoglobin in Saccharomyces cerevisiae. Evidence for a role in the 
oxidative stress response. J Biol Chem, 271, 25131-25138. 
Zhu, M., Li, J. and Fink, A.L. (2003) The association of alpha-synuclein with membranes 
affects bilayer structure, stability, and fibril formation. J Biol Chem, 278, 40186-40197. 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S., Kachergus, J., 
Hulihan, M., Uitti, R.J., Calne, D.B., Stoessl, A.J., Pfeiffer, R.F., Patenge, N., Carbajal, I.C., 
Vieregge, P., Asmus, F., Muller-Myhsok, B., Dickson, D.W., Meitinger, T., Strom, T.M., 
Wszolek, Z.K. and Gasser, T. (2004) Mutations in LRRK2 cause autosomal-dominant 
parkinsonism with pleomorphic pathology. Neuron, 44, 601-607. 
 
 
List of Figures 
116 
List of Figures 
Figure 1. Schematic overview of human αSyn with the three distinct domains. ..................... 6 
Figure 2. Posttranslational modifications of αSyn in Lewy bodies. ......................................... 9 
Figure 3. Tyrosine nitration and di-tyrosine formation. ..........................................................11 
Figure 4. Localization of αSyn in yeast and its impact on growth. .........................................16 
Figure 5. Schematic assembly of an immunoblot device. .....................................................38 
Figure 6. αSyn forms dimers in vivo in yeast. .......................................................................51 
Figure 7. Analysis of di-tyrosine dimers from αSyn. ..............................................................54 
Figure 8. MS2 analysis of crosslinked peptides. ...................................................................55 
Figure 9. Mutation of tyrosines of αSyn prevents dimerization and nitration of αSyn. ...........57 
Figure 10. Blocking of αSyn tyrosine nitration decreases cytotoxicity. ..................................58 
Figure 11. Blocking of αSyn tyrosine nitration decreases aggregation. .................................59 
Figure 12. The nitric oxide oxidoreductase Yhb1 reduces A30P toxicity. ..............................61 
Figure 13. The nitric oxide oxidoreductase Yhb1 reduces A30P aggregation. ......................62 
Figure 14. Overexpression of YHB1 impairs growth of Saccharomyces cerevisiae. .............63 
Figure 15. Yhb1 decreases sensitivity of A30P expressing cells to nitrative stress. ..............64 
Figure 16. αSyn expression does not affect sensitivity of yeast cells to H2O2. ......................65 
Figure 17. C-terminal tyrosine replacements of A30P decrease toxicity in ∆yhb1. ................66 
Figure 18. Expression of αSyn increases accumulation of ROS. ..........................................68 
Figure 19. Δyhb1 increases accumulation of reactive nitrogen species (RNS) in A30P 
expressing cells. ...................................................................................................................69 
Figure 20. Yhb1 protects mitochondria from A30P toxicity. ...................................................71 
Figure 21. Mitochondrial functionality is not affected by Yhb1 in A30P expressing yeast cells.
 .............................................................................................................................................73 
Figure 22. The human NGB gene for neuroglobin complements A30P growth in YHB1 
deletion yeast. ......................................................................................................................75 
Figure 23. The human NGB gene for neuroglobin alters αSyn aggregation in mammalian 
cells. .....................................................................................................................................76 
Figure 24. Yhb1 affects nitration of A30P. ............................................................................77 
Figure 25. Yhb1 affects nitration but not dimerization of αSyn and A30P. .............................78 
Figure 26. αSyn has a higher S129 phosphorylation level than A30P. ..................................79 
Figure 27. Tyrosine 133 is required for phosphorylation of αSyn at serine 129. ....................80 
Figure 28. Y133F and S129A mutations increase αSyn-mediated cytotoxicity. .....................81 
Figure 29. Tyrosine 133 mutation does not alter the accumulation of reactive oxygen and 
nitrogen species. ..................................................................................................................82 
Figure 30. αSyn aggregate clearance after promoter shut-off. ..............................................84 
List of Figures 
117 
Figure 31. αSyn posttranslational modifications and nitrative stress in yeast. .......................88 
Figure 32. Putative conserved domain of Yhb1 and NGB. ....................................................90 
List of Tables 
118 
List of Tables 
Table 1. Yeast strains ...........................................................................................................20 
Table 2. Plasmids .................................................................................................................20 
Table 3. Oligonucleotides .....................................................................................................21 
Table 4. Enzymes .................................................................................................................23 
Table 5. Media .....................................................................................................................24 
Table 6. Antibiotics ...............................................................................................................25 
Table 7. Primary antibodies ..................................................................................................26 
Table 8. Secondary antibodies .............................................................................................26 
Table 9. Reaction mix for Phusion DNA polymerase ............................................................30 
Table 10. PCR program for Phusion DNA polymerase .........................................................30 
Table 11. Reaction mix for Taq DNA polymerase .................................................................30 
Table 12. PCR program for Taq DNA polymerase ................................................................31 
Table 13. Reaction mix for PfuTurbo Cx hotstart DNA polymerase.......................................32 
Table 14. PCR program for PfuTurbo Cx hotstart DNA polymerase .....................................32 
Table 15. Determination of nitrated peptides from αSyn and A30P. ......................................52 
Table 16. Phospho-peptides identified by MS/MS. ...............................................................53 





%   percent 
2μ (2 µm)  2 micrometer high-copy yeast expression vector 
μg   microgram 
μL   microliter  
µm   micrometer 
µM   micromolar    
3-NT   3-nitrotyrosine 
Å   Ångström 
AA   amino acids 
Ade (A)  adenine 
Ala (A)   alanine  
AmpR   ampicillin resistance 
ANOVA  analysis of variance 
approx.  approximately 
APS    ammonium persulfate  
Arg (R)  arginine 
AS   ammonium sulfate  
Asn (N)  asparagine  
Asp (D)   aspartic acid  
αSyn   α-synuclein 
ATG   autophagy-related gene 
ATP   adenosine triphosphate 
ATP13A2  ATPase type 13A2 
BLAST   basic local alignment search tool 
bp   base pair(s) 
BSA   bovine serum albumin 
°C   degree Celsius 
cDNA   complementary DNA 
CEN/ARS  centromere/autonomously replicating sequence 
CKs   casein kinases   
cm   centimeter 
CMV   cytomegalovirus 
C-terminus  carboxy terminus 
ctrl   control  
CYC1   cytochrome C-1 
Abbreviations 
120 
Cys (C)  cysteine 
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SEM    standard error of the mean 
Ser (S)   serine  
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SNCA   synuclein alpha 
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